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Abstract 
The blood-brain barrier (BBB) is the most extensive and restrictive barrier to brain 
delivery for therapeutic agents. A low proportion of low molecular-weight agents can 
cross into the CNS. This decreases further as the molecular weight increases, meaning 
therapeutic antibodies, oligonucleotides and other supramolecular entities effectively 
cannot reach therapeutic levels within the CNS. Targeting ligands against receptors 
thought to undergo transcytosis across the brain microvascular endothelial cells 
(BMECs), can boost CNS delivery of therapeutics. Understanding these mechanisms, in 
an in-vitro setting, has proved challenging, due to the constraints of cell culture systems 
and the difficulty to replicate the in-vivo environment. With even the most extensively 
studied targeting receptor, transferrin receptor, not producing clear evidence to suggest 
the occurrence of transcytosis.  
To understand in-vitro trafficking of brain targeting ligands a pulse-chase assay, in 
combination with sub-cellular localisation microscopy was developed and compared to 
the current permeability-based assay method. The characterisation was done by 
comparison of transferrin receptor ligands; native holo-transferrin, the 8D3 antibody and 
a low-affinity variant; with the non-specific uptake probe, dextran. The method could 
distinguish between the two endocytosis methods, with concentration-dependent efflux 
efficiency observed with the targeted probes. The combination of techniques was then 
applied to the novel targeting ligand, Rabies-Virus Glycoprotein (RVG) peptide, to assess 
its suitability as a brain delivery. Studies were performed to confirm the target receptor 
of the RVG peptide, including competitive uptake, siRNA knockdown methods. The 
RVG peptide demonstrated desirable delivery characteristics, and the target receptor was 
confirmed as the α7 nicotinic acetylcholine receptor. Finally, attempts were made to 
develop a total internal reflection fluorescence (TIRF) microscopy assay for the 
assessment of ligand arrival at the basolateral membrane of BMECs.  Initial work for this 
was performed with the transferrin receptor and transferrin, using both labelled ligand 
and photoswitchable receptor constructs. In summary, the pulse-chase assay provides a 
complementary technique to permeability assays for the assessment of brain targeting 
ligand trafficking in BMEC cell-lines in-vitro.  
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Chapter 1: General Introduction 
 
The microenvironment of the central nervous system (CNS) is tightly regulated, through 
the complex nature of the barriers surrounding it. While transportation mechanisms exist 
for the passage of essential nutrients, oxygen, glucose, proteins and immune cells into the 
brain. These transport processes must be closely regulated maintain the homeostatic 
composition of extra-cellular fluid within the brain. Regulation of the CNS 
microenvironment (brain parenchyma) is essential for the support of neuronal 
connectivity within the brain; highlighting the importance of barriers to the CNS. 
The primary barrier of the CNS from the systemic circulation is the Blood-Brain Barrier 
(BBB). This barrier was first observed by Paul Ehrlich (1854-1915), who observed that 
dyes injected into the circulation were able to stain all organs, apart from the brain and 
spinal cord. Further experiments, by Erwin Goldmann, demonstrated that injection of 
trypan blue into the cerebral spinal fluid (CSF) stained the brain and spinal cord, but not 
the systemic organs. Max Lewandowsky first introduced the phrase Blood-Brain Barrier 
(BBB); after investigations with another water-soluble dye, potassium ferrocyanate was 
unable to reach the CNS (Hawkins and Davis 2005). 
As a barrier, the BBB regulates the trafficking of molecules across the microvascular 
capillary beds of the brain. Due to the extensive vascularisation of the brain, an organ 
with high metabolic demands, the BBB makes up approximately 99% of the barrier 
surface area of the brain, ~ 20 m2  in humans (Boado and Pardridge 2011). The extensive 
branching of the cerebral microvasculature means individual neurons receive nearly a 
unique blood supply, to provide the nutrients required (Schlageter et al. 1999). Although 
the brain microvascular endothelial cells (BMECs) form the restrictive barrier, that is the 
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BBB; they would be unable to without the close interactions and cellular signalling with 
multiple cell types within the CNS. Thus, it is deemed correct to view the BBB, not as a 
single cell type barrier, but a neurovascular unit (NVU) comprising endothelium, 
astrocytes, pericytes, microglial and neuronal cross-talk. These interactions facilitate the 
differentiation and phenotypic characteristics of all cell-types involved. The restrictive 
barrier created by the NVU, required for the preservation of the ionic balance of the brain 
microenvironment, presents a challenge in the field of drug delivery. While some small 
molecular weight, lipid-soluble drugs can penetrate the CNS. Large molecular weight, 
macromolecular therapeutic agents, such as antibodies, proteins, DNA and RNA 
therapies are limited in their ability to cross into the brain to elicit the desired therapeutic 
effect. The use of targeting ligands have been shown to interact with known putative 
receptors on BMECs, to increase delivery of a therapeutic across the BBB. 
1.1 Biologic Macromolecules and their role in the CNS 
Disorders affecting the CNS are placing an increased burden on healthcare systems 
around the world. Due to ageing populations across the world, the occurrence of CNS 
disorders has grown and is projected to be the second leading cause of death globally in 
2030 (Mathers and Loncar 2006). Neurodegenerative diseases such as Parkinson’s 
disease, Alzheimer’s disease, multiple sclerosis and conditions like CNS cancers all 
contributing to the pressures of CNS disorders. In Europe in 2010, 38% of all Europeans 
were reported to have suffered from some form of CNS disorder (Olesen et al. 2012). A 
study into the leading causes of death in the UK in 2013, by the Office for National 
Statistics, found Dementia and Alzheimer’s disease to be the leading cause of death in 
Women of all ages, and the third highest cause of death in men (ONS 2015).  
Despite the burden of CNS disorders, the current clinical treatments are lacking in 
therapeutic output. Small molecule therapeutics offer a method to relieve symptoms of 
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the CNS disorders. However, the disease modifying effects are limited when these 
approaches. Substantial funding opportunities are available for CNS research; however, 
despite this, there is still a disconnect between in vitro and pre-clinical efficacy studies, 
with the clinical, patient setting. This may be due to the increased complexity of human 
brains, compared to the animal models used in pre-clinical work and the complexity of 
the neuronal networks of the brain. 
It is widely accepted that to have a disease modifying effect in chronic conditions requires 
intervention with a biological therapeutic. Biological therapeutics are typically large 
molecules, such as peptides, proteins (antibodies), DNA or RNA, that can correct the 
disease phenotype and restore normal functioning of a cell/tissue. The effects may include 
reducing protein levels within the CNS (Aβ protein – Alzheimer’s Disease), prevent 
interaction from taking place in a cell signalling event, induce the production of a new or 
correct the form of a protein to correlated to a given disease. 
For the treatment of Alzheimer’s Disease, several macromolecular approaches have been 
shown to have efficacy in vitro, including the anti-BACE-1 antibody of Roche, siRNA 
targeted therapies. These mechanisms have demonstrated in vitro efficiency in reducing 
disease causing Aβ protein. However, used alone in vivo are limited in their efficacy. Due 
to the restrictive nature of the BBB, restricting the entry of large biological therapeutics 
to the brain. Typically, untargeted therapeutic antibodies, only show 0.1-0.2% of injected 
dose reaching the CSF (Poduslo et al. 1994). To improve the delivery efficiency of 
biologics into the CNS a “shuttle” mechanism or a targeting approach is required to 
overcome the barriers to CNS entry. 
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1.2 Components of the Neurovascular Unit 
  
 
1.2.1 Brain Microvascular Endothelial Cells 
The BMECs are the primary barrier cell type within the NVU, providing both a physical 
and chemical barrier to the passage of molecules from the blood into the brain 
parenchyma. Unlike the capillary networks of peripheral organs, the microvasculature of 
the brain displays several unique, phenotypic characteristics. These include the presence 
of tight and adherens junctions between adjacent BMECs, leading to the almost complete 
closure of paracellular pathways between cells. And a lack of fenestration in the cerebral 
capillaries.  
Tight junctional (TJ) complexes comprise Claudins, Occludins, Junctional Adhesion 
Molecules (JAM) and Zona-Occludens (ZO-1, -2, -3) proteins. Claudins and occludins 
Figure 1.1: The structure and composition of the 
Neurovascular Unit 
The neurovascular unit (NVU) is centred around the endothelial cells and the 
capillary lumen of the micro vessels. However, these cells are only one part of 
the NVU. The diagram highlights the close interaction with the multiple cell 
types of the NVU. Pericytes are in direct contact with the endothelial cells and 
the surrounding astrocyte endfoot processes are the main contributors to the BBB 
phenotypes. Other neuronal processes and microglial cells are also having a role 
in NVU formation and normal functioning. Adapted from Abbot et al (2006). 
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are closely associated and extend into both the cytosol and the extracellular space. These 
molecules recognise claudins and occludins on adjacent cells to form the apical limit of 
the tight junction (Yaffe et al. 2012; Piontek et al. 2008). It has been shown 
phosphorylation of the intracellular domains of occludin molecule, by receptor-mediated 
processes, regulates the restriction of paracellular permeability across a tight junction 
(Murakami et al. 2009; Wong 1997). Additionally, the removal of calcium from the 
extracellular domains of occludin causes the loss of tight junction restriction.  
The family of claudin molecules are proteins consisting of 4 transmembrane domains, 
which form the barrier properties of the tight junction. Within BMECs, claudin-3 and 
claudin-5 are mainly expressed, with claudin-12 also thought to be expressed within 
endothelial cell tight junctions (Morita et al. 1999; Soma et al. 2004; Schrade et al. 2012). 
Studies in vitro show that  the addition of exogenously expressed claudin-5 to BMEC 
cultures, decrease paracellular permeability and increase the trans-endothelial electrical 
resistance (TEER) of the culture model (Coyne et al. 2003). Further, claudin-5 is known 
to contribute to early-stage angiogenesis within the CNS (Escudero-Esparza et al. 2012). 
The intracellular, C-terminal domain of claudin molecules interacts with the Zona 
Occludins proteins, facilitating cytoskeletal rearrangement and cell polarisation. 
Basolateral to this, junctional adhesion molecule, JAM-1, is highly expressed in BMECs, 
whereas other members of the JAM family (JAM-2, JAM-3) are expressed throughout 
the cardiovascular system. JAM-1, contains an immunoglobulin like extracellular 
domain, within a single intracellular chain facilitating interaction with ZO-1, AF-6, 
cingulin and Cas kinase (Ebnet et al. 2004; Ozaki et al. 2000). The extracellular loops of 
JAM-1 use hydrophobic interactions to associate with molecules on adjacent cells. 
Within the cells, the ZO proteins interact with the cytosolic regions of the tight junctional 
proteins. ZO proteins contain multiple domains for signal transduction. Within the ZO-1 
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protein, the PDZ-domain is vital for the interaction with the intracellular domains of 
claudins and JAM-1 (Ebnet et al. 2000), while the SH3 domain allows a connection with 
the cytoskeletal proteins (Balda et al. 1996). Dissociation or removal of the ZO-1 protein 
from the tight junction complex of BMECs causes a reduction in TEER and the increase 
in paracellular permeability across the barrier (Mark and Davis 2002; Van Itallie et al. 
2009). Additionally, the interaction of ZO-1 with claudin is required for the claudin 
polymerisation seen within tight junctions. The cytoskeletal arrangement allows for the 
segregation of apical (blood plasma) and basolateral (brain parenchymal) membranes and 
cell polarisation. 
Within BMECs further proteins including cingulin, AF-6 and 7H6 also interact with the 
tight junctional complexes to further facilitate a restriction in the paracellular 
permeability across BMECs (Satoh et al. 1996; Cordenonsi et al. 1999). This is done 
through either direct interaction with TJ proteins or increasing the presence of co-factors 
essential for TJ regulation. The knockdown or removal of these proteins from BMECs 
and other barrier cell lines has shown to reduce TEER. 
To further restrict the paracellular pathway between BMECs, adherens junctions (AJs), 
form an unbroken link between adjacent cells. This link between the cells facilitates the 
formation of the tight junctions, discussed above. The main protein involved within AJs 
are cadherins, a transmembrane glycoprotein. Cadherins form Ca2+ dependent 
interactions with cadherin on the surface of neighbouring cells (Gumbiner and Simons 
1986; Heimark et al. 1990). The intracellular domain of cadherin proteins interacts with 
several anchor proteins, belonging to the Armadillo superfamily. These include β-catenin, 
γ-catenin and p120 (Dejana et al. 2008). Between endothelial cells specifically cadherin 
5 is found in AJs, this member of the cadherin family is also known as VE-cadherin 
(vascular endothelial). Expression of VE-cadherin is a phenotypic characteristic of 
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endothelial cells. The catenin molecules also contain an actin-binding domain to link the 
adherens junction with the cytoskeleton. β-catenin binds to several growth factor 
receptors. When stimulated β-catenin complexes dissociate and translocate away from 
the cell membrane, this causes the breakdown of the AJs between BMECs increasing 
paracellular permeability (Nagafuchi 2001). Without the presence of AJs between 
BMECs, the formation of tight junctions would not be possible, and therefore the physical 
barrier associated with the BBB cound not be formed (Dejana 2004). 
The restrictive nature of the cell-cell junctions between BMECs at the BBB produces a 
physical barrier to the entry of substrates into the brain parenchyma. However, this alone 
is not enough to maintain the privileged microenvironment of the brain. BMECs also 
exhibit several other traits which aid in limiting access of substrates to the CNS. An 
example of this would be the low rate of endocytosis which occurs within BMECs in 
comparison to the peripheral vasculature. The BBB has a chemical barrier, consisting of 
metabolic enzymes, to break down unwanted substrates, as well as efflux transporters to 
remove lipophilic drugs and metabolites from the BMECs before they can reach the CNS. 
The efflux transporter on BMECs and the other cells of the neurovascular unit are critical 
in the maintenance of the homeostatic environment of the CNS. While also preventing 
many potentially therapeutic agents from entering the CNS. Chief among the transporters 
of the CNS are the ATP-binding cassette (ABC) transporters, more specifically P-
glycoprotein (Pgp). Expressed on the luminal membrane of BMECs, Pgp, has been shown 
to limit the uptake of antipsychotic agents to the CNS (Laduron and Leysen 1979). In 
addition to this, anti-viral drugs, including acyclovir and saquinavir, are prevented from 
entering the CNS by the Pgp protein. Knockout of the Pgp produced an increase in CNS 
penetration of antiviral drugs in mice, compared to wild type animals (Kim et al. 1998). 
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Other ABC transporters on the luminal membrane of BMECs include breast cancer 
resistance protein (BCRP) (Cooray et al. 2002). BCRP has been shown to have a critical 
role in limiting the penetration of chemotherapeutic agents, such as methotrexate, across 
the BBB and brain-tumour barriers in neuroblastoma, glioblastoma and brain metastases, 
preventing imatinib and topotecan from effectively treating tumours (de Vries et al. 
2007).   
  
Another large family of transporters found on the cell surface of BMECs are the organic 
anionic transporters (OATs) and organic cationic transporters (OCTs). These are solute 
Figure 1.2: Transporter Localization at the BBB 
This highlights some of the major transporter proteins present on BMECs 
and the direction in which they translocate their substrate. The breast 
cancer resistance protein (BCRP), P-glycoprotein (Pgp) and multidrug 
resistance protein 4 (MRP4) are ATP-Binding Cassette (ABC) proteins, 
shown in yellow. The organic-anion-transporting polypeptide 
(OATP1A2) is shown in purple as it is an influx transporter. While the 
OAT3 efflux transporter is shown in pink. Adapted from Dalvi et al 
(2006) Figure 3. 
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carriers that can transport compounds in different directions based on the sub-type. OATs 
are responsible for the removal of metabolic byproducts from the CNS, which includes 
metabolised neurotransmitters and uric acid (Koepsell and Endou 2004). In contrast, 
OCTs regulate the removal of negatively charged waste products, such as those 
containing chloride ions. In the BBB, OAT3 has been shown to be localised to the 
basolateral and apical cell membranes to facilitate waste clearance from the CNS (Mori 
et al. 2003). 
Not all transporters at the BBB remove drugs from the brain, the organic anionic 
transporting polypeptide 1A2 (OATP1A2, Figure 1.2 - purple) facilitates the transport of 
some drugs, including synthetic peptides, from the brain capillaries into the brain 
parenchyma (Urquhart and Kim 2009). However, mutations in this transporter can vary 
the levels of CNS exposure of certain drugs. One study showed that such a mutation could 
increase methotrexate delivery to the CNS by 2-fold, which caused severe damage to 
neurones and CNS pathology (Sioka and Kyritsis 2009). 
It is the combination of physical and metabolic features that allows the BMECs of the 
BBB to form such a restrictive barrier to the CNS. However, for this differentiated 
phenotype to occur, the role of the surrounding cell types and the interaction between 
them is critical. 
1.2.2 Astrocytes 
The restrictive phenotype displayed by the BMECs of the neurovascular unit (NVU) 
would not be possible without the interaction with multiple cell-types within the CNS. 
The astrocyte endfoot processes are basolateral to the endothelial cells and surround the 
microvasculature of the CNS, creating a perivascular channel around the vessels of the 
CNS. The perivascular endfoot of astrocytes contain aquaporin 4 (AQP4) water channels 
and Kir4.1 K+ channels. These are involved in the regulation of fluid volume around the 
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microvessels (Fukuda and Badaut 2012). And the expression of these channels is related 
to the production of proteoglycans in the basal lamina, for support of the BMECs. The 
expression of the AQP channels and differentiation of the endfoot processes requires 
exposure to agrin, released from BMECs.  
Astrocytes release several modulation factors, including the growth factors: transforming 
growth factor-β, glial-derived neurotrophic factor, basic fibroblast growth factor (bFGF) 
and angiopoietin 1. These factors are known to act on BMECs in differentiation to induce 
the restrictive phenotype of the BBB. Astrocytes also release small molecule mediators 
of vascular tone and diameter, including nitric oxide and prostaglandins, to control 
localised blood flow within the CNS (Gordon et al. 2007; Iadecola and Nedergaard 2007). 
Astrocytes serve as the link between neuronal synaptic signalling and the local 
vasculature creating changes in blood flow to react to neuronal stimulation (Attwell et al. 
2010). In disease states, such as stroke and epilepsy, the functioning of astrocytes may be 
altered. In vitro models of ischemic stroke demonstrated that secreted astrocytic factors, 
from the C6 cell line, altered the expression of tight junctional proteins in BMECs 
(Neuhaus et al. 2014). This work also showed the impact on ABC efflux pump expression 
in the BMECs in hypoxic vs. normoxic conditions. In epilepsy, astrocyte expression of 
AQP4 is decreased, and as such the presence of Kir K+ channels at the astrocyte endfoot 
is also reduced (Binder et al. 2006). This compromises the brain parenchyma, as K+ ions 
within the local parenchyma remain elevated for a prolonged time following electrical 
stimulation. This causes altered osmolarity of the extracellular environment of the CNS 
which will impact on the regulation of vascular tone. 
1.2.3 Pericytes 
Pericytes are present to differing levels in vasculature of multiple tissue types around the 
body, with the greatest coverage of the vasculature seen with the CNS. Here, pericytes 
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are another cell type surrounding the microvasculature of the brain, forming the 
neurovascular unit. As with astrocytes, pericytes have a critical role in the development, 
functionalization and stabilisation of the NVU. Pericytes are a smooth muscle-type cell 
that surrounds the endothelial cells and has a direct function in regulating the vessel 
diameter in response to neuronal and astrocytic stimulation. The presence of pericytes, in 
other tissue vasculature, is more likely to occur at vessel junctions and bifurcations. 
However, in the CNS coverage of the abluminal surface of the brain microvasculature 
can be as high as 99% in some regions of the CNS (Dalkara et al. 2011). Surrounding 
BMECs, pericytes strictly regulate the tight junctional integrity and vesicular transport 
rates of BMECs.  
Dysregulation of pericytes and CNS disorders are closely linked. For example, in 
ischaemic stroke contraction of the pericytes around the BMECs restricts blood flow into 
regions of the brain around the damaged area. Pericytes themselves require changes in 
intracellular Ca2+ levels to regulate their contractility. Exposure to external factors, such 
as reactive oxygen species (ROS), can induce uncontrolled changes in Ca2 within the 
pericytes, leading to excitotoxicity and excess contractility, reducing local blood flow. 
This is particularly prevalent in ischemic conditions and has been demonstrated in mouse 
models of ischemic stroke (Yemisci et al. 2009). In neurodegenerative disorders, such as 
Alzheimer’s Disease, pericytes have been observed to behave as macrophages, clearing 
amyloid toxin from perivascular regions (Sagare et al. 2013).  
1.3 In vitro models of the BBB 
1.3.1 Primary vs Immortalized vs IPSC Cell models 
There is inherent difficulty in studying the in vitro transport of drugs across BMECs. 
Almost all BMEC models, even in co-culture with astrocytes and pericytes, are 
considered to have “leaky” paracellular pathways. This is most profound when using 
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immortalised cell line models of BMECs (Gumbleton and Audus 2001; Deli et al. 2005). 
Data from in vivo studies of rat brain capillaries revealed a trans-endothelial electrical 
resistance (TEER) more than 1000 Ω.cm2 (Chrone and Olesen 1982; Crone and 
Christensen 1981). The apparent permeability of an in vivo endothelial monolayer to 
paracellular markers, such as sucrose, in a rat, was shown to range from 0.03 – 0.1cm.s-1 
(Rapoport et al. 1978). 
However, there are several BMEC models, used for the in vitro assessment of transport 
therapeutics across the BBB, which include both immortalised and primary cell cultures. 
TEER is often the key parameter described by users of such models; however, is prone to 
variation based on the electrode types and the measurement methodologies used. The use 
of paracellular markers, such as sucrose, dextrans or mannitol, allows for a more in-depth 
understanding of the integrity of the model barrier. And the relationship of the in vitro 
model to the in vivo reality.  BBB models extend beyond a simple culture of the BMECs 
(Bowman et al. 1983), to co-cultures, with several additional cell lines (astrocytes and 
pericytes). Other studies also include the use of switch media (hydrocortisone and 
phosphodiesterase inhibitors) that transiently increase the paracellular resistance of the 
systems (Hoheisel et al. 1998; Cucullo et al. 2004).  As a general trend, primary cell lines 
exhibit a high TEER value in comparison to immortalised cells, such as the b.End3 mouse 
cell line (Omidi et al. 2003; Smith et al. 2007). The co-culture systems again have been 
shown to increase TEER and decrease in the permeability of paracellular markers (Li et 
al. 2010).  
There are various ways to create a co-culture system involving BMECs and astrocytes.  
The most basic of these is using astrocyte conditioned medium (ACM) which is used in 
the culture media of BMECs, grown on semi-permeable membrane inserts such as 
Transwells™. In this way, ACM can modulate the phenotypic characteristics of the 
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BMECs. The ACM contains growth factors and other chemical mediators released by the 
astrocytic cell line to regulate BBB permeability (Yamagata et al. 1997; Sobue et al. 
1999); a process mimicking the in vivo situation. More advanced co-culture systems 
involve the pre-seeding of astrocytic cell lines, either onto the base of the culture plate 
well plate or the basal surface of the inserts themselves. The astrocytes are allowed to 
grow until confluence, and then the BMECs are seeded onto the apical surface of the 
inserts (Gaillard et al. 2001).  All of these models have been shown that astrocytes or 
astrocyte-released factors enhance the expression of the phenotypic markers of brain 
endothelial cells such as ZO-1, claudins and Pgp (Omidi et al. 2003; Huber et al. 2001; 
Nitz et al. 2003).  
The discovery and use of human induced pluripotent stem cells (iPSCs) in research have 
allowed for the differentiation of these cells into almost any other cell type of the body. 
The iPSC cells will differentiate based on the microenvironment they are grown in, 
including the generation of a neurovascular unit, derived from the iPSCs of an individual. 
In the long-term, generation of barrier models using healthy and disease state iPSCs 
which will allow for greater understanding of the disease phenotypes and inter-patient 
variability in barrier functionality. This has allowed for the development of multiple 
methods for the differentiation and culture of iPSC derived human brain endothelial cells. 
In the simplest studies, iPSCs, in embryoid bodies, undergo spontaneous differentiation 
into endothelial cells. However, the efficiency of differentiation increased by the addition 
of growth factors, including bFGF, vascular endothelial growth factor (VEGF), and low 
serum media. Also, Lippmann et al. (2012), showed that culturing the iPSCs on a 
collagen/fibronectin extracellular matrix lead to the development of an endothelial cell 
phenotype (Lippmann et al. 2012). Other differentiation methods include the culturing of 
the stem cells with neuronal cell-types. The hypothesis here is that the neuronal cells act 
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to complete the differentiation of the endothelial cells to BMECs. Co-culture in this way 
has been performed through the direct mixing of cell-types and subsequent selection of 
the BMECs from the resultant cell pool. The development of sequential differentiation 
protocols such as the Lippmann protocol, and other protocols have made the formation 
of iPSC-derived BMECs standardised and easy to replicate (Lippmann et al. 2012; 
Lippmann et al. 2015). 
Having established protocols for BMEC differentiation, work has begun to study the 
effect of neurodegenerative conditions, on the phenotype of BMECs in patients. Most 
recently, a study of the transcriptome of Huntington’s disease cells vs “healthy” iPSC-
derived BMECs revealed deficits in angiogenic and barrier properties of the cells (Lim et 
al. 2017). The loss of functionality includes a reduction in the capabilities of the BMECs 
to efflux foreign molecules from the CNS.  
When compared to immortalised cell lines, iPSC-derived BMECs show greater 
paracellular restriction, reflected in increased TEER values. Monoculture of the iPSCs-
derived BMECs show TEER values more than 250 Ω.cm2, which rises to over 1500 
Ω.cm2 when grown in culture with astrocytes and pericytes (Lippmann et al. 2012). The 
permeability of sucrose showed a 100-fold decrease in iPSCs compared to the 
permeability in hCMEC/D3 cell model (Culot et al. 2008). With these characteristics are 
maintained throughout the lifetime of the iPSC cells.  
Protein markers of BMECs allow for validation of a cell-based model for the study of 
trafficking events in vitro. A study comparing multiple, different iPSC-derived BMECs 
found that vascular endothelial markers, such as PECAM-1 and VE-cadherin generally 
showed increased expression compared to hCMEC/D3 cells (Patel et al. 2017). However, 
the BMECs derived from the CTR54F stem cell line showed lower expression of these 
markers, and lower expression of Glut-4, and the ABC transporters ABCB1, ABCC1 and 
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ABCG2. The CTR54F stem cell line also showed a lower TEER value than the 
hCMEC/D3 cells. Highlighting the heterogeneity of patient-derived samples. 
Overall it seems likely that in the coming years a shift will be made towards the use if 
iPSC-derived BBB models over immortalised and primary cell lines. The iPSCs offer the 
advantage of allowing for the creation of disease-specific BBB models to examine the 
pathophysiology of the BBB in association with CNS disorders. Allowing for a more 
tailored approach to treatment strategies to restore normal CNS and BBB phenotypes. 
However, it must also be considered that, while the iPSC cells have been effective in 
recreating models of the BBB in Huntington’s Disease, a mono-factorial disease. It is yet 
to be established if these cell models may be used to recreate the conditions of more 
complicated, multi-factorial diseases, such as Multiple Sclerosis, from patient stem cells. 
1.3.2  Co-culture, microfluidic models of the BBB 
The capillary endothelial cells of the BBB form a highly restrictive barrier to the entry of 
therapeutics into the CNS. Surrounding BMECs are astrocyte end-foot projections and 
pericyte cells. It is the crosstalk between these cell types that produce the characteristic, 
physical and metabolic barrier that is seen at the BBB. Mechanistically, promising 
therapeutics, for the treatment of CNS disorders, often fail in clinical trials due to an 
inability to reach efficacious levels within the CNS.  
In CNS research, the long-established, preferred method of studying drug delivery to the 
brain has been in vivo studies in rodents. They offer the benefit of allowing the studies to 
take place in the physiological microenvironment of a live brain. However, rodents and 
other animals are not humans, and drug candidates that showed promise in vivo, often go 
on to lack clinical efficacy in human trials (Perel et al. 2007). Due to the increased ethical 
considerations associated with animal research, there has been a shift to establish a cell-
based approach, in vitro, to allow for the screening of drug candidates. Drug delivery 
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research is continually looking to improve the in vitro models available, to mimic, more 
closely, the physiological conditions of patients and thus reducing the failure of 
therapeutics in clinical trials. 
Traditionally, in vitro BBB models, have been static systems, with endothelial cells 
grown on either plastic, glass or semi-permeable membranes (Transwells), with probes 
applied to the apical surface and uptake or permeability studied. These systems looking 
at uptake and loss from endothelial cells only give one aspect of the puzzle, especially 
with regards to brain delivery. The static models have proved useful tools in research, but 
their departure from the physiological conditions around the endothelial cells of the 
neurovascular unit often leads to discrepancies between in vitro and in vivo work. To 
progress from the monoculture of BMECs, co- or tri-culture methodologies have been 
developed to culture the BMECs in “close” proximity to astrocytes and pericytes, using 
the Transwell system. Endothelial cells are grown on the apical side of the Transwell 
insert, with astrocytes and pericytes grown in the basolateral chamber or directly onto the 
basolateral membrane of the inserts. Studies using these multi-cellular systems have 
demonstrated increases in the trans-endothelial electrical resistance (TEER) across the 
monolayer. However, despite being demonstrated in multiple cell models, these values 
are still significantly outside the in vivo TEER ranges, reported in a review by Wolff et 
al. (2015). Other markers of physiological restriction include sucrose and mannitol 
permeability. These are often seen to be 10-100 times lower in vitro models than reported 
in vivo values. 
Static BBB models inherently lack the circulation of fluids across cell surfaces. Both the 
luminal blood flow in the capillaries, the perivascular drainage of fluid outside the blood 
vessels, between the endothelium and astrocyte end-foot processes and circulation of 
interstitial fluid within the CNS itself. The blood-flow has significant physiological 
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effects on all endothelial cell types, regardless of tissue type, through mechanoreceptor-
mediated differentiation mechanisms.  It is known that the number of caveolae pits, at the 
luminal membrane of endothelial cells is influenced by the flow-rate of blood in 
circulation (Rizzo et al. 2003). As many surface receptors associate to caveolae and 
caveolin-mediated endocytosis is the second most common endocytic pathway, their 
presence on BMECs will undoubtedly influence the validity of drug delivery data from 
any in vitro models. In models of aortic endothelium, the increase in caveolae is believed 
to facilitate the adaptation of the endothelial cells to mechano-transduction signals (Rizzo 
et al. 2003). Other work has shown that the surface expression of adhesion molecules on 
the surface of HUVEC cells is influenced by the flow-rate and the turbulence across the 
endothelial cell surface (Khan and Sefton 2011; Morigi et al. 1995; Huang and Eniola-
Adefeso 2012). Shear-stress across endothelial cells is also known to impact on the 
cytoskeletal arrangement and the expression of polarising proteins, including those of 
tight junctions (Cucina et al. 1995; Frame and Sarelius 2000; Loufrani and Henrion 2008). 
Without shear-stress across the surface of BMECs, they are unable to completely 
differentiate and produce the BBB-phenotype, and the cell-based model lacks fidelity in 
the results generated from it.  
Flow over BMEC cultureswas first created using a rotating device, which was placed into 
the apical compartment of the Transwell system (Dewey et al. 1981). However, this 
model was widely refuted and short-lived, due to the variations in the shear-stress across 
the endothelial monolayer, affected by the distance from the centre of the dish (Wolff et 
al. 2015). The lack of control and uniformity in shear stress and the lack of co-culture 
data within this system led to this model’s discontinuation. Other early methods to 
generate flow across BMECs in permeability studies also included the use of rotary plate-
shakers to circulate fluid over the BMECs.  
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In an attempt to better mimic blood-flow in vivo, recent research work has focused on the 
creation and development of microfluidic devices. These are narrow channels, into which 
the BMECs can be seeded. Once cells have adhered to the growth surface, it is possible 
to then modulate the flow across them, recreating the shear-stress conditions the BMECs 
would typically experience in vivo. By using peristaltic or syringe pumps, it is possible to 
re-create physiological shear-stress across the BMECs in the capillary vessels of the brain 
(10-20 dynes/cm2) (Kamiya et al. 1987).  
In the simplest form, these microfluidic devices will be a single channel for the 
monoculture of BMECs, while exposed to flow over a cell surface. This system allows 
for direct measures on the influence of shear-stress on the physiology of BMECs. 
Biochemical and fluorescence microscopy assays on cells exposed to flow enables direct 
comparisons between the flow and static models. Comarison allows the quantification of 
changes to cell protein levels and the distribution of cellular proteins.  
Improvements in the manufacturing methodologies, of microfluidic devices, have 
allowed for the creation of devices, with bifurcating channels, where the flow is split at 
junctions. The bifurcations in the channel create turbulence over the endothelial cells and 
alter their behaviour further. More complex networks can be formed with multiple 
junctions, both separating and re-joining. One such example of the vascular network chips 
have been designed by the company SynVivo and has a customisable structure that allows 
for up to seven bifurcations within the channel.  Although these channels have been 
created, the direct effect on the BMECs has yet to be reported in the literature. Typically, 
these have been used to study leukocyte migration and endothelial interactions in vitro, 
as shown successfully by Morigi et al. (1998) Studies in vivo looking at the neurovascular 
unit have demonstrated the importance of the bifurcations in the regulation of capillary 
tone and cell distribution. Typically, pericytes are seen surrounding endothelial cells at 
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vessel bifurcations, its believed these regulate the flow within specific regions of the 
brain. Within animal models of cardiac arrest, the pericytes at “early”-generation 
capillary junctions show increased contractility to reduce vessel diameter (Glyn and Ward 
2000). 
1.3.3 Microfluidics with multiple channels for co-culture models 
Having established that simulated flow, over cultured endothelial cells, causes changes in 
their phenotype and an enhancement of their BBB characteristics, several groups have 
looked to take this further and established co-culture systems for transport studies 
underflow.  These devices have often been custom-manufactured for the purpose; 
however, there is a growing number that have become commercially available. In these 
“chips” an apical channel is separated from a basolateral channel, at the point of overlap, 
by a semipermeable membrane. This partitioning of channels allows for endothelial cells 
to be grown in the apical-most channel and form a cell monolayer over the membrane, as 
happens in the Transwell model. However, in this case, the endothelial cells can be 
exposed to a simulation of vascular flow, to mimic microvascular capillary blood flow. 
The first 3-dimensional microfluidic model of the BBB was the DIV-BBB model 
(Cucullo et al. 2010). In this system, porous channels allow cells to be grown in the lumen 
and permeability to be measured outside of the simulated channels. The DIV-BBB model 
required a large density of cells for seeding (108 cells) to correctly fill the channels with 
cells. Measurements of TEER across endothelial cell monolayers, grown under flow 
conditions in this model was measured as 524 Ω.cm2, much higher than the static culture 
equivalent with the cell line (Cucullo et al. 2010). 
In 2012 Booth and Kim fabricated a much smaller, multi-channel microfluidic BBB 
model, known as the µBBB model (Booth and Kim 2012). This was the first BBB model 
to be made on a “chip”, meaning a reduction in size, without compromising the quality 
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of the output. The µBBB model was fabricated from PDMS polymer, using micro-etching 
to design and produce the channels. A semipermeable insert, between the channels, forms 
the barrier surface for TEER and permeability measures to be made across. The 
fabrication technique allows for low channel volumes (~20 µl of buffer). Co-culture 
systems can be easily setup to add astrocytes “below” the endothelial cells, to more 
accurately represent the in vivo setting. The fabrication techniques used in this chip device 
means cells in the basolateral chamber are within 400 µm of the endothelial cells in the 
apical channel. The ability to maintain cells underflow in the µBBB chip improves the 
barrier characteristics of BMECs with TEER values of 250 Ω.cm2 using the b.End3 cell 
line, ten-fold greater than static culture with these cells (Booth and Kim 2012). The 
permeability of the paracellular probe, dextran, was reduced in the µBBB system. 
However, the permeability values attained were still significantly higher than in vivo, 
suggesting further optimisation was required, but this could have been due to the choice 
of cell line. If a primary cell line was used here in the microfluidic device, these 
permeability values may have been closer to in vivo. The µBBB chip has been used to 
test the permeability of several CNS therapeutics, showing a decrease in permeability of 
all drugs compared to static culture (Booth and Kim 2014). Highlighting how flow-based 
culture systems may decrease the gap between in vitro and in vivo research of the BBB. 
SyM-BBB model, created by Prabhakarpandian et al. (2013) has a different architecture 
to the earlier Booth and Kim µBBB model. The SyM-BBB chip has a broad central 
channel and a narrower outer channel separated by columns to form a semi-permeable 
barrier. The columns have a greater depth than the membrane used in other models but 
allow for cells to grow on all surfaces of the channel, to create a 3D vessel, through which 
flow can be simulated. RBE4 cells grown in these channels showed increased expression 
of tight junctional proteins (ZO-1 and claudin-1) as well as an increase in P-gp expression 
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compared with cells grown in Transwell (Prabhakarpandian et al. 2013). Additionally, 
the permeability of 5 kDa dextran across the SyM-BBB monolayer was 10-times less than 
the permeability in Transwells. The fluid capacity of this BBB chip is greater than the 
µBBB model. However, allows for improved coating of the device with collagen and 
fibronectin, to form a basement matrix and further support cell growth (Booth and Kim 
2012). The SyM-BBB models have advantages over other microfluidic models in that it 
allows for microscopy of cells grown under flow, without destruction of the chip.  
The refinement of 3D-printing technology has allowed for the creation and fabrication of 
more complex devices and templates for devices.  Using this fabrication method has 
enabled the creation of microfluidic channels in a collagen hydrogel (Kim et al. 2015). 
By printing the channel structure as a series of aligned, cylindrical channels into a 3D 
frame, with a space between the inlet and outlet sides, for needles to be inserted which 
span the gap in the channel. Collagen matrix can be poured around these needles and 
jellified to form pores through the centre of the matrix. The needles can be removed to 
form a hollow lumen through the hydrogel into which endothelial cells may be seeded. 
The use of hydrogel matrices for modelling the BBB have several advantages over other 
microfluidic and static culture models. Firstly, the hydrogels support cell-growth and 
homeostasis for longer periods of time, meaning BMECs can be cultured in this way for 
weeks not days. Secondly, it is possible to introduce neuronal, astrocytic or pericytic cells 
into the matrix to create a neurovascular unit with all cell types in direct contact. 
Hydrogels have been used in this way in several over articles to create a 3-dimensional 
neurovascular unit within the matrix (Cho et al. 2015; Kohn et al. 2015). The combination 
of multiple cell types in this way allows for studies into the brain-tumour barrier and 
chemo-attractive drugs on cells within the matrix (Prabhakarpandian et al. 2015). 
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1.4 Cellular Trafficking 
Owing to the highly restrictive nature of the BBB, it is widely accepted that for 
macromolecular and nanoparticulate therapeutics to be effective in treatment of CNS 
disorders some form of cellular trafficking must occur across BMECs. With the high 
density of capillaries throughout the brain, if a therapeutic can cross the BMECs it would 
be within almost direct contact with the target neuronal cells. Specifically, a therapeutic 
must undergo the process of transcytosis to gain access to the brain (see Figure 1.3). With 
respect to the BBB, transcytosis involves the endocytosis of the therapeutic at the luminal 
(blood) side of a BMEC. The sorting and transportation of the therapeutic through the 
endothelial cells to the basolateral membrane and its exocytosis into the brain 
parenchyma. Due to the high vascularization of the brain, a therapeutic released into the 
brain parenchyma is near the desired target site. 
 
Figure 1.3: Simplification of transcytosis and cellular trafficking 
pathways 
This is a schematic to show the potential trafficking routes of transferrin targeted antibodies. 
Following endocytosis at the luminal membrane, sorting within the endothelial cell can lead 
to: recycling back to the luminal membrane, lysosomal degradation (high affinity divalent 
antibodies), or transcytosis across the cells to the abluminal membrane.   
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1.4.1 Endocytosis 
Endocytosis is the active process of uptake into a cell, involving the movement of cellular 
membranes and cellular components, to form structures which are capable of 
internalization of extracellular material. It is required for the normal homoeostasis of 
cells, with cargos including nutrients, plasma proteins, ligand bound to receptors. 
Pathogenic organisms are also able to enter cells by this process.  
Endocytic events can be classified by the intracellular proteins associated with the vesicle 
formation. Clathrin-mediated endocytosis (CME) occurs at clathrin-coated pits. Here the 
clathrin triskelion assembles around adaptor proteins (AP) which link the cell surface 
receptors with the clathrin proteins. Briefly, the process involves: 1) initial invagination 
of the vesicle at the cell membrane (Henne et al. 2010). 2) Adaptor protein association 
with the intracellular domains of cell surface receptors (Stimpson et al. 2009). 3) 
Assembly of clathrin proteins onto the APs and the formation of the clathrin-coated pit 
(Saffarian et al. 2009). 4) Dynamin-mediated cleavage of the vesicle from the plasma 
membrane, to bring the vesicle entirely within the cell (van der Bliek et al. 1993). 5) 
Clathrin proteins dissociate from the vesicle surface to allow for interaction with 
intracellular compartments (Taylor et al. 2011). The vesicles formed by CME are 
typically between 100-200nm in size; due to the limitations of the clathrin network 
coating the vesicle. The process of CME is believed to occur in the majority of eukaryotic 
cell types as the predominant endocytic mechanism. The archetypal receptor that 
undergoes CME is the transferrin receptor, used by cells for the internalisation and 
recycling of the transferrin protein and the delivery of iron into the cells. 
Partitioning of plasma membrane lipids, through non-enzymatic and non-protein-based 
processes, allows for the formation of “lipid rafts” which contain specific lipids. The main 
classification of these lipid rafts are those which contain the caveolin family of proteins 
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(Caveolin-1, -2 and -3). Numerous proteins associate with caveolin in these lipid rafts, 
including src, protein kinase C and actin.  Caveolin-mediated endocytosis occurs at pits 
formed in lipid rafts of the plasma membrane (Figure 1.4). The formation of caveolin pits 
in endothelial cells is directly related to the uniformity and strength of flow across the 
luminal membrane of the cells (Rizzo et al. 2003). Caveolin-1 forms multimeric 
complexes at the cell membrane (14 – 16 monomers/complex) and in association with 
cavin form the curvature of the caveolae pits (Nabi 2009). Scission of the vesicle from 
the cell membrane is done by the dynamin protein, and once within the cytosol, fusion to 
other cellular trafficking compartments is through vesicle-associated membrane protein-
2 (VAMP-2) and synaptosome-association protein (SNAP). Perhaps, the most 
advantageous feature of caveolin-mediated endocytosis is its ability to bypass the 
lysosomal compartment of cells. Caveolin-mediated endocytosis is therefore associated 
with several pathogenic organisms and toxins that need to avoid lysosomal degradation 
to elicit a cellular response, including cholera toxin B and Shiga toxin. However, both 
toxins also utilise other endocytic mechanisms to enter cells.  
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In the nanoparticle delivery across biological barriers field, the ability of a trafficking 
pathway to avoid lysosomal degradation is an advantageous feature of a delivery system. 
If more of the cargo can cross the barrier, without being degraded, then the therapeutic 
effect will be higher at the target site (Oh et al. 2007). 
Of the remaining endocytic pathways in eukaryotic cell biology, the most relevant to 
consider for BBB delivery would be macropinocytosis (fluid phase endocytosis). 
Macropinocytosis, involves the rearrangement of the actin cytoskeleton of cells, at the 
plasma membrane, to cause membrane ruffling (Lim and Gleeson 2011). In this process, 
molecules do not require contact with the cell membrane or surface receptors to be 
internalised. Instead, the ruffling of the plasma membrane traps extracellular fluid with 
the molecules in and internalised it into the cell. This method is believed to be the main 
route of entry into the CNS, for the plasma protein albumin, which has no known 
receptors on BMECs (Smith and Gumbleton 2006). The process of macropinocytosis can 
Figure 1.4: Endocytosis mechanisms 
The above is a simplification of the endocytic mechanisms within eukaryotic cells. 
While other endocytic processes exist, these three: Macropinocytosis (yellow 
triangles), clathrin-mediated endocytosis (blue circles) and caveolin-mediated 
endocytosis (purple pentagons) are the main focus of this work. Adapted from Figure 
1. Mayor and Pagano 2007. 
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be triggered by activation of the EGF receptor to induce increased membrane ruffling and 
formation of lamellipodia, some of which fold back on themselves and close (Kerr et al. 
2006). This creates a vesicle with a non-uniform shape, typically larger than 200 nm in 
diameter that can be internalised (Racoonsin and Swanson 1993; Lim and Gleeson 2011). 
However, constitutive membrane turnover can also allow for macropinocytosis to take 
place.  
Due to the non-specificity of macropinocytosis, it is a commonly exploited route of entry 
of pathogens (bacteria and viruses) (Mercer and Helenius 2008). With some bacteria able 
to induce membrane ruffling and gain access to host cells for survival and replication 
(Alpuche-Aranda et al. 1994). The endocytosis of the complex sugar molecule dextran is 
another example of macropinocytosis. Once within cells, as dextran does not have a 
molecular target, it initially distributes itself across all endocytic compartments (within 2 
hours of uptake). However, if left for longer it will accumulate in lysosomal 
compartments, for degradation, as dextran cannot direct its distribution in the cell. As 
fluid is “turned-over” and sent for degradation, so dextran accumulates in the lysosomes 
(Lencer et al. 1990). This property of dextran makes it a highly useful tool in the analysis 
of cellular trafficking and compartment localisation of potential transcytosis-mediating 
ligands.  
1.4.2  Exocytosis 
For drug delivery to occur across the BMECs cargos that have been internalised into the 
endothelial cells at the lumen surface must undergo exocytosis at the basolateral 
membrane of cells. Exocytosis has been extensively characterised in neuronal cell 
models, looking at the release of neurotransmitters at synaptic junctions. The proteins 
involved in exocytosis are seen to be derived from a common ancestral predecessor, 
which evolve to the gain specificity for the required role. Proteins are required for docking 
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of a vesicle with the cell membrane, vesicle priming (preparation for release), a signal to 
trigger release and finally the fusion of vesicle and cell membrane. 
The SNARE recognitition protein complex forms at the cell membrane for the docking 
of vesicles. Membrane-bound, syntaxin-1, associates with Munc18. Munc18 is necessary 
for the SNARE interactions, and if knocked out, causes complete attenuation of 
exocytosis from cells (Sudhof and Rothman 2009; Furgason et al. 2009). Ex-vivo studies 
of liposome fusion revealed how Munc18 selects the optimal structure of the R-SNARE 
complex for the zippering process (Shen et al. 2007; Xu et al. 2010). Recruitment of 
Munc18 by syntaxin-1 allows the complex to bind SNAP-25 (Fassshauer and Margittai 
2004). SNAP-25 can associate with the N-terminal region of the forming complex and 
has the capability of recognising up to two complexes at a given time (Fassshauer and 
Margittai 2004). Fusion to two syntaxin-1 complexes prevents the activation of further 
membrane fusion processes. To complete the recognition complex for vesicular binding, 
the Munc13 protein associates to the complex. Through interaction with vesicular Rab 
proteins, (rab3 and rab27) the Munc13 facilitates vesicular priming at the membrane. 
On a vesicle surface are the proteins synaptotagmin and synaptobrevin. When localised 
in the recognition zone of the SNARE complex, helical domains of synaptobrevin 
associated to syntaxin-1, forming a “groove” on the surface of the complex. Into this 
space, complexins can associate, to mediate the unzipping of the complex at the point of 
membrane fusion. However, this unzippering is dependent on completion of the complex 
with vesicular synaptotagmin. The synaptotagmin protein is modulated by calcium, with 
the ability to bind two molecules of ionic calcium. Calcium binding induces a 
conformational change in synaptotagmin and triggers the release of complexins and the 
unzipping of the complex (Vrljic et al. 2010). With the conformation of the proteins 
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before unzipping, the process of unzipping causes membrane fusion and exocytosis of 
vesicular content from the cell. 
The process of cargo exocytosis is required for transcytosis to take place. Without an 
ability to under exocytosis from the barrier cell type, a drug delivery system would be 
trapped at the barrier, unable to reach the target site.  
1.5 Nanoparticle Targeting Strategies for CNS delivery 
Due to the restrictive nature of the BBB and the efflux transporters present, a small 
proportion of all low molecule drugs are able to reach the CNS to have a therapeutic 
effect. The ability of large molecules, such as proteins and DNA therapeutics to cross 
BMECs is further restricted, due to their size, unless targeted in some way. Several 
methods have been developed, which fall into two categories: disruptive (non-specific) 
and targeted.  An invasive approach would involve direct injection of the therapeutic into 
the brain, either into the ventricular system of the brain or intracerebral injection (Bobo 
et al. 1994; Haley and McCormick 1957). Other disruptive methods would involve 
temporary disruption of the BBB, using osmotic modulators (bradykinin, mannitol) 
(Siegal et al. 2000), or ultrasound disruption (Sheikov et al. 2006). Although these 
methods allow for doses of drugs to be delivered directly into the CNS, invasive methods 
can involve complex surgical and are non-targeted methods, potentially causing adverse 
effects. To prevent this from occurring and reduce the risk, brain targeting of therapeutics, 
either in macromolecule complexes or on nanoparticles aims to improve safety and 
efficacy of brain delivery. 
The targeted, selective approach to delivery across the BBB can be through adsorptive 
mediated transport (AMT) or receptor-mediated transcytosis (RMT). Both of these will 
involve trafficking within the vesicle pathway of cells. In AMT, the surface charge of a 
nanoparticle allows it to interact with the cell membrane of the BMECs, positively 
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charged (cationic) particles can associate with anionic domains of the luminal membrane 
of cells (Hervé et al. 2008). Once internalised within the endothelial cells the vesicular 
trafficking will allow a small fraction of the internalised particles to reach the abluminal 
membrane and the CNS. Due to the non-targeted nature of this delivery mechanism, 
accumulation in the CNS by intravenous dosing is limited. However, AMT delivery has 
been demonstrated to be effective through intranasal delivery (Thorne et al. 2004).  
Receptor-mediated trafficking processes work on the principle that a targeting ligand on 
the surface of the particle can dock onto its receptor on the luminal side of the BMECs. 
The receptor binding will trigger the process of endocytosis, to form a vesicle within the 
endothelial cell containing the receptor-ligand-nanoparticle complex. Internalised 
particles are then able to undergo trafficking across the BMECs to the abluminal cell 
membrane. Here, vesicles containing the nanoparticles can fuse with the membrane and 
exocytose the contents into the CNS (Tuma and Hubbard 2003). 
Target receptors for RMT for CNS delivery include: transferrin receptor, insulin receptor, 
low-density lipoprotein (LDL) receptor, nicotinic acetylcholine receptor (nAchR), lamin 
receptor, leptin receptor, tetanus receptor (Fang et al. 2017). This is not an exhaustive list, 
however, it represents the most commonly targeted receptors for CNS delivery. A 
summary of the receptors and targeting ligands can be seen in Table 1.1. Targeting ligands 
themselves may be native ligands for the receptors (i.e. transferrin for the transferrin 
receptor) or antibodies and peptides, designed to bind to an allosteric domain of the 
receptor that will not be competed by native ligands, present in the blood plasma.  
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Table 1.1: Summary of receptor targeted BBB delivery strategies 
Receptor Ligand Delivery System Model System Reference 
Transferrin 
Receptor 
Transferrin Albumin nanoparticles, 
dendrimers 
Albino rats, 
b.End3, BALB/c 
mice, ICR (CD-1) 
mice 
(Mishra et al. 
2006; Somani et 
al. 2014; 
Ulbrich et al. 
2009) 
OX26 Albumin nanoparticles, 
pegylated liposomes, 
radiolabelled OX26, 
chitosan-peg particles 
ICR (CD-1) mice,  
BMVECs/C6, mice 
(Ulbrich et al. 
2009; H. W. A. 
J. Lee et al. 
2000; Yue et al. 
2014; Aktaş et 
al. 2005) 
8D3 Gold Nanoparticles, 
fusion protein 
Mice (Paris-Robidas 
et al. 2011; 
Zhou et al. 
2010) 
Insulin 
Receptor 
mAb83-14 Radiolabelled, SLNPs  Rhesus Monkey, 
hCMEC/D3 
(Pardridge et al. 
1995; Kuo and 
Ko 2013) 
HIRMAb Fusion proteins, Rhesus Monkey (Boado, Hui, Lu 
and Pardridge 
2010; Boado, 
Hui, Lu, Zhou, 
et al. 2010; 
Boado et al. 
2008) 
29B4 Albumin Nanoparticles ICR (CD-1) mice (Ulbrich et al. 
2011) 
Lactoferrin 
Receptor 
 Polyersomes, DNA 
loaded nanoparticles 
b.End3, BCECs (Gao et al. 
2010; Huang et 
al. 2009) 
LDL Receptor Melanotransferrin Fusion protein, SLNP C6 mice; ZR-75-1 
mammary tumour 
mice 
(Karkan et al. 
2008; Kuo and 
Wang 2015) 
Angiopep-2 Polymeric micelle,  Immunosuppressed 
mice, glioma model 
mice, U87 Glioma 
cells 
(Shao et al. 
2012; Xin et al. 
2011) 
Ganglioside 
GT1b 
 
 
Tet peptide Phage display HEK293, PC12 (Liu et al. 2005) 
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Diphtheria 
Toxin 
Receptor 
CRM197 Polybutylcyanoacrylate 
nanoparticles, 
liposomes, 
hCMEC/D3, 
HBMEC, HA, SK-
N-MC cells 
(Yung Chih 
Kuo and Chung 
2012; Kuo and 
Liu 2014; Wang 
et al. 2010) 
Laminin 
Receptor 
AAV9 Protein cargo C57Bl/6 mice (Xue et al. 
2010) 
Acetylcholine 
Receptor 
RVG peptide Dendrimers, Exosomes, 
DNA complexes 
Neuro 2A cells, 
mice 
(Kumar et al. 
2007; Alvarez-
Erviti et al. 
2011; Liu et al. 
2009) 
Opioid 
Receptors 
G7 peptide PLGA nanoparticles C57BL/6 mice, rat 
model 
(Salvalaio et al. 
2016; Tosi et al. 
2011) 
 
1.5.1 Transferrin Receptor 
Possibly the most studied receptor for RMT across BMECs, the transferrin receptor (TfR) 
is known to be expressed at high levels in BMEC, to facilitate the delivery of iron, bound 
to transferrin (the endogenous ligand) from the blood plasma into the brain parenchyma. 
The TfR itself is a dimeric transmembrane protein, with two sub-units being joined by 
covalent, disulphide bonds between the chains. Each sub-unit of the TfR is capable of 
binding one molecule of the transferrin protein (Moos and Morgan 1998). Transferrin is 
a globular protein, with two high affinity, iron-binding domains. The binding of iron to 
transferrin changes the structure of the transferrin protein and increases its affinity for the 
TfR (Dautry-Varsat et al. 1983). This change in affinity with addition or loss of iron from 
transferrin is vital for the intracellular delivery of iron once within the endosomal sorting 
system of cells.  
Despite the quantity of research on the TfR as a candidate to undergo RMT, questions 
still exist about the ability of a TfR ligand to undergo transcytosis. Research has shown 
that while the iron is shuttled across BMECs from the vasculature, the amount of 
transferrin within the CNS is lower than would be expected. Regardless of these concerns, 
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several studies have used transferrin as a targeting ligand for nanoparticles (Mishra et al. 
2006) and antibodies (Shin et al. 1995) and shown to strongly increase delivery of the 
nanoparticles. The delivery of the antiviral agent, azidothymidine, into rat brains using 
Tf-targeted albumin nanoparticles produced a 2.26-fold increase in CNS accumulation 
with targeting versus untargeted control particles (Mishra et al. 2006).  
It should be noted, that as with other endogenous ligands that circulate within the plasma, 
the use of transferrin as a targeting ligand is limited. The homeostatic concentration of 
transferrin in circulation is thought to be 25 µM, so any targeting ligand must compete 
with this transferrin for the receptor (Qian et al. 2002). More successful tools for targeting 
the TfR include antibodies, raised against an allosteric binding site on the extracellular 
domain of the TfR. In this approach the antibody binding is unaffected by circulating 
ligand and so competition of the therapeutic is avoided. Several anti-TfR antibodies have 
been developed for use in pre-clinical models; these include the OX26 (anti-rat), 8D3 
(anti-mouse), 128.1 Mab (anti-human/monkey). Of these antibodies, the characterisation 
of OX26 is the most complete. Radio-labelled forms of the OX26 antibody have been 
shown to accumulate in the CNS and cargo targeted with OX26 has demonstrated 
enhanced CNS delivery (H. J. Lee et al. 2000). Coupling of the OX26 to NGF improved 
the prognosis of Huntington’s Disease model rats. Reducing neurodegeneration and 
stabilising the condition in the treated animals. OX26 has successfully delivered plasmid 
DNA to the CNS, in pegylated, targeted liposomes (Yue et al. 2014). Liposome targeting 
with OX26 also allowed delivery of small oligonucleotides, peptides and low molecular 
weight therapeutics, all of which demonstrated increased efficacy with targeting 
compared to untargeted. 
In mice, the 8D3 antibody has been used for over a decade as a targeted delivery strategy 
against the murine TfR (Kissel et al. 1998). As with the OX26 antibody, a radiolabelled 
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8D3 antibody was seen to accumulate in the CNS. However, examination of electron 
micrographs, of gold-targeted nanoparticles have shown this appears to be localised to 
the cerebral vascular endothelial cells, and parenchyma accumulation of these particles 
was limited (Paris-Robidas et al. 2011; Niewoehner et al. 2014). More successfully, 
however, 8D3 was used to deliver plasmid DNA to the CNS, confirmed by gene 
expression in neuronal cells. Although the same study also found the delivery of the 
plasmid to other TfR-rich tissue, including the liver and spleen. These antibodies have 
not only been used for a therapeutic application. Conjugation of radiolabelled Aβ-peptide 
to the 8D3 antibody has provided an imaging tool for the visualisation of amyloid plaques 
within Alzheimer’s Disease model mice (Lee et al. 2002). 
Despite the time invested into these antibodies and the measurable improvements in 
therapeutic outcome, or genetic alteration within neuronal cells, these antibodies have 
failed to reach clinical trials. This is mainly due to the lack of selectivity for the CNS, 
owing to the global expression of the transferrin receptor in nearly every tissue type of 
the body. Toxicity of the drug delivery systems at peripheral sites has limited their 
progression into the clinic. Additionally, neither the 8D3 antibody or OX26 have been 
demonstrated to recognise the same epitope on the human form of the TfR and the use of 
non-human-derived immunoglobulins, in the clinic has been shown to trigger severe 
immune reactions to the antibodies. Attempts to overcome this have been made with 
insulin receptor antibody and this will be discussed in the coming section. 
1.5.2 Insulin Receptor 
In vivo, the insulin receptor (IR) is a four domain, glycosylated receptor, which in 
BMECs, is able to transport insulin across the BBB into the brain parenchyma from the 
blood (Pardridge et al. 1985). However, insulin itself is not used as a targeting ligand, due 
to its short plasma half-life and competition with native insulin in circulation (Matthews 
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et al. 1985). Instead several antibodies have been synthesised, against different epitopes 
of the murine and human insulin receptor (mAb83-14, mAB83-7 and mAB29B4) 
(Ulbrich et al. 2011). The mAB83-14 has shown high delivery into the brain with 3.8% 
injected dose (ID) per 100g brain (Pardridge et al. 1995). Control IgG showed no brain 
association. mAB83-14 has been shown to be able to enhance delivery of anti-nociceptive 
drugs in solid-lipid nanoparticles (SLNP) and polymeric nanoparticles in Rhesus 
monkeys and across hCMEC/D3 cell monolayers (Kuo and Ko 2013). Attempts to use 
mAB83-14 in humans, however resulted in immune responses to the antibody. To 
overcome this, a humanized form of the antibody was developed, by attachment of the 
variable domain to the human IgG Fc region to form the HIRMAb antibody (Boado et al. 
2007). The HIRMAb has been used in fusion constructs with therapeutics for genetic or 
metabolic conditions, such as mucopolysaccharidosis type I (Boado et al. 2008), or as a 
vector to deliver enzymes to compensate for lack of expression in patients. These fusion 
constructs have shown an ability to deliver to the CNS in Rhesus monkeys and to restore 
normal functioning in cell line models of the conditions. The success of the fusion protein 
method for delivery across the BBB has led to its application with other 
biopharmaceutical macromolecules, including erythropoietin (EPO), tumour necrosis 
factor receptor (TNFR) and glial-derived neurotrophic factor (Boado, Hui, Lu, Zhou, et 
al. 2010; Boado, Hui, Lu and Pardridge 2010).  
1.5.3 Lactoferrin Receptor 
Lactoferrin is a glycoprotein with similar properties to transferrin; it is able to bind two 
molecules of iron in plasma for transport into multiple cell types, including BMECs. 
Lactoferrin itself can recognise and bind to both the lactoferrin receptor (LfR) and LRP 
protein. Studies have shown that lactoferrin targeting of nanoparticles increases the CNS 
accumulation to a greater extent than TfR ligands (transferrin and OX26 antibody) (Ji et 
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al. 2006). However, other studies have shown the opposite effect on particle delivery with 
Tf and OX26 targeted polymeric particles and liposomes showing increased delivery 
potential compared to lactoferrin-targeted equivalents (Gao et al. 2010). Dendrimers and 
solid lipid nanoparticles (SLNPs) showed increased delivery with lactoferrin targeting 
(Huang et al. 2009). These results would suggest that both thetargeting ligand and the 
nature of the nanoparticle are critical for efficient brain delivery.  
1.5.4 LDL Receptor 
The most extensively utilised ligands of the LDL receptor and its related proteins (LRP1 
and LRP2) are the angiopep-2 and melanotransferrin. Radiolabelled melanotransferrin, 
injected into mice showed an almost 6-fold increase in volume of distribution (VD) to the 
brain compared with radiolabelled transferrin (Demeule et al. 2002). Melanotransferrin 
(MTF) has such been considered and used as a targeting ligand for CNS delivery. Fusion 
with adriamycin (ADR) increased the uptake into the CNS of the drug, compared to 
albumin and lactoferrin fusion constructs (Karkan et al. 2008). MTF-ADR constructs 
have successfully been used to treat mouse glioma models. The use of MTF as a targeting 
ligand for particle delivery to the CNS has also been demonstrated with SLNP for tumour 
therapy and the delivery of the adenovirus gene therapy vector into the CNS (Kuo and 
Wang 2015). 
The angiopep-2 peptide recognises and binds to the LRP1 receptor on BMECs and has 
demonstrated an ability to cause transcytosis of cargo into the CNS. Modifications have 
been made to the angiopep-2 peptide including the synthesis of the peptide with 
“unnatural” D-amino acids (Xin et al. 2011). This has improved the serum stability while 
maintaining the capability of delivery to the brain. Angiopep-2 has been used to 
functionalise multiple types of nanoparticles, including: polymeric particles, gold 
nanoparticles and carbon nanotubes. Polymeric nanoparticles, decorated with the 
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angiopep-2 peptide and containing amphotericin (antibiotic for the treatment of 
meningitis), have been able to deliver the therapeutic into the CNS with greater efficacy 
than the antibiotic alone or untargeted control particles (Shao et al. 2012). Other 
therapeutics which showed increased CNS delivery when incorporated into angiopep-2 
targeted nanoparticles include the doxorubicin, paclitaxel and its derivative ANG1005 
(Thomas et al. 2009). 
1.5.5 Tetanus Receptor 
Tetanus virus-derived peptide (Tet) is thought to undergo retrograde axonal transport 
along neurones to access the CNS. When expressed by viruses the Tet peptide is formed 
of two sub-chains: a light (neurotoxic) and heavy (non-toxic) chains. The non-toxic form 
is known to bind to ganglioside GT1b with high affinity on neurones (Shapiro et al. 1997). 
This target has been used in phage display to generate a small peptide targeting ligand 
(tet1) to be identified, which has similar binding kinetics to the heavy chain of the Tet 
peptide to ganglioside GT1b (Shapiro et al. 1997; Liu et al. 2005). The tetanus toxin-
derived vectors offer an alternative delivery route to the CNS. Rather than transport across 
the BBB, these vectors allow transport through neurones to the brain parenchyma. This 
route of brain delivery is one utilised by other viruses that infect the CNS and so may 
offer an enhanced delivery over “traditional” BBB targeting methods (Fang et al. 2017). 
1.5.6 Diphtheria Toxin Receptor 
The diphtheria toxin receptor (DTR) or the heparin-binding epidermal growth factor 
(HBEGF) is known to be expressed on the cell surface of BBB endothelial cells (Gaillard 
et al. 2005). HBEGF itself has no native ligands, as it is a precursor to the final receptor. 
However, it can bind to the non-toxic mutant of the diphtheria toxin CRM197. In vivo 
experiments on PLGA targeted with CRM197 demonstrate accumulation into CNS cells 
with time (Wang et al. 2010; Kuo and Liu 2014). Low diameter particles decorated with 
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CRM197 and containing zidovudine increase the permeability of zidovudine across in 
vitro BBB models (Y.C. Kuo and Chung 2012). 
1.5.7 Laminin Receptor 
Extra-cellular domains of the Adeno-Associated Viruses (AAVs) have multiple forms, 
each of which can bind to a different receptor subtype. AAV-9 can interact with the 
laminin receptor present in BMECs (Akache et al. 2006). This targeting method has been 
used to deliver erythropoietin gene into a Parkinson disease mouse model. These studies 
confirmed the gene was expressed within the CNS and the EPO had a therapeutic effect 
within the mouse model (Xue et al. 2010).  
1.5.8 Acetylcholine Receptors - RVG 
Virus protein-derived peptides have shown some success as potential targeting ligands 
for CNS delivery. One such peptide is derived from the rabies virus glycoprotein (RVG) 
and is believed to interact with the alpha 7 nicotinic acetylcholine receptor (α7nAchR). 
The RVG peptide itself is a 29-amino acid peptide, with a region that of highly conserved 
sequence with loop neurotoxins, including α-bungarotoxin. Indeed, early work with RVG 
peptide was to test its ability to compete the binding of neurotoxins for the α7nAchR 
(Lentz et al. 1987; Lentz 1982; Lentz TL 1990; Lentz et al. 1986). The abundance of 
α7nAchR within the CNS and their potential expression in the microvasculature of the 
brain leading to the increase in brain delivery of the cargo (Abbruscato et al. 2002). Some 
evidence has also arisen to suggest a potential alternate receptor for the RVG peptide. 
There is some thought that the GABA receptors may also provide a binding site for the 
RVG peptide as the co-incubation of RVG-targeted dendrimers with GABA decreased 
uptake into neuronal SH-SY5Y cell (Liu et al. 2009). This evidence is supported by work 
which showed the α-bungarotoxin is able to act on GABA-A receptor (Hannan et al. 
2015). Further study of the interaction of the whole glycoprotein and the whole virus 
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reveals two further receptors, NCAM-1 and p75NTR (Thoulouze et al. 1998; Gluska et 
al. 2014). The RVG peptide was first shown to have potential for BBB targeting when 
Kumar et al showed it was able to enhance brain accumulation of siRNA polyplexes 
(Kumar et al. 2007). Silencing of GFP expression in transgenic mice was observed in the 
brain, with limited silencing effects observed in the liver and spleen. Further work with 
RVG targeted exosomes again showed the peptide increased brain accumulation of the 
exosomes and siRNA encapsulated within them had a silencing effect on BACE-1 within 
the brains of mice (Alvarez-Erviti et al. 2011). Overall, the evidence for the use of the 
RVG peptide as a brain targeting ligand appears to show potential. However, the 
uncertainty over the target receptor would present a concern. 
1.5.9 TAT Peptide 
A second, viral-derived peptide, derived from the Human Immunodeficiency Virus 
(HIV), the TAT-peptide is a cell-penetrating peptide (CPP), that will globally increase 
cell uptake and tissue distribution. Thus, allowing for an increase in tissue penetration of 
a drug delivery system into the brain. The TAT peptide has a cationic charge to facilitate 
cell membrane interactions and internalization. The functionalization of quantum dots, 
and biologically active proteins with the TAT peptide all showed increases in the 
accumulation within the CNS (Santra et al. 2005; Schwarze et al. 1999). However, in 
vitro work to support these findings has been less conclusive, with the TAT peptide failing 
to enhance the permeability of GFP-TAT conjugates across endothelial monolayers 
(Georgieva et al. 2011). 
1.5.10 G7 peptide 
The g7 peptide is modified from the MMP-2200 opioid, an agonist of the δ- and µ-opioid 
receptors. The modifications when forming the g7 peptide reduce the nociceptive effects 
on opioid receptors (Tosi et al. 2011). The g7 peptide has been shown to increase the 
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delivery of PLGA nanoparticles and encapsulated fluorescent dyes to the brain 
parenchyma  (Tosi et al. 2011; Tosi et al. 2013), with a study using rhodamine-123 
finding 15% of total animal fluorescence located in the brains of injected animals (Vilella 
et al. 2014). G7-targeted particles have also been shown as a potential vector for the 
delivery of treatments for lysosomal storage disorders of the CNS. Particles loaded with 
corrective enzymes were able to restore lysosomal functionality in in vivo models of 
disease (Salvalaio et al. 2016).  
1.6 Thesis Goals 
Having looked at the literature of cellular trafficking methodologies concerning BMECs, 
there is a lack of clarity as to whether a probe can undergo both endocytosis into the 
endothelial cell and subsequent efflux from the cell. In permeability assays, BMEC 
models are subject to paracellular leakage, contributing to higher permeability levels of 
probes. The main goals of this thesis were to around the investigate the capability of the 
targeting ligands to undergo the process of transcytosis in an in vitro BMEC model. The 
development of a transcytosis index was pursued. This combined permeability assays 
with sub-cellular microscopy and pulse-chase flow cytometry, to allow for a multifaceted 
evaluation ligand trafficking in BMECs. Looking at, barrier permeability of the ligand, 
alongside the ability of it to undergo some form of uptake and efflux process. This was 
initially developed using a receptor-targeted ligand (transferrin) and a fluid-phase uptake 
marker (dextran) to test the ability of the methods to distinguish between the two 
trafficking routes.  
Using the transcytosis index, the particularly the pulse-chase assay as the primary method, 
further trafficking ligands were tested in this manner to evaluate their ability to bind to 
BMECs and undergo cellular trafficking. This was done with antibodies against the 
transferrin receptor of high affinity (8D3) and a low-affinity variant, supplied by Abbvie 
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(8D3-4). This was with the aim to assess the impact of ligand affinity on the efflux 
potential of the targeting ligand from cells. With consideration being given to the work 
of Roche and Genentech with decreased affinity targeting ligands enhancing brain 
delivery of therapeutic cargos. 
Following the work with transferrin receptor ligands, the viral derived rabies virus 
glycoprotein peptide (RVG) was examined as a candidate brain targeting ligand. Due to 
concerns over receptor specificity and the ability of the peptide to be taken up by the 
COMPACT consortium work was done to characterise RVG uptake in BMECs. The RVG 
peptide was also tested in the pulse-chase assay to confirm it is a probe that can undergo 
active efflux from BMECs and assess the subcellular distribution of the peptide following 
the assay. 
In the final section of this thesis, work was undertaken to explore the use of complex 
microscopy techniques in the understanding of cellular trafficking at the basolateral cell 
membrane. This included the use of total internal reflection fluorescence microscopy 
(TIRF) to image targeting ligands at the basolateral membrane of BMECs. The associated 
analysis of the collected microscopy videos, to classify trafficking events into putative 
exocytic events and other trafficking events taking place within the cells. To explore the 
trafficking of receptors within BMECs further, the photoswitchable protein PSmOrange 
was conjugated to the transferrin receptor. In this work, a formula to calculate the 
distribution of the fluorescent states of a photoswitchable protein was derived. And initial 
studies into the distribution of the receptor at the basolateral cell membrane were 
attempted. With the overall goal to develop a technique which could be used examine the 
dynamics of receptor localisation in the basolateral region of barrier cell types. 
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1.7 Thesis Aims 
1. Establish an in vitro model for cellular trafficking that can be used to differentiate 
between brain targeting ligands. 
2. Characterise the uptake and intracellular trafficking of transferrin receptor 
antibodies, with differing affinities in brain microvascular endothelial cells in 
vitro. 
3. Characterise the uptake and intracellular trafficking of the RVG peptide in brain 
microvascular endothelial cells in vitro. 
4. Identify the target receptor, mediating endocytosis of the RVG peptide into 
BMECs using multiple methodologies. 
5. Use TIRF microscopy to examine basolateral membrane trafficking of the 
transferrin receptor and its ligands. 
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Chapter 2: The Role of the Transferrin Receptor in Brain 
Microvascular Endothelial Cells and its use as a drug delivery 
target 
 
2.1 Introduction 
It is well established that transferrin is the molecular shuttle to aid in the uptake and 
transport of iron across highly restrictive biological barriers, as well as into cells for 
physiological functioning. Transferrin itself is an 80kDa, globular protein which can bind 
ferric iron (Fe3+) with an affinity of 10-24M and fully saturated can bind two molecules of 
Fe3+, one to each lobe of the protein. In the di-ferric (holo) conformation transferrin binds 
more strongly to the transferrin receptor (TfR), at plasma pH, than mono-ferric or iron-
free (apo) transferrin. This difference in affinity between holo- and apo-transferrin is 
essential in the trafficking and recycling dynamics of transferrin and the TfR (Dautry-
Varsat et al. 1983). Despite the main trafficking route pathway of transferrin being 
recycling, there is some evidence of alternative trafficking of transferrin through cells.  
The transferrin receptor is membrane spanning, dimeric glycoprotein, each subunit is 
90kDa and capable of binding one molecule of transferrin. Uptake of the TfR is 
constitutive and controlled by clathrin-mediated endocytosis (CME). Briefly, adaptor 
proteins associate with the intracellular domain of the receptor and recruit clathrin heavy 
and light chains to the receptor, allowing the formation of the clathrin triskelia and 
clathrin-coated pits (CCP). There are several adaptor protein (AP) complexes that are 
utilised in CME, AP1-3, with the main complex being AP2. The AP2 complex is formed 
of four subunits, α-, β-, μ- and σ-units, each with its role in the CME process. To form 
fully internalised vesicles from the CCPs, dynamin, a helical GTPase, associates with the 
neck of the CCP and cleaves the vesicle from the membrane. The removal of clathrin, 
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from the vesicles, once internalised, is an ATP-dependent process, using heat shock 
protein 70 and auxilin. The uncoating allows trafficking of the vesicles through 
association to various proteins within the cell.  
When in the late endosome, the pH surrounding the TfR-Tf complex is approximately 
5.5, resulting in the loss of Fe3+ from the transferrin molecule (Dautry-Varsat et al. 1983). 
This low pH environment allows the now apo-transferrin to remain bound to the TfR 
while trafficked back to the luminal membrane of the cells (Dautry-Varsat et al. 1983).  
The TfR is highly expressed in brain microvascular endothelial cells (BMECs) relative to 
most other organs’ microvasculature, with an exception being the hepatic vasculature. 
Studies into the number of TfRs present in primary bovine BMECs estimated 100,000 
receptors per cell (Raub and Newton 1991). In the immortalised rat cell-line, RBE-4, TfR 
expression was approximated at 70,000 receptors per cell (Huwyler et al. 1999). In 
normal physiological states, approximately 10-20% of TfRs are localised at the cell 
membrane; the remaining are localised in intracellular vesicles due to constitutive 
recycling of the receptor. The levels of TfR expression in cell culture appear to depend 
on the metabolic demand of the culture, and expression decreases when cells are grown 
beyond the point of confluence (Tripothi et al. 1992). This increase in TfR expression 
relative to metabolic demand can be seen in tumour cells where the continual cell division 
in tumour growth places a high metabolic demand on the cells and increases their iron 
demand (Huebers and Finch 1987). 
In BMECs transferrin and the transferrin receptor are believed to be required for the iron 
trafficking into the brain parenchyma for neuronal and glial metabolism. However, it is 
unclear as to the precise mechanism by which iron transcytosis occurs in BMECs. 
Experiments using perfused rat brains to assess uptake and loss of radiolabelled 
transferrin revealed retention of transferrin by the microvascular endothelium (Fishman 
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et al. 1987). Of the transferrin lost from the cells in, this study, it appears 20% is recycled 
back into the perfusate, while 80% of the radiation is detected in the brain supernatant, 
suggesting a transcytosis process has occurred. Roberts et al. (1993) performed 
morphological studies with transferrin conjugated to horse-radish peroxidase (Tf-hrp) and 
used electron microscopy to assess the localisation within the BMECs. There was no 
apparent evidence of transferrin at the abluminal membrane at any stage; however, the 
presence of Tf-hrp in recycling vesicles was seen in the final time point of the experiment 
(Roberts et al. 1993).  
The examinations of rat brain sections, after perfusion with anti-TfR conjugated colloid 
gold, confirmed the localisation of the TfR to all areas of the brain vasculature (Bickel et 
al. 1994). Immunofluorescence microscopy of brain capillaries shows TfR expressed on 
both the apical and basolateral endothelial cell membranes (Huwyler and Pardridge 
1998). More recently, studies looking at the co-localisation of anti-TfR antibodies with 
markers for the apical and basolateral membranes revealed high localisation with the 
apical marker (Paris-Robidas et al. 2011; Niewoehner et al. 2014). These studies also saw 
slight co-localisation of the antibody with type IV collagen also confirmed trafficking to 
the basolateral membrane, across the brain microvascular endothelium. 
2.1.1 Antibody targeting of the TfR 
Several antibodies against the transferrin receptor have been generated to examine the 
trafficking of the TfR and the ability to enhance the uptake of therapeutics into the brain. 
The OX-26 and 8D3 antibodies are both monoclonal antibodies that bind to rat and mouse 
TfR respectively. These antibodies bind with high affinity to allosteric sites on the TfR 
and do not disrupt transferrin binding. The 8D3 has a Kd of 2.3nM (Boado et al. 2009). 
Both antibodies have been shown to associate to BMEC cells in vivo and in vitro and have 
shown to gain entry to the brain parenchyma (H. W. A. J. Lee et al. 2000; Bickel et al. 
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1994). A chimeric form of the 8D3 antibody has been generated by introducing the mouse 
IgG1 heavy chain and kappa regions into the antibody to improve fusion protein 
constructs for studies in mice (Boado et al. 2009). The chimeric antibody was shown to 
have the same binding and bio-distribution properties as the wild-type 8D3 antibody. 
Further modification of the chimeric 8D3 antibody has been performed by Sanofi, as part 
of the COMPACT consortium, to reduce the formation of cross-linking between 
antibodies when labelling nanoparticles (unpublished work).  
The RI7 antibody is another high-affinity antibody, which has been used to target the TfR 
in mice. However, the 8D3 antibody has superseded RI7 for targeting mouse TfR. For 
assessment in human cell lines and monkey animal models, the monoclonal antibody 
128.1 has been used (Walus et al. 1996). Although this antibody was primarily designed 
for use in tumour targeting therapies (Ng et al. 2002), it has also been assessed with 
relation to BBB targeting (Sade et al. 2014; Walus et al. 1996). 
Antibodies against the transferrin receptor have been shown to increase the brain 
association of a targeted drug delivery systems (DDS) compared to control particles. 
However, electron microscopy studies have shown that while TfR-targeted gold 
nanoparticles accumulate within BMECs, relatively fewer nanoparticles are actually 
observed within the brain parenchyma (Cabezon et al. 2015; Wiley et al. 2013). This was 
exemplified by electron microscopy of brain slices, at post-dosing time points, to assay 
the distribution of the antibody targeted particles within the BMECs (Cabezon et al. 
2015). Using techniques in this manner confirms that the TfR-targeted particles have 
limited penetration to the brain parenchyma.  
2.1.2 Genentech and Roche anti-transferrin receptor antibody studies 
Recent studies in Genentech using a bi-specific antibody, with both anti-TfR and anti-
BACE targeted variable regions (see Figure 2.1 and 2.2 below) showed increased brain 
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penetration than a previous high specific anti-TfR antibodies (Yu et al. 2011; Couch et 
al. 2013). The bispecific construct has a lower affinity for the TfR than a standard anti-
TfR IgG (Yu et al. 2011). The constructs created by Genentech have been tested both in 
vitro and in vivo and revealed that high-affinity anti-TfR antibodies appear to become 
“trapped” within lysosomes of cells as the exposure time increases, while the lower 
affinity antibody does not remain in the cells for longer than necessary. This accumulation 
is thought to result from the inability of the high-affinity antibody to dissociate from the 
transferrin receptor once bound, and therefore continual association with the receptor. 
Time point analysis of the TfR expression following exposure to both constructs sees a 
decrease in TfR protein with the high-affinity antibody variants, while the lower affinity 
antibodies do not alter the levels of TfR protein within the cells (Couch et al. 2013). 
Further studies, changing the affinity of the bi-specific construct to TfR revealed that 
there appears to be an optimal affinity range for the receptor where delivery is enhanced. 
If the antibody affinity is too low, then maximal binding and uptake into the brain cannot 
occur at therapeutic doses, and the clearance of the antibody from plasma is sub-optimal 
for safe dosing strategies (Yu et al. 2014).  
 
Figure 2.1: Genentech Bispecific, TfR targeted antibody construct 
Taken from Figure 5. Yu et al (2011), it shows the structure of the bispecific antibody 
created by Genentech, with the dark purple arm targeting the TfR and the light purple 
arm targeting BACE-1 protein for therapeutic effect. Graph B shows the effect on 
affinity for the TfR with the bispecific antibody (purple) compared to a high affinity 
monospecific anti-TfR antibody. 
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These studies have been performed in several test animal species, including rodents and 
monkeys. Thus far in all species the moderate affinity, bi-specific antibody appears to be 
the most effective and safest construct for brain delivery.  
Roche is also studying the effect of lower affinity constructs on enhancing brain delivery. 
This has been done using a payload of the anti-BACE-1 antibody mAb31, conjugated to 
Fab fragments specific to the TfR (Niewoehner et al. 2014). These constructs are formed 
of either one or two Fab fragments and showed that the valency altered the TfR affinity 
as well as the trafficking that was observed in vitro and in vivo. The lower affinity mono-
valent construct had enhanced brain delivery of the payload, did not alter TfR expression 
within BMECs in culture and had a lower retention time in the BMECs in vivo while the 
di-valent construct appeared within the endothelium throughout their studies 
(Niewoehner et al. 2014). The effect of the avidity of a targeted construct to TfRs on the 
BBB has also been reported with relation to transferrin-targeted liposomes, the number 
of transferrin molecules associated to the surface of the liposomes appeared to alter the 
penetration into the brain (Wiley et al. 2013). 
 
Overall, these studies from Roche and Genentech have shed some light on the mystery of 
transferrin receptor trafficking at the BBB and factors that alter it. The studies suggest 
Figure 2.2: Roche mono- and divalent, TfR targeted antibody construct 
Taken from Figure 1. Niewoehner et al (2014), The above figure shows the structure of the 
antibody constructs used in the Roche research. The therapeutic antibody (green and grey) 
is coupled to either one (sFab) or two (dFab) transferrin receptor targeting domains.   
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three potential pathways for receptor trafficking that are dependent on both the affinity 
for the receptor and the avidity of the targeting.  
 
 
 
2.1.3 Chapter Aims 
The primary aim of this chapter was to develop an assay for assessing the potential of 
nanoparticle and supramolecular delivery systems to undergo transcytosis at the BBB. 
This work was done for the COMPACT Consortium as a deliverable for the Brain 
Delivery work package. The focus of the development was around the transferrin 
receptor, and initial work was done to characterise the uptake of TfR ligands into the 
b.End3 cell line.  
 
Figure 2.3: Potential cellular trafficking routes of TfR targeted 
antibodies and the BBB 
This is a schematic to show the potential trafficking routes of transferrin targeted antibodies. 
Following endocytosis at the luminal membrane, sorting within the endothelial cell can lead 
to: recycling back to the luminal membrane, lysosomal degradation (high affinity divalent 
antibodies), or transcytosis across the cells to the abluminal membrane.   
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The objectives of this study were as follows: 
1) To design and test the assay that used multiple components to assess the potential 
for an endogenous ligand to undergo transcytosis across the BBB. To characterise 
the methodology with respect to the transferrin receptor. As a non-specific mark, 
dextran was used to give a reference for the behaviour of a fluid-phase endocytic 
probe. Having established an assay, it was then tested with further transferrin 
receptor ligands, 8D3 antibodies. 
2) As part of the development of the assay, the effect of ligand concentration on the 
ability of the cells to efflux a ligand was also examined with transferrin, and two 
different affinity 8D3 antibodies.  
3) To demonstrate that the uptake of the TfR ligands used is through a receptor-
mediated process, regulated by clathrin-mediated endocytosis. 
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2.2 Methods 
2.2.1 Materials 
Dulbecco’s modified eagle medium (DMEM) + Glutamax, Medium 199 (M199), 
Sensicell MEM, Opti-MEM, fetal calf serum (FCS), horse serum, trypsin-EDTA 
dissociation solution, Penicillin and Streptomycin (10,000U/mL), Dextran 10kDa 
conjugated to Alexa 488 and Alexa 647, Dextran 70kDa conjugated to tetra-methyl 
Rhodamine, Holo-transferrin conjugated to Alexa 488 and Alexa 568 and the 
AlexaFluor® 488 protein labelling kits (1mg of IgG/ labelling procedure) were obtained 
from Invitrogen, UK. EBM-2 media was purchased from Lonza, Germany. 
Transwell inserts for 24-well plate (0.33 cm2) with pore sizes 0.4 µm and 3.0 µm, and 
Hoechst was obtained from Sigma Aldridge, UK. All other plastics for cell culture were 
purchased from Fisher Scientific,UK, as well as paraformaldehyde (PFA), sodium 
chloride, potassium chloride, magnesium chloride, calcium chloride, disodium hydrogen 
phosphate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium 
bicarbonate, D-glucose, bovine serum albumin (BSA). Cell imaging dishes were 
purchased from MatTek, UK 
The anti-mouse transferrin receptor antibody 8D3 was kindly provided from Sanofi 
through COMPACT. The low-affinity variant 8D3-4 was kindly supplied from Abbvie 
through the COMPACT consortium. 
Type 1 Rat Tail Collagen was purchased from Millipore-Merck. 
2.2.2 Cell Culture 
The b.End3 cell-line was supplied by COMPACT from the GSK source and grown in 
accordance with their SOP and replenished from stocks when the cells had undergone 20 
passages or 60 days after defrosting the vial. b.End3 cells are cultured in 90% DMEM + 
Glutamax (Invitrogen) with 10% FCS (Invitrogen) (summarised in Table 2.1below).  
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2.2.3 Fluorescent labelling of 8D3 and Isotype control antibodies 
The antibodies were kindly supplied by Sanofi, through the COMPACT consortium, and 
labelled with either Alexa Fluor 488 or Alexa Fluor 647 using the Life Technologies 
antibody labelling kit. Briefly, 500μL of 2mg/mL antibody solution was added to the dye, 
in powder form, and vortexed to dissolve. The mixture is stirred for 90 minutes at room 
temperature to allow the reaction of the dye with the antibody. Purification of the labelled 
antibody from free dye was performed by size exclusion chromatography, using the 
columns provided within the kit, with samples of fluid collected every 1mL. The 
absorbance of these samples was analysed using the Cary 60 UV-spectrophotometer to 
scan from 250nm to 800nm. The relationship between the fluorophore absorbance peak 
(488nm or 647nm, depending on dye) and the absorbance of tryptophan residues in the 
antibodies (280nm) allows the calculation of the concentration of antibody (Eqn 2.1. + 
2.2.) and the labelling efficiency of the dye (Eqn 2.3 + 2.4). Within the equations 203,000 
cm-1M-1 is the molar extinction coefficient of a typical IgG molecule, 71,000 cm-1M-1 is 
the extinction coefficient of the Alexa Fluor 488 dye and 239,000 cm-1M-1 the extinction 
coefficient of Alexa Fluor 647. Labelling integrity was checked five months post-
Table 2.1: Summary of growth conditions for cell-lines and media supplements 
Cell Line 
(Source) 
Medium Serum Antibiotics Dissociation 
Media 
Seeding 
Density 
b.End3 
(COMPACT) 
DMEM + 
Glutamax 
(90%) 
Fetal Bovine 
Serum (10%) 
NO Trypsin-EDTA 
(0.05%) 
1 x 104 
cells/cm2 
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labelling by re-purification of the antibody through the size exclusion column to ensure 
only labelled antibody remained present in the sample. 
 
Equation 2.1.  
𝐼𝑔𝐺 𝑀𝑜𝑙𝑎𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =  
𝐴280 − (𝐴494 × 0.11) × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
203,000
 
Equation 2.2.  
𝐼𝑔𝐺 𝑀𝑜𝑙𝑎𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =  
(𝐴280 − (𝐴647 × 0.03)) × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
203,000
 
Equation 2.3. 
𝑀𝑜𝑙𝑒𝑠 𝑜𝑓 𝐷𝑦𝑒 𝑝𝑒𝑟 𝑀𝑜𝑙𝑒 𝑜𝑓 𝐼𝑔𝐺 =  
𝐴494 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
71,000 × 𝐼𝑔𝐺 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑀)
 
Equation 2.4. 
𝑀𝑜𝑙𝑒𝑠 𝑜𝑓 𝐷𝑦𝑒 𝑝𝑒𝑟 𝑀𝑜𝑙𝑒 𝑜𝑓 𝐼𝑔𝐺 =  
𝐴647 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
239,000 × 𝐼𝑔𝐺 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑀)
 
 
 
2.2.3 siRNA Transfection 
To modulate the expression of the clathrin adaptor protein AP2µ2, in b.End3 cells, siRNA 
against the murine AP2µ2 was used (sequence – GUGGAUGCCUUUCGGGUCAdTdT) 
(Al Soraj et al., 2012). As well as a control siRNA against luciferase (sequence – 
CGUACGCGGAAUACUUCGAdTdT). b.End3 cells were seeded, at a density of 10,000 
cells/cm2 into individual wells of a 6-well plate for both lysis and uptake assays and 
allowed to grow for five days before transfection. For transfection siRNA stock solutions 
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(20 µM) are added to Opti-MEM® at a ratio of 10 µL:160 µL and mixed gently. In 
parallel to this, 6 µL of the Oligofectamine reagent is diluted in 30 µL Opti-MEM®. The 
two mixtures (siRNA and Oligofectamine) are combined and mixed gently, before 
incubating them at room temperature for 20 minutes to allow for complex formation. 
After the incubation, the cells to be transfected are washed with PBS twice before the 
addition of the siRNA complexes (200 µL per well). Additionally, 800 µL of Opti-
MEM® was added to each well. The cells are incubated with this mixture for 4-6 hours, 
before the addition of 500 µL growth media, containing 30% FBS. Cells are then left for 
48 hours before performing the uptake assay or cell lysis for Western blot. 
2.2.4 Western Blot 
Following the incubation with siRNA sequences for 48 hours, the cells to be lysed were 
dissociated from the 6-well plates and pelleted by centrifugation at 500 x g for 5 minutes 
at 4 oC. The media was then aspirated, and the pellets washed with PBS, using the same 
centrifuge configurations. The pellets were stored at -20 oC until lysis or proceeded 
straight to lysis.  
The initial Cell Lysis buffer was prepared by the combination of 0.875g NaCl (150 mM), 
0.6g Tris (50 mM), 0.19g EDTA (5 mM) and 1 mL Triton (1%) to a final volume of 100 
mL, pH 7.5. To prepare this buffer for lysis, 10 mL of Cell Lysis Buffer is aliquoted and 
to it the following is added: 200μl NaVO4 (100mM), 50μl NaF (10M), 100μl PMSF 
(100mM), 10μl Phenylarsine oxide (20mM), 100μl Sodium Molybdate (1M), 20μl 
Leupeptin (5mg/ml), 40μl Aprotinin (2μg/ml). This buffer is stored on ice until lysis was 
performed. To each cell pellet, 40-50 µL of lysis buffer was added and incubated with the 
cells for 30 minutes at 4 oC, with regular agitation of the cells throughout the incubation. 
After the lysis, cells are centrifuged at 10,000 x g for 30 minutes at 4 oC. 
Chapter 2 
 
54 
 
Protein quantification was performed using the Bicinchoninic Acid (BCA) assay, using 
the BCA assay kit (Thermo Fisher, Paisley, UK). Briefly, the reagents within the kit 
Reagent A and Reagent B, are combined in a 50:1 ratio, to produce 200 µL of reagents 
per sample. The combination of reagents was added to 25 µL of lysate (diluted 1:2) or a 
protein standard (BSA – range 2 mg/mL – 25 µg/mL). The samples are incubated at 37oC 
for 30 minutes, before the absorbance at 562 nm is measured, using an LT5000MS ELISA 
reader (Labtech International Ltd, Uckfield UK). From the protein standards, the 
concentration of the cell lysates may be calculated. 
For gel electrophoresis, a running buffer is prepared, containing 25mM Tris Base, 192 
mM Glycine at a pH of 8.3. Pre-cast, 10% Mini-PROTEAN® TGX™ gels (BIORAD, 
Hertfordshire, UK) were loaded into the Mini-PROTEAN apparatus. 10 µg of cell lysate 
was loaded per well, plus the protein ladder, Precision Plus Protein™ Dual Colour 
Standards (BIORAD, Hertfordshire, UK). The gels were exposed to a 100V for 2 hours. 
At the conclusion of the electrophoresis stage, the proteins are transferred, via semi-dry 
blotting, to a nitrocellulose membrane. For this, filter paper and the nitrocellulose 
membrane are pre-incubated in a blotting buffer, containing: 25 mM Tris Base, 192 mM 
Glycine, 20% Methanol. The components were assembled in the BIORAD Transblotting 
system, so the electrophoresis gel is in contact with the nitrocellulose membrane. The gel 
was exposed to 25V for 30 minutes to allow blotting to take place. 
The membrane was then removed and washed in Washing Buffer (0.1 M Tris, 0.1 M 
NaCl, 0.1% Tween 20), to remove residual methanol, before blocking, by incubation with 
Washing Buffer containing 5% milk. This is done with continual agitation for 1 hour at 
room temperature. The membrane was cut in two at 42 kDa, and the high molecular 
weight section incubated with mouse anti-AP50 antibody (BD Bioscience, UK), diluted 
1 in 200 with the blocking buffer overnight. The low molecular weight section of the 
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membrane was incubated with a rabbit anti-GAPDH antibody (Cell Signalling, UK), 
diluted 1 in 1000 in blocking buffer.  
After, the primary antibody incubation, membranes are washed 6 times for 5 minutes with 
Washing Buffer, before incubation with a secondary, HRP-linked antibody, against the 
respective species of the primary. Anti-rabbit IgG secondary antibody (Cell Signalling, 
UK) or anti-mouse IgG secondary antibody (Cell Signalling, UK), in both cases the 
antibody is diluted 1 in 10,000 with blocking buffer. Following the secondary incubation, 
membranes are washed a further 6 times for 5 minutes with Washing Buffer. Antibodies 
are detected using SuperSignalTM West Dura Substrate (Thermo Fisher, UK) and imaged 
using the BIORAD ChemiDoc XRS system. 
2.2.5 Pulse-Chase Flow Cytometry in b.End3 cells. 
Cells are seeded onto either 12-well or 24 well plates for growth at a seeding density of 
10,000 cells/cm2 and allowed to grow until a confluent monolayer could be observed by 
light microscopy (typically day 6-7 post seeding). When a confluent monolayer was 
observed, the growth media is replaced by Krebs-Ringer buffer containing 0.1% bovine 
serum albumin (KRB+BSA) for 30 minutes to remove serum proteins from the cells. The 
cells are then pulsed with one of the formulations shown in Table 2.2, for 45 minutes at 
either 37oC or 4oC, to confirm active uptake into the cells. Following the pulse, cells are 
washed with PBS three times to remove non-internalised probes from the cells and then 
incubated in blank KRB-BSA for the duration of the chase (0, 10, 30, 60 minutes). The 
chase steps are performed at both 37oC and 4oC to confirm an active efflux process has 
occurred. After the conclusion of the chase phase, the cells are placed at 4oC and washed 
three times in PBS to remove effluxed probes from the solution. A pH 2.5 acid wash is 
then applied to remove and surface-bound probes before dissociation of the cells, using 
EDTA solution (2.5mM). The dissociation is performed at 4oC for approximately one 
Chapter 2 
 
56 
 
hour and completed by repeated pipetting of cells to ensure maximum collection from a 
well. The dissociated cells were added to tubes containing PBS + 5% fetal bovine serum, 
and centrifuge at 300 x g for 10 minutes at 4oC three times to remove EDTA from the 
cells. Following the final centrifuge, the cells are re-suspended in serum-free PBS for 
analysis using the FACS Verse (BD Biosciences). From 24-well plates a minimum of 
10,000 events are collected per tube, and from 6-well plates, 50,000 events were 
collected. Further analysis of the data collected is performed using FlowJo software, and 
non-linear regression of fluorescence loss from cells is performed using GraphPad Prism 
5.  
Table 2.2: Concentration of Macromolecules used in Pulse-Chase Flow Cytometry 
Macromolecule Concentration (nM) Source 
Transferrin-Alexa fluor 
488 
588, 50 or 5 Life Technologies 
Dextran 10kDa Alexa fluor 
647 
10,000 Life Technologies 
8D3 anti-TfR Alexa fluor 
647 
170, 30, 10 or 1 Sanofi, Labelled in Lab 
Isotype control Alexa fluor 
647 
30 Sanofi, Labelled in Lab 
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2.2.6 Transferrin Receptor Competition Flow Cytometry Studies 
Competition studies to confirm receptor-mediated uptake were performed in b.End3 cells 
using fluorescently-labelled transferrin receptor targeting strategies, transferrin Alexa 
fluor 647, 8D3 Alexa fluor 647 and an isotype control antibody labelled with Alexa Fluor 
647. B.End3 cells were seeded, as before, onto 24- or 6-well plates at a density of 10,000 
cells/cm2 and grown until a confluent monolayer could be observed. When confluent, cell 
growth media was replaced with KRB-BSA for 30 minutes at 37oC to remove serum 
proteins from cells. Fixed concentrations of the labelled proteins were applied to the cells 
with various concentrations of unlabelled protein, to compete for the receptor, and the 
probes allowed to internalise for 45 minutes at 37 oC. To assess the specificity of the 8D3 
antibody, supplied by Sanofi, for the transferrin receptor a further competition study using 
a fixed concentration of labelled 8D3 with varying concentrations of isotype control 
antibody. 
 Following the conclusion of the uptake, cells were washed three times in PBS and 
incubated with a pH 2.5 acid wash buffer for 30 seconds. The cells were washed a further 
three times in PBS containing EDTA (2.5mM) and allowed to dissociate in PBS-EDTA 
solution for approximately 1 hour on ice. After dissociation, cells were collected into 
centrifuge tubes containing PBS + 5% FBS and washed three times by centrifugation at 
300 x g, for 10 minutes, at 4oC. Following the final wash, cells were re-suspended in 
serum-free PBS for analysis using the FACS Verse.  
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Table 2.3: Transferrin competition study setup 
Concentration of unlabelled 
Transferrin (nM) 
Concentration of Transferrin 
Alexa fluor 488 (nM) 
0 10 
0.5 10 
1 10 
5 10 
10 10 
50 10 
100 10 
500 10 
 
Table 2.4: 8D3 competition study setup 
Concentration of unlabelled 
8D3 (nM) 
Concentration of 8D3 Alexa 
fluor 647 (nM) 
0 30 
5 30 
10 30 
50 30 
100 30 
500 30 
1000 30 
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Table 2.5: Isotype control competition study setup 
Concentration of unlabelled 
Isotype Control (nM) 
Concentration of Isotype 
control fluor 647 (nM) 
0 30 
5 30 
10 30 
50 30 
100 30 
500 30 
1000 30 
 
Table 2.6: 8D3 vs Isotype control competition study setup 
Concentration of unlabelled 
Isotype control (nM) 
Concentration of 8D3 Alexa 
fluor 647 (nM) 
0 30 
5 30 
10 30 
50 30 
100 30 
500 30 
1000 30 
 
2.2.7 Macromolecule Permeability Assays and confocal microscopy, using B.End3 
cells  
The b.End3 cells were seeded onto the apical side of Transwell inserts for 24-well plates 
(0.4 μm pore diameter, polycarbonate membrane), at a seeding density of 10,000 
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cells/cm2. During cell growth measurements of trans-endothelial electrical resistance 
(TEER) are taken daily to gauge the confluence of the cells on the inserts. TEER values 
are taken using Endohm chambers connected to the EVOM2 ohmmeter (World Precision 
Instruments). Briefly, the Endohm chamber is washed with ethanol to sterilise and filled 
with 1mL, b.End3 growth media. A blank insert, with no cells grown on it, is placed into 
the chamber, containing culture media and the resistance recorded. The resistance of the 
membrane will contribute to the total resistance when cells are grown on the inserts and 
must be subtracted to reveal the resistance of the monolayer. In parallel to TEER 
assessment, cells seeded at the same density on plastic, well-plates can be examined to 
assess monolayer formation. 
In the permeability studies, cells are incubated with KRB-BSA for 30 minutes at 37oC to 
remove serum proteins from cells. The media is aspirated from the apical chamber and 
replaces with KRB-BSA containing fluorescent macromolecules (Transferrin Alexa fluor 
488, 588nM; Dextran Alexa fluor 488nm 10kDa, 10μM; Dextran rhodamine 70kDa, 2.85 
μM; 8D3 Alexa Fluor 488 anti-TfR, 170nM). The plates are placed at 37oC for 90 
minutes, with samples taken from the basal well at 10, 30, 60 and 90 minutes, and 
replaced with an equal volume of blank KRB-BSA. The fluorescence of the collected 
samples was measured using FluoStar Optima plate-reader (BMG Labtech). The 
permeability coefficients (Papp) can be calculated according to Equation 2.5 below. This 
accounts for differing concentrations of a probe and differing surface areas of the inserts. 
Papp has the units, cm/s.  
Equation 2.5: 
𝑃𝑎𝑝𝑝 =  
∆𝑚𝑎𝑠𝑠
∆𝑡𝑖𝑚𝑒. 𝐴𝑟𝑒𝑎. 𝐶0
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Following the conclusion of the permeability study, the inserts are washed three times 
with PBS, to remove free probes from the cells. Fixation of cells is performed using 3% 
paraformaldehyde incubated with the cells for 15 minutes at room temperature. Following 
the fixation, cells are washed a further three times with PBS before the application of the 
nuclear stain Hoechst (0.1μg/mL) for 15 minutes at room temperature. The inserts are 
then washed three times with PBS, and the membrane cut away from the insert and placed 
onto a microscope slide in Daco Mounting Media for confocal fluorescence microscopy. 
The imaging of the inserts removed from the Transwell studies was done on a Leica TCS 
SP5 confocal microscope, using a series of three sequential scans to compensate for the 
different fluorophores used. The main fluorophores analysed were Hoechst (excitation 
laser = 405nm, emission detection = 420-440nm), Alexa fluor 488 (excitation laser = 
488nm, emission detection = 510-540nm), Tetramethyl Rhodamine (excitation laser = 
544nm, emission detection = 560-600nm) and Alexa fluor 647 (excitation laser = 633nm, 
emission detection = 650-680nm). 
2.2.8 Statistical Analysis 
2.2.8.1 Flow Cytometry 
For analysis of all flow cytometry fluorescence data, the geometric mean of the 
fluorescence intensity of the gated the single cell population was used as a single technical 
replicate for these experiments (see figure for gating example). In all studies, blank cells 
are initially tested to measure cellular autofluorescence and this value is subtracted from 
the fluorescence intensities of the assayed cells in that experiment. To normalize data 
from for each fluorescence probe, the mean fluorescence intensities of the technical 
replicates, of 37 oC pulsed cells (minus blank cell fluorescence) is taken as 100% and the 
intensities of the other cell treatments are expressed as a percentage of this value. 
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In the pulse-chase assays, to confirm there has been a significant change in cell associated 
fluorescence over the duration of the chase. The fluorescence associated to chase cell time 
points were compared to the fluorescence associated to the cell that have only undergone 
the pulse at 37 oC, through a one-way ANOVA with Dunnett’s post-test. In this the pulse 
only cells were used as the reference for the multiple comparison analysis. Significance 
is defined as a p-value < 0.05. In addition, to confirm that any efflux from cells was due 
to an active process, the chase time points at 37 oC were compared to the same time point 
at 4 oC. This was done using a one-way ANOVA with Tukey post-test, significance was 
defined as a p-value < 0.05. 
Competitive uptake assays, using TfR ligands, were analysed by comparison of cells that 
were only pulsed with the fluorescent ligand only, at a fixed concentration. With cells that 
were pulsed with the same concentration of fluorescent ligand and variable concentrations 
of unlabelled ligand. The comparison was made with a one-way ANOVA with a 
Dunnett’s post-test, using the non-competed cells as the control group for the post-test. 
Significance was defined as an output p-value < 0.05. 
For graphical representation of the data, presented in this chapter, unless stated otherwise 
in the figure legends, the data within a graph will be expressed as the mean ± standard 
deviation. Flow cytometry gating and extraction of the geometric means of the data was 
performed using the FlowJo software package. Initial normalization of the data was 
performed in Microsoft Excel, with statistical analysis and graph production done using 
GraphPad Prism 5 (CA, USA).  
2.2.8.2 Microscopy Co-localization: 
Following collection of z-stack image files, these were imported into the Fiji image 
analysis software for processing and co-localization analysis. Here each stack is split into 
Chapter 2 
 
63 
 
individual slices for analysis using JACoP (Just Another Colocalization Plugin) in Fiji. 
In this analysis the Mander’s Colocalization method was selected, to observe the 
proportion of thresholded ligand fluorescence which was co-localized with thresholded 
dextran fluorescence, at the conclusion of the chase phase (Manders et al. 1993). 
Thresholding in this way of the images allows for the removal of background fluorescence 
from the analysis. The colocalization fractions for each slice in the z-stack were averaged 
to produce an output for value for that replicate, and for final analysis the combination of 
multiple microscopy stacks were used to produce the output colocalization fractions for 
the ligands with dextran labelled lysosomes. These were expressed as mean ± standard 
deviation.  
2.2.8.3 Permeability Assays: 
TEER values of bEnd3 cells alone were calculated by subtracting the resistance across a 
blank insert from the resistance of the inserts with cells grown on them. The resistance 
value of the cells alone was then multiplied by the area of the inserts (0.33 cm2) to 
calculate the TEER value. The TEER value of the inserts used in all permeability studies 
was expressed as mean ± standard deviation. 
The permeability co-efficient of each probe, across the endothelial cells, was calculated 
using the equation below. This is done by considering the permeability of the probe across 
the filter alone, before it reached saturation if applicable. 
Equation 2.6:  
1
𝑃𝑎𝑝𝑝𝑇𝑜𝑡𝑎𝑙
=  
1
𝑃𝑎𝑝𝑝𝐸𝑛𝑑𝑜
+
1
𝑃𝑎𝑝𝑝𝐹𝑖𝑙𝑡𝑒𝑟
 
Comparison of the apparent permeability coefficient of all probes across the b.End3 cells 
was performed using a one-way ANOVA and Tukey post-test, to compare all possible 
combinations of the probes. Significance was defined as a p-value < 0.05 from the post-
test. Graphical representation of the data was done using the mean ± standard deviation 
for all data points and were produced using GraphPad Prism 5 software. 
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2.3 Results and Discussion 
2.3.1 Fluorescent Labelling of 8D3 and Isotype Control IgGs 
The Life Technologies IgG labelling kits provided sufficient labelling and purification of 
both IgGs. The 8D3 antibody had a calculated 4.19 moles of Alexa Fluor 647 dye per 
mole of IgG, while the isotype control had 4.8 moles of the dye per mole of IgG. Re-
purification of both 8D3 and isotype control antibodies at 5 and 4 months respectively 
showed that the isotype control labelling remained intact. However, of the labelled 8D3, 
only 80% of Alexa Fluor 647 absorbance remained associated with the 8D3 antibody, 
with 20% appearing as free-dye, unbound to the antibody. The presence of free dye 
altered the calculation of the concentration of antibody and the dye binding, showing a 
lower than expected IgG concentration, but an increase in the number of molecules of dye 
per molecule of antibody. The decrease in antibody concentration is likely due to a loss 
of protein within the column, which may be present in other elution volumes from the 
column.  
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2.3.2 Retention of fluid-phase endocytic probe dextran by b.End3 cells 
The uptake of 10kDa dextran by the cells was confirmed to be an active process, with a 
significant increase in the uptake at 37oC compared to 4oC (P<0.0001). Active efflux of 
the 10kDa dextran was not observed during the chase steps, with no significant difference 
(P>0.05) at all pairs of chase time-points (4oC and 37oC). Retention of the 10kDa dextran 
Figure 2.4. Labelling of 8D3 and Isotype Control IgGs with 
Alexa Fluor 647 
Graphs A and B refer to 8D3 labelling, A shows a absorbance of the labelled 
antibody from 250nm-800nm, with the peaks at 280nm (tryptophan residues) 
and 647nm (fluorophore) highlighted. B shows the integrity of the labelling, 
and the presence of free dye in the sample, 5 months after labelling. Graphs C 
and D refer to Isotype Control IgG labelling and it can be seen that all dye is 
associated with the antibody and no free dye is seen in the re-purification (D). 
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is highly likely, due to the known, fluid-phase uptake and trafficking to lysosomes of 
dextrans. Some loss may occur with longer chase durations. This was confirmed by the 
data in these studies, with only 10-20 % of pulsed fluorescence lost from cells over the 
one hour chase.   
 
  
 
 
 
2.3.3 Modulation of transferrin endocytosis into b.End3 cells. 
Three strategies were examined to modulate the uptake of transferrin by b.End3 cells, 4 
oC vs 37 oC uptake, the direct competition of holo-transferrin Alexa Fluor 488 uptake 
using unlabelled holo-transferrin and siRNA against the clathrin assembly protein AP2μ2.  
The b.End3 cells pulsed at 4ºC show a similar fluorescence intensity to that seen with the 
blank cell population, with the flow cytometry, intensity profiles overlapping. This 
confirms endocytosis was unable to take place at 4 oC in b.End3 cells. In contrast to blank 
cells and 4ºC pulse cells, those pulsed at 37ºC, produce a significantly increased cell-
associated fluorescence at the conclusion of the pulse. This would indicate that the 
Figure 2.5. Dextran 10kDa Alexa Fluor 647 Pulse-Chase studies in b.End3 cells 
Graph A and B show the proportion of dextran 10kDa remaining in cells, following a 45 minute 
pulse and chase at either 4oC (blue) or 37oC (red). The fluorescence associated with cells at 4oC is 
also shown in black on graph A. n=3 in triplicate for all time points and background auto-
fluorescence of cells has been subtracted from all data points, mean ± std. 
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internalisation of transferrin into b.End3 cells is an active process, requiring cellular 
metabolic activity to induce (Figure 2.8). The transferrin receptor is known to be 
internalised by clathrin-mediated endocytosis, which involves several GTPase proteins. 
Therefore, for optimal endocytic activity 37oC is likely to be required for the metabolic 
demands of the process.  
The competitive uptake studies demonstrate that the process of transferrin endocytosis is 
a self-competitive process. Maximum fluorescence intensity was obtained in the case of 
the 10nM labelled holo transferrin incubated with 0nM unlabelled holo transferrin. 
Increasing the concentration of unlabelled transferrin reduced the cell-associated 
fluorescence from transferrin Alex Fluor 488. This allows the inference that uptake of 
holo transferrin is saturable. The data in Figure 2.6, also confirms that the transferrin 
protein has a defined ligand-binding site on the transferrin receptor and that its 
internalisation is due to a receptor-mediated process within the cells. 
By using the existing data in the literature on the affinity of transferrin for the TfR, it is 
possible to calculate an experimental Ki for the efficiency of the competition with 
unlabelled transferrin in this experiment. Modelling of the curve in Figure 2.6.B. allowed 
for the calculation of the Ki, which was found to be 7.5 nM. This value for the Ki is 
representative of the Kd of transferrin for the receptor. Reported values in the literature 
for holo transferrin’s affinity for the TfR range from 2-8 nM, confirming that this 
methodology enables accurate and comparable measures of ligand-receptor interactions. 
Additionally, the experimental IC50 was calculated to confirm that the labelling of the 
transferrin protein had not altered its ability to bind to the TfR. The IC50 was calculated 
as 33.2 nM, within acceptable tolerance accepted for these studies. As the labelled and 
unlabeled compounds are the same, the IC50 (50% displacement of fluorescence) should 
occur at the when the concentration of both probes is approximately equal.  
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The demonstration of the self-competitive nature of transferrin uptake confirms why the 
transferrin protein itself has limited use in vivo as a targeting ligand. The high plasma 
concentrations of the transferrin protein were represented by the increasing 
concentrations of the unlabelled ligand in these studies. Transferrin targeted DDS’s are 
seen to be competed in vivo by transferrin in circulation, and overall, they lack effective 
brain penetration ability.  
 
 
 
Finally, the uptake of transferrin was reduced through siRNA knockdown of the AP2μ2 
adaptor protein of CME. Knockdown of this protein prevents the assembly and formation 
of the clathrin-coated pits at the plasma membrane of cells. Flow cytometry demonstrated 
that the knockdown AP2μ2 reduced transferrin uptake to 55% of the uptake of 
untransfected or control transfection cells (Figure 2.7.B). Due to the heterogeneity of 
Figure 2.6. Competition of holo-transferrin Alexa Fluor 488 uptake by 
unlabelled  
Both graphs show the effect of increasing concentrations of unlabelled transferrin on the uptake of. 
Transferrin Alexa Fluor 488 concentration – 10nM, all values expressed as a percentage of 
unchallenged cellular fluorescence. *** denotes P<0.001 when compared to unchallenged 
fluorescence, n = 3 in triplicate, mean ± std. 
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siRNA uptake into b.End3 cells, it is always unlikely that siRNA transfection would 
reduce transferrin uptake to the levels of blank cells or 4 oC treated cells. However, the 
fact the reduction of transferrin uptake is significant, using the AP2μ2 siRNA, confirms 
the involvement of clathrin-mediated endocytosis in the internalisation of the transferrin 
receptor in b.End 3 cells. The knockdown of the AP2μ2 was confirmed by Western Blot 
analysis of cell lysates. This confirmed the effects seen by flow cytometry were due to 
direct modulation of the AP2μ2 protein and not the results of the transfection protocol. 
 
 
 
2.3.4 Effect of ligand concentration of transferrin efflux from b.End3 cells 
Transferrin is known to undergo receptor-mediated endocytosis in BMEC cells. However, 
by increasing the concentration of the ligand to beyond saturation of the receptor, it 
appears possible to drive uptake through both receptor-mediated and fluid phase 
pathways. Transferrin-AlexaFluor 488 again showed significantly increased uptake at 
37oC compared to 4oC in all studies (P<0.001, Figure 2.8.). The efflux of transferrin was 
Figure 2.7. siRNA Modulation of Transferrin uptake in b.End3 cells 
A. shows the Western Blot images confirming siRNA knockdown of AP2μ2 protein levels. B. 
shows AP2µ2 knockdown to reduces transferrin uptake in b.End3 cells, n=3 in triplicate, * = 
P<0.05.  
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confirmed as an active process by the comparison of fluorescence remaining within cells 
at matched 4 oC and 37 oC time points.  
In the pulse-chase experiments, it was demonstrated that receptor saturation, with 
transferrin-AlexaFluor 488, altered the proportion of transferrin lost from cells during the 
chase phase. Unlike the 10kDa dextran, transferrin can enter the cell via receptor-
mediated endocytosis, as shown in Figure 2.6. Uptake of transferrin-AlexaFluor 488 was 
competed by the addition of increasing concentrations of unlabelled transferrin. When 
10nM of fluorescent transferrin was added to the cells Ki for unlabelled transferrin 
competing for the receptor was found to be 33.2 nM (range 19-46nM, n=3).  When low 
concentrations of transferrin were applied to cells (5nM), the proportion remaining 
associated to the cells after a 60-minute chase was 12% of the pulse fluorescence. Pulse 
concentrations above the Kd of transferrin for the TfR, 50nM and 588nM, resulted in an 
increased proportion of pulse fluorescence retained by cells, 25% and 52% respectively.  
The half-life of transferrin loss from cells does not appear to be altered by varying pulse 
concentrations of transferrin, ranging from 6-10 minutes across all concentrations. 
Comparisons to dextran pulse-chase data show the fluid phase marker is retained by cells 
with only 10-20 % of pulsed dextran fluorescence lost from cells over the 60-minute chase 
phase at 37 oC. 
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Figure 2.8: Transferrin Pulse-Chase Studies: the effect of Pulse concentration on 
transferrin retention 
Figures .A-C show varying concentrations of fluorescently-labelled transferrin applied to the cells in 
a single 45 min pulse, and the proportional  retention of the ligand remaining cell associated during  a 
60 min ‘chase’ performed at 4oC (BLUE) and the 37oC (GREEN). The concentrations shown in each 
graph are as follows: A = 588 nM, B = 50 nM, C = 5 nM. Figure D shows a summary graphic of the 
37oC chase from Figures A-C. n = 3, in triplicate, *** denotes P<0.001 compared to [P37]. 
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2.3.5 Characterisation of 8D3 Antibody  
As with the transferrin protein, initial characterisation of the 8D3 antibody was made by 
studying the endocytic process of the antibody. This was done by comparing the uptake 
of 8D3 at 4 oC and 37 oC, as well as confirming the antibody’s affinity for the transferrin 
receptor. Throughout these studies, comparisons were made between the 8D3 antibody 
and an isotype control antibody.  
When cells were pulsed at 4 oC, there was limited fluorescence associated with cells for 
both antibodies. The fluorescence was only slightly increased over that of cellular auto-
fluorescence. Both the 8D3 antibody and the isotype control antibody required 37 oC 
conditions to increase uptake into the b.End3 cells. This confirmed the uptake of both 
antibodies was an active cellular process. Confocal microscopy of the 4 oC and 37 oC 
conditions for the 8D3 and isotype control antibodies also confirmed the uptake of both 
as an active process. This was to be expected with the 8D3 antibody, as it targets the TfR 
to be internalised within the cell. In contrast, it was unexpected that the isotype control 
be taken up as it has no target receptor. However, some of the uptake of the isotype control 
antibody may be due to interactions with the Fc Receptor, more specifically the neonatal 
Fc Receptor (FcRn) on the surface of the b.End3 cells. The localisation of these receptors 
with BMECs is unclear and evidence in the literature suggest expression of FcRn is varied 
throughout the CNS, limiting its use as a target receptor for brain delivery (Schlachetzki 
et al. 2002). There may also be the possibility for the isotype control IgG to be internalised 
through non-specific, fluid phase mechanisms, in a similar manner to dextran in the 
previous study (Figure 2.5). 
To confirm the specificity of the uptake mechanism, competitive uptake studies were 
performed using both antibodies. To look at the self-competitive uptake of both 
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antibodies as well as confirming the specificity of the 8D3 antibody by attempting to 
compete its uptake using the isotype control antibody.  
 
 
The uptake of labelled 8D3 antibody was competed using an unlabelled 8D3 antibody, 
confirming receptor-mediated uptake, a process which appears saturable. The apparent 
affinity constant of 8D3 for the receptor was calculated as a Ki of 1.6 nM, confirming 
Figure 2.9: Comparison of the Competitive Uptake of Chimeric 8D3 and 
Isotype Control IgG 
Figures 3.A-C show the competition of labelled antibody (either 8D3 or isotype control) uptake by 
varying concentrations of unlabelled antibody (either 8D3 or isotype control). A = 8D3-647 
competed by unlabelled 8D3, B = Labelled Isotype control competed by unlabelled isotype control 
and C = 8D3-647 competed by unlabelled isotype control antibody. The data indicates 8D3 uptake 
to be specific and saturable.   Figure D shows the competitive uptake curves for the labelled 8D3 
and labelled isotype control (competed by respective unlabelled species) predicting an apparent 
affinity constant Ki =1.6nM. n = 3, in triplicate, *** = p < 0.001 compared to unchallenged cells 
(white bar), * = p < 0.05 compared to unchallenged cells (white bar), ns = p > 0.05. 
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8D3 as a high-affinity antibody. The calculated Ki, from Figure 2.9, validates published 
work with the 8D3 antibody which has a measured the affinity of the antibody as between 
2-3 nM in mouse brain microvascular endothelial cells (Lee et al. 2000). 
The specificity of 8D3 uptake was confirmed by competition with unlabelled isotype 
control antibody, which did not affect labelled 8D3 uptake by b.End3 cells (Figure 2.9. 
C). This confirms that the 8D3 antibody has a specific receptor binding site, that is not 
shared with an untargeted control antibody. 
Finally, the uptake of the isotype control antibody into BMECs was confirmed as a non-
specific, endocytic process. Attempted competition of the control antibody with 
unlabelled control antibody failed to decrease the fluorescence associated with the b.End3 
cells.  Thus, confirming a non-saturable, non-specific uptake pathway for the isotype 
control antibody (Figure 2.9.B). 
The 8D3 anti-TfR antibody shows active efflux from cells at all concentrations and all 
time points (Figure 2.10). This was confirmed by significant differences between the 
pulse fluorescence and the 37oC chase time points. Additionally, significant differences 
were seen between 4oC and 37oC chase time points. As with transferrin a similar 
concentration-dependent efflux potential from b.End3 cells were observed with the 8D3 
antibody in the pulse-chase studies. At low concentrations (1nM) of labelled 8D3, only 
22% of the pulse fluorescence remains associated with cells after a 60-minute chase at 
37oC (Figure 2.10.C). Whereas, at the high pulse concentrations (10 nM and 170 nM) the 
fluorescence was retained by the cells at 60 minutes was 40 and 45 % of the pulse 
fluorescence, respectively.  
Following the conclusion of the chase phase, cells imaged by confocal microscopy 
exhibited high levels of co-localization between the 8D3 antibody and dextran labelled 
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lysosomes when pulsed with the highest concentration of 8D3 antibody (170 nM). Using 
the Manders co-localization test, ~87% of 8D3 fluorescence, remain in cells, was seen to 
be associated with lysosomal compartments, Figure 2.11.  Indicating trapping of the 
antibody and an inability for it to undergo further transcellular trafficking. When looking 
at the data from the pulse-chase flow cytometry study (Figure 2.10.A.), in parallel to 
microscopy, it would indicate that at the conclusion of the chase, 39.15% of the pulsed 
antibody is unable to undergo further cellular trafficking. That is to say, it will remain 
trapped within the endothelial cells and be unable to undergo an efflux process at either 
the apical or basolateral cell membrane, as the ligand is within the lysosomes and 
therefore degraded. In the Roche and Genentech studies with high and low affinity 
antibodies against the TfR, they demonstrated high affinity antibodies becoming trapped 
within lysosomes and downregulation cell surface TfR expression (Niewoehner et al. 
2014; Bien-Ly et al. 2014).  This would be supported by the high localisation of 8D3 with 
dextran-loaded lysosomes in this study. These findings could suggest that high 
concentrations of 8D3 antibody leads to surface crosslinking of the TfR, by antibodies, 
prior to endocytosis. If crosslinking does take place, Moody et al (2015) demonstrated 
that this can lead to increased lysosomal trafficking of the crosslinked receptor, as 
observed by colocalization with dextran labelled lysosomes (Moody et al. 2015; 
Humphries et al. 2011). 
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At the lowest 8D3 pulse concentration (1 nM), less co-localization was observed between 
the antibody and lysosomes, with more distinct separation between the fluorescence 
channels. Quantification of the co-localization with low 8D3 concentrations showed 23% 
Figure 2.10: 8D3 Pulse-Chase Studies: the effect of Pulse concentration 
on 8D3 retention  
Figures A-C show varying concentrations of fluorescently-labelled 8D3 applied to the cells 
in a single 45 min pulse, and the proportional retention of the ligand remaining cell 
associated during a 60 min ‘chase’ performed at 4oC (BLUE) and the 37oC (RED).  The 
concentrations applied to cells are as follows: A = 170 nM, B = 10 nM, C = 1 nM. Figure 
D shows a combined graphic of the 37oC chase from Figures A-C. n = 3 in triplicate, mean 
± std, ** = p < 0.01, *** = p < 0.001, this is when compared to the [P37] cells. 
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of the fluorescence remaining in cells was associated to lysosomal compartments of the 
cell. This would equate to 5.06% of the pulsed fluorescence which is unable to undergo 
further cellular trafficking at the conclusion of the chase phase. This proportion is based 
on the Mander’s colocalization coefficient for 8D3 1 nM multiplied by the percentage of 
pulse fluorescence associated to cells from Figure 2.10.C. 
 
Figure 2.11: Sub-cellular localization of 8D3 following the chase 
The above shows the distribution of the 8D3 antibody from Sanofi, at the conclusion 
of the 1 hour chase at the highest and lowest applied concentrations. The figure 
shows both a single slice and a max projection for each concentration. In the merged 
images, red = 8D3, green = dextran, blue = Hoechst, Scale Bar = 25 µm.  
Chapter 2 
 
78 
 
The saturation of the TfR, with an excess 8D3 antibody, as with the Tf ligand, will lead 
to a proportion of the antibody being taken up by fluid-phase, non-specific uptake 
mechanisms. This proportion is unable to undergo the same cellular trafficking as the 
antibody bound to the receptor, and as exemplified by other fluid-phase markers like 
dextran. In a clinical/in vivo setting, this over-saturation would represent “wasted” 
formulation, that although reaching the vasculature of the brain (i.e. the barrier to entry) 
is unable to reach the brain parenchyma and target site. Degradation of a formulation 
within lysosomes the brain endothelial cells would be a costly outcome, due to the 
wastage of expensive materials. By optimizing the concentration used in studies in vitro 
and in vivo, there will be minimal wastage of the dose, with the maximal proportion of 
the compound available to undergo further cellular trafficking in the BMECs and 
potentially undergo transcytosis. However, when considering the total amount/mass of 
compound available to undergo potential transcytosis, high, receptor saturating 
concentrations may result in a greater mass compound reaching the target site. Even 
though at high concentrations this may represent a lower proportion of the internalized 
compound. 
The isotype control antibody, although taken up by b.End3 cells were not seen to be 
effluxed from the cells during the chase phase of the study. No significant difference was 
observed between the pulse fluorescence and the fluorescence associated with the cells at 
the 37oC chase time points. Additionally, there was no difference between the 4oC chase 
and 37oC chase matched time points. This confirms the lack of a specific uptake pathway 
for the isotype control IgG. 
2.3.6 Characterisation of the 8D3-4 antibody 
The recent work of Roche and Genentech, studying the effect of affinity and valency on 
the ability of TfR targeting ligands to highlights the importance of these factors in 
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delivery across the BBB. The 8D3 antibody, provided by Sanofi and previously 
characterised is a high-affinity antibody, with low nanomolar (2-3 nM) affinity for the 
TfR. However, this high-affinity causes decreased TfR levels on the cell surface of 
endothelial cells and show limited delivery capacity across the barrier.  
To test the effects of antibody affinity on the cellular trafficking and uptake of anti-TfR 
antibodies, the 8D3-4 antibody was obtained from Abbvie. This is a mutated form of the 
8D3 antibody with an estimated 10-fold lower affinity for the TfR compared to the native 
8D3 antibody. The 8D3-4 antibody was fluorescently labelled with the same method as 
previously described. However, with the 8D3-4 antibody, this lead to over-labelling of 
the antibody, with 11.95 moles dye/mole of antibody. The degree of antibody labelling 
was reduced by decreasing the labelling time and the fluorophore concentration. Firstly, 
the labelling time was reduced to 40 minutes, with the same quantity of fluorophore, this 
produced a labelling efficiency of 7.51 moles dye/mole of antibody. This would still be 
considered over-labelling of the protein. To further reduce the labelling efficiency the 
quantity of fluorophore used was reduced to 1/4 of the sample provided. The labelling 
reaction time was also reduced to 20 minutes. This enabled the labelling efficiency to be 
decreased to 1.38 moles dye/mole antibody.  
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To confirm that over-labelling of the 8D3-4 antibody would alter the kinetics of receptor 
interaction and uptake all three labelling efficiencies were tested in competitive binding 
and uptake studies in b.End3 cells. Self-competition of 8D3-4 binding to b.End3 cells at 
4 oC produced three different profiles for the fluorescence associated with cells. 
  
Figure 2.12: The elution profile and UV-vis spectra for the labelling 
of 8D3-4 
Figure A shows the elution of the profile of the 8D3-4 antibody through a Sephadex-
g70 column. The red line represents the absorbance of the fluorophore at 650 nm at a 
given elution volume, while the blue line represents tryptophan absorbance at 280 nm. 
The full absorbance spectra, from 250 – 800 nm is shown in Figure B. The labelling 
efficiency in this case was equivalent to 1.38 moles dye/ mole IgG. 
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Figure 2.13: The effect of fluorophore labelling efficiency on 8D3low ability to 
bind to the TfR 
The figure summarizes the effects of over labelling of an antibody on its ability to interact correctly 
with the target receptor. Challenge of an over-labelled IgG, as occurs in graphs A-D, with unlabelled 
antibody fails to decrease fluorescence. In A and B the antibody is labelled with 11.95 moles 
dye/mole IgG, while in C and D 7.51 moles dye/mole IgG. Figures E and F show appropriately 
labelled antibody (1.38 moles dye/mole IgG) and self-competition was observed and the binding 
curve model can be applied. For all labelling efficiencies n = 3, mean +/- std., background of 
unlabelled cells subtracted from all values prior to analysis. 
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With the highest over-labelled antibody, the addition of increasing concentrations of 
unlabelled 8D3-4 caused the cell-associated fluorescence to increase. This may be due to 
a self-quenching effect of high fluorophore concentrations, in close proximity, at regions 
of high levels of TfR on the surface of the cells. When unlabelled antibody was added, 
this would cause a spacing out of the labelled antibodies on the cell surface. The increased 
space between labelled antibodies is then likely to reduce the effect of self-quenching and 
so caused an increase in cell-associated fluorescence, as seen in Figure 2.13.  The 
intermediately labelled antibody (7.51 moles dye/mole antibody) showed non-significant, 
the competition of binding to the b.End3 cell surface. While there was no visible 
competition of uptake at this labelling efficiency, it is also likely that the over-labelling 
is still having a self-quenching effect, as seen with the higher labelling efficiencies. 
However, as the degree of labelling is lower, the self-quenching effects are likely to be 
less. Therefore, the increased spacing of labelled 8D3-4, on the b.End3 cell surface, with 
increased unlabelled 8D3-4 concentrations, produces a less observable effect on the 
fluorescence (See Figure below). 
 
  
Figure 2.14: The effect of over labelling on antibody fluorescence intensity 
The above is a schematic as the potential effect of over labelling an antibody with fluorophore. The schematic 
at the top of the figure shows how over labelling can cause self-quenching of fluorophores and diminished 
fluorescence from the labelled antibody. When these over-labelled antibodies are applied to the cell surface, 
in the case of receptor saturation (lower left), the fluorophore is further quenched by the close proximity of 
neighbouring antibodies. When unlabelled IgG is applied to cells (lower right) competition occurs, and the 
space between labelled IgGs increases. This causes the fluorescent intensity from the labelled IgG to increase, 
resulting in a net increase in cell associated fluorescence. 
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With the lowest labelling efficiency of 8D3-4 (1.38 mole dye/mole antibody) the binding 
to b.End3 cells was decreased in the presence of unlabelled 8D3-4. This confirms the 
binding of 8D3-4 to b.End3 cells as a self-competitive process. Modelling of the binding 
curve using standard kinetic models calculates the experimental IC50 of the antibody to 
be 24.6 nM (Figure 2.13.F). As the labelled concentration of 8D3-4 was 30 nM for these 
studies, this would also provide evidence of the self-competitive nature of 8D3-4 binding. 
This competition data also serves as proof that the over-labelling of the antibody in the 
previous studies was contributing to the lack of competition seen in the analysis. The self-
quenching of the fluorophore and the potential for a reduction of antibody specificity with 
over-labelling of the antibody were confirmed by these binding studies with the different 
affinities.  
Pulse-chase analysis of the low-affinity 8D3-4 antibody’s uptake and efflux from b.End3 
cells confirmed that the uptake into cells is an active process. This was seen by 
comparison of 37 oC to 4 oC pulse phases, with a 10-fold increase in fluorescence 
associated to cells in the 37 oC pulse. As with the other transferrin receptor probes, this 
was to be expected, as previously stated, the turn-over of the TfR from the cell membrane 
is an active endocytic process. Involving, rac GTPase proteins in the assembly and 
cleavage of vesicles from the cell membrane, to form the clathrin-mediated endosome. 
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The 8D3-4 antibody exhibits active efflux from b.End3 cells using the pulse-chase assay 
(Figure 2.15). All 37 oC chase time-points show a significant decrease when compared to 
the 37 oC pulse associated fluorescence. At all chase time-points, a significant difference 
was observed between the 37 oC and 4 oC chase fluorescence values. Varying the pulse 
concentration of 8D3-4 again demonstrated how receptor saturation has an impact on the 
proportion of internalised ligand that can be effluxed from cells. As the labelled 8D3-4 
concentration was increased, from 10 nM and then to 100nM, the fraction of pulsed 
fluorescence remaining cell-associated after a 60 minutes chase at 37 oC also increased 
from 24.4% to 36%. However, when comparing these values to those of the 8D3 (high-
affinity antibody), the 8D3-4 antibody has a greater efflux potential at these 
concentrations than that of the 8D3. Due to the lower affinity for the receptor with the 
8D3-4 antibody, TfR saturation will not occur until a significantly higher concentration 
Figure 2.15: The effect of pulse concentration of retention of 8D3low 
antibody in b.End3 cells 
The figure above shows how increasing the concentration of the low affinity antibody 
decreases the proportional release of fluorescence over the chase. Figure A shows the 
pulse concentration of 10nM (lower than Kd) while figure B a higher concentration, 100 
nM. Blue signifies the chase at 4 
o
C, while red indicates the active chase at 37 
o
C. Data 
shown as mean ± std, n = 3 in duplicate, all data points have the auto-fluorescence of 
blank cells subtracted prior to further analysis. 
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than the 8D3 antibody. As such, at high concentrations, more of the 8D3-4 antibody will 
be internalized when bound to the TfR versus the fluid-phase uptake that could occur 
when the receptors are fully saturated. Therefore the 8D3-4 antibody that is within b.End3 
cells still retain the ability to be trafficked throughout the cell. 
In Roche and Genentech studies, the high affinity and bivalent forms of the targeting 
strategy caused down-regulation of the TfR within BMECs in vitro. This was believed to 
be due to both receptors cross-linking, with the bivalent forms, triggering lysosomal 
delivery signals for the bound TfR (Bien-Ly et al. 2014; Yu et al. 2014). Additionally, it 
has been theorised that the high-affinity forms of the anti-TfR antibodies are unable to 
release from the receptor when they reach the basolateral membrane of BMECs. Whereas, 
low-affinity antibodies against the TfR, can be taken up into BMECs from the luminal 
cell surface, undergo a transcellular trafficking process, and release from the receptor at 
the basolateral membrane.  
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2.3.7 Permeability Assay 
The data presented here relates to the b.End3 cell line and transport studies using different 
molecular weight dextrans (10kDa and 70kDa), recombinant human holo-transferrin and 
the chimeric anti- TfR antibody 8D3 (a rat anti-mouse IgG1 isotype). Figure 2.16.A shows 
the percentage mass transported of dextran 10kDa across a Transwell insert. Across the 
blank inserts there was nearly 40 % mass transport, a permeability coefficient of 1539 x 
10-6 cm.s-1. The presence of cells reduced the mass transport over the 90-minute 
experiment to approximately 13 % of loaded dose, and did not reach an equilibrium over 
the duration of the study. Dextran 10 kDa had a permeability coefficient of 12.5 ± 6.3 
cm.s-1 across the b.End3 monolayer. Dextran 70 kDa (Figure 2.16.B) showed a lower 
permeability coefficient than dextran 10 kDa, with a Papp across the b.End3 monolayer 
of 9.2 ± 5.1 x 10-6 cm.s-1. This was expected, as dextran is used in permeability assays as 
a marker of paracellular permeability and barrier integrity. It is widely believed that any 
observed dextran in the basolateral chamber is due to paracellular leakage in the system. 
As the molecular weight of dextran increases, the permeability is expected to decrease, 
which was seen in this study. The permeability of dextrans across the across the b.End3 
monolayer does appear to be slightly high, when compared to the permeability of sucrose 
across b.End3s  in the literature. Omidi et al. (2003) measured sucrose permeability as 
19.6±2.6 x 10-6 cm.s-1 in b.End3 cells. Further studies of b.End3 permeability found lower 
permeability coefficients for both 10 and 70 kDa dextrans (Li et al. 2010), approximately 
10-fold  lower than the Papp calculated in this chapter. Again demonstrating the 
limitations of a purely permeability assay based approach to evaluating targeting ligands 
and delivery systems. 
Transferrin permeability studies showed the a permeability coefficient of 4.6±1.8 x 10-6  
cm.s-1 across the monolayer (Figure 2.16.C). This was lower than the permeability of all 
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other probes used in the study. As transferrin is a targeted ligand it may be possible that 
the uptake or cell association was greater than that of dextran, and so was internalised 
rather than exploiting paracellular transport mechanisms. When considering the 
hydrodynamic radius of transferrin, it is greater that both dextran 10 and 70 kDa, and so 
this may be a factor influencing the permeability of transferrin. Studies of transferrin 
permeability across primary BMECs in vitro have shown permeability coefficients of 
approximately 1 x 10-7 cm.s-1 (Hersom et al. 2017). This is a far lower than the transferrin 
permeability seen in this study and indicates how limiting permeability assays across 
immortalised BMECs can be.  
The final ligand studied in this chapter was the 8D3 anti-TfR antibody. Across the b.End3 
cell monolayer this antibody was found to have a higher apparent permeability than the 
endogenous ligand transferrin, as shown in Figure 2.16. Indeed, 8D3 had a higher 
permeability coefficient than dextran 70 kDa, suggesting there may be some form of 
trafficking enhancement to the delivery of 8D3 across the monolayer. This is to be 
expected as 8D3 is a targeting ligand and as such has been shown to gain access to the 
CNS and enhance delivery of a cargo to the CNS.  
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Figure 2.16 Permeability Assay Data, b.End3 cells 
The above figure shows the permeability assay data for the following probes: Dextran 10 kDa (A), 
Dextran 70 kDa (B), Transferrin (C) and 8D3 anti-TfR IgG (D). The studies were performed on 
Transwell inserts with 0.4 µm pores, 0.33 cm
2
 area. Each graph shows the delivery across blank 
inserts (squares) and inserts with b.End3 cells grown on (circles). Prior to conducting the 
permeability assay all inserts with cells grown on had a mean TEER value of 12.2 ± 1.6 Ω.cm
2 
(n = 
40 inserts). The data in graphs A-D is expressed as mean ± std with the following number of 
replicates. Dextran 10 kDa: insert only n = 4, cells and insert n = 6. Dextran 70 kDa: insert only n = 
6, cells and insert n = 13. Transferrin: insert only n = 6, cells and insert n = 15. 8D3: insert only n = 
4, cells and insert n = 8. 
The table in E summarises the permeability coefficients for the probes used in this study. Looking 
at the permeability across insert only, the combined cells and insert and the permeability of the 
b.End3 monolayer only. The data in the table is shown as mean ± std. 
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From an initial comparison of the permeability coefficients, it would appear to suggest a 
size-dependent restriction of transport across the barrier, based on the data for dextran 
10kDa, dextran 70kDa and transferrin. However, the antibody against the transferrin 
receptor appears to behave against this trend, showing the highest Papp of all 
macromolecules used. Both the lower percentage mass transported and the lower Papp 
for transferrin could serve to demonstrate the recycling process from cells, which is the 
dominant trafficking pathway of transferrin within cells. The other macromolecules used 
do not exhibit as defined a process as transferrin and so this data could suggest that 
transferrin taken in by the cells is then re-released into the apical compartment, thus 
lowering the rate permeability across the monolayer and insert. 
A consideration that must be considered in the permeability assay is the numerous 
possible routes a molecule could take to cross the barrier system, not only transcellular 
pathways but also paracellular routes. These will contribute significantly to the observed 
permeation of the macromolecules. The b.End3 barrier integrity can be questioned based 
on the low electrical resistance values recorded, 12Ω.cm2, which in comparison to rodent 
in vivo cerebrovascular capillaries resistances, which typically exhibit greater than 
1000Ω.cm2 TEER (Crone and Christensen 1981; Crone and Olesen 1982). In vitro studies 
with BBB models of increasing resistance have shown that the permeability of molecules 
such as dextran is reduced in a manner reflecting the increase in resistance of the system 
(Gaillard and de Boer 2000). The in vivo permeability coefficient of the paracellular 
marker, sucrose, to the brain is has been observed to be typically less than 0.1x10-6 cm.s-
1 (Ohno et al. 1978; Rapoport et al. 1978). The in vitro permeability of these 
macromolecules is greatly above this known in vivo marker and therefore raises further 
questions as to the integrity of the b.End3 monolayer used in these experiments. 
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2.3.8 Confocal Microscopy of Inserts 
 
 Dextran 10kDa 
(green) 
Dextran 70kDa (red) Merge 
Apical 
   
Basal 
   
Figure 2.17 – Dextran 10kDa and Dextran 70kDa co-incubation 
Cells grown on apical surface of 0.33cm2 Transwell membrane, pore size = 0.4µm, mean TEER value = 
12.2 ± 1.6 Ω.cm2. Cells are incubated with 200µL of Dextran 10kDa (10µM) and Dextran 70kDa 
(2.9µM) in the apical well for 90 minutes at 37°C. Frame depth varies by 2.0µm from a z-stack image. 
Red = Dextran 70kDa, Green = Dextran 10kDa, Blue = nuclear dye Hoechst, scale bar = 20 µm, n =3 in 
triplicate.   
 
As shown in the Figure 2.17 above, both the 10kDa and the 70kDa dextran can enter into 
the cell and are present across the entire depth of the cell. The punctate nature of the 
internalised structures in both greyscale images as well the merge confirms the vesicular 
localisation of both dextrans in the cells. Within all cells in the field of view there was 
evidence of both probes, showing uptake across the monolayer as a whole, not just 
localised regions of cells. There is almost complete co-localisation of the probes within 
the cells suggesting they are trafficked through common pathways following endocytosis, 
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as expected for dextran 10kDa and 70kDa combinations. This is due to dextrans non-
specific fluid phase entry and therefore localisation many aspects of all endocytic 
pathways. 
 Transferrin 80kDa 
(green) 
Dextran 70kDa (red) Merge 
Apical 
   
Basal 
   
Figure 2.18 – Dextran 70kDa and Transferrin co-incubation in b.End3 cells 
Cells grown on apical surface of 0.33cm2 Transwell membrane, pore size = 0.4 µm, mean TEER value = 
12.2 ± 1.6 Ω.cm2. Cells are incubated with 200µL of Dextran 70kDa (2.9µM) and Transferrin (625nM) in 
the apical well for 90 minutes at 37°C. Frame depth varies by 2.0µm from a z-stack image. Red = Dextran 
70kDa, Green = Transferrin, Blue = nuclear dye Hoechst, scale bar  = 20 µm, n = 3 in triplicate.  
 
In these images (Figure 2.18), as in the previous set, there are clear, punctate structures 
visible throughout all planes of the cells, indicative of vesicular structures and confirming 
cell entry of the macromolecules. The presence of both transferrin and dextran 70kDa can 
be seen throughout all cells within the image, confirming a distribution throughout all 
cells within the monolayer. Colocalisation between the two macromolecules appears to 
be to a lesser extent than observed in Figure 2.18, dextran 10kDa – dextran 70kDa co-
incubation.  The regions of co-localisation may be due to a fluid phase encapsulation of 
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dextran 70kDa molecules within regions of TfR mediated internalisation. There is also 
the potential for co-trafficking following sorting to regions such as the lysosomes of both 
transferrin and dextran that are applied to the cells (Baravalle et al. 2005). 
Overall the use of confocal microscopy of Transwell inserts to confirm cellular uptake of 
the probes used was beneficial, as it allowed confirmation of uptake into cells during the 
permeability assay. However, quantitative comparison of this uptake, with different 
probes is not possible, due to differences in factors such as laser power variation and 
fluorescent intensity of different probes. As all probes showed uptake into cells during 
the permeability assay it would suggest that this methodology is ineffective as a 
differentiator between ligands. More detailed information on the uptake and loss of 
probes from the cells was gained in the pule-chase assays performed earlier in the chapter. 
2.4 Conclusion 
In other studies looking at anti-TfR antibody uptake and transport, in either perfused 
brains or cell monolayers, the isotype control antibody used also shows uptake into the 
brain microvascular endothelial cells (Bickel et al. 1994). The control IgG used in these 
studies is raised against tri-nitrophenol and so has no expected activity on BMEC cells. 
Although uptake of the control is unexpected, it is likely due to fluid phase uptake through 
non-specific cell processes in a similar manner to the behaviour of dextran.  
It should be noted, that in these studies there is no way to determine whether efflux is 
from the apical or basal membranes. However, the ability to measure the uptake and 
subsequent loss from the cells is a key tool in the characterisation of potential targeting 
ligands. Permeability assays, as used here and in other research work are limited by the 
poor paracellular restriction seen with in vitro brain microvascular endothelial cells. Even 
the “best” in vitro models, using primary cells, still show paracellular permeability values 
that are one or two orders of magnitude worse than the in vivo systems (Smith et al. 2007; 
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Gumbleton and Audus 2001). By focusing on endocytosis and efflux trafficking in single 
cell-type culture, the actual trafficking kinetics can be examined directly.  
As seen with the data presented here, non-specific, fluid-phase markers, like dextran are 
seen to have high permeability across the b.End3 cell model used. However, when 
looking at the kinetics of uptake and loss of dextran in b.End3 cells, it was observed that 
the dextran is “trapped” within the endothelial cells. This contradictory evidence was 
observed with transferrin, where the permeability assay showed lower permeability than 
the non-targeted dextran. However, in the pulse-chase assay, transferrin was shown to 
have the desirable characteristic of being able to be effluxed from cells. Also, this assay 
has shown it could distinguish between probes that have undergone fluid-phase uptake 
and trafficking versus receptor-mediated endocytic probes, with a defined trafficking 
pathway. The pulse-chase methodology therefore, provides a more robust and useable 
measure of a ligands potential to undergo transcellular trafficking. 
The pulse-chase technique, in combination with sub-cellular colocalization microscopy, 
will be used in other work within this thesis to validate the potential of other BBB 
targeting ligands. In this chapter, we have validated the findings of other transferrin 
antibody papers, which have shown lowering the affinity for the TfR, improves the 
capabilities of the delivery system. Exemplified by comparison of the pulse-chase low 
affinity and high-affinity antibody data. This methodology will be used throughout the 
remainder of this thesis to characterise the RVG peptide. Further work will also be done 
to expand on this assay, by combining it with total internal reflection fluorescence (TIRF) 
microscopy, to view exocytosis events taking place at the basolateral cell membrane.  
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Chapter 3: Rabies Virus Glycoprotein trafficking through 
brain microvascular endothelial cells 
 
3.1 Introduction 
The Rabies Virus is a negative-strand RNA virus that belongs to the Rhabdoviridae family 
of viruses in the Lyssavirus genus. Infection of rabies virus is usually following a bite to 
the skin from an infected animal (Warrell and Warrell 2004). The virus can undergo a 
retrograde transport process from the site of infection, along the axons of neurons to enter 
the CNS at the spinal cord and ascend into the brain (Schnell et al. 2010). Ingestion of 
infected meat has also been shown to be a potential route of entry for rabies virus into the 
body (Lejeune and Hancock 2001), in this situation the virus is absorbed across the 
mucosal lining of the gut. Studies in mice have shown that there is no observed viral 
replication in the site of infection. Instead, the viruses migrate along unmyelinated 
neurones to cell bodies in the spinal cord and transmit between neurones across synapses 
(Shankar et al. 1991). The virus particles must reach neurones of the brain for replication 
to occur. This ability to pass through a cell without causing infection, it to reach a 
replication target is also observed in human immunodeficiency virus (HIV) entry across 
the mucosal epithelial cells of the gut (Amerongen et al. 1991). Here the virus crosses the 
epithelial cells by transcytosis. However, no replication occurred within these cells 
(Bomsel 1997).   
Several studies looking at the uptake mechanism of rabies virus by cells suggested that 
clathrin-mediated endocytosis is the dominant uptake pathway of the rabies virus. 
Piccinotti et al. (2013) showed co-localisation of labelled virus particles with GFP 
conjugated AP2 protein, as a marker of clathrin-mediated endocytosis. It was observed in 
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these studies that 76% of virus particles appeared in the same region as the AP2-GFP 
construct and 24% appeared to enter into the cells through an alternate pathway (Piccinotti 
et al. 2013). Earlier studies into rabies infection of cells gave evidence that acidification 
of the endosome alters the rabies virus glycoprotein (RVG) to facilitate viral aggregation 
and membrane fusion (Gaudin et al. 1993; Finke et al. 2004). 
Retrograde transport of rabies virus along axons is believed to occur through the 
interaction of the external surface glycoprotein, RVG, with the microtubule cytoskeleton 
of the neurone. Transport in this manner occurs at varying rates, but generally between 
3-10mm/hr depending on the virus (Sodeik 2000). To facilitate transport viruses will 
interact with the microtubules, through the dynactin, dynein cytoskeletal proteins within 
neurones. This movement along neuronal axons can occur in multiple states, through 
direct interaction of the viral coat protein with cytoskeletal motors. Alternatively, viruses 
within an endosome may also undergo trafficking along an axon through the interaction 
of endosomal membrane proteins with neuronal cytoskeletal proteins. The virus can move 
across neuronal synapses to facilitate its trafficking to the brain and the subsequent 
transport to other peripheral infection and replication sites. 
The complexity of RVG has meant a single receptor has not been identified to mediate 
rabies virus internalisation. The RVG protein is seen on the surface of the virus particles 
arranged in a trimer, as confirmed by SEM imaging of rabies virus particles (Gaudin Y et 
al. 1992; Sissoëff et al. 2005). Additional studies with other Lyssavirus surface 
glycoproteins have shown glycoprotein trimers can extend or contract into the virus 
depending on the local environment (Gaudin et al. 1993; Ferlin et al. 2014; Albertini et 
al. 2012). However, this has not been performed on the crystalline structure of RVG. 
Chapter 3 
 
96 
 
Although initially rabies virus was thought to enter cells through the nicotinic 
acetylcholine receptor, more recent studies have highlighted multiple potential targets for 
endocytosis of the virus (Gluska et al. 2014). In this chapter the potential receptor targets 
for RVG and the evidence supporting them in the literature was examined. Furthermore, 
the expression of these receptors on cerebral vascular endothelium and therefore their 
potential use as a target for ligands for brain-specific delivery of nanoparticle and 
macromolecular entities was examined. 
3.1.1 Evidence for Nicotinic Acetylcholine Receptor Binding of Rabies Virus 
There have been links shown between the administration of α-bungarotoxin and a 
reduction in the effects of rabies virus infection in vivo (Lentz 1982; Lewis et al. 2000). 
The amino acid sequence of RVG has been shown to have regions of homology with 
known neurotoxins that can target the nicotinic acetylcholine receptor (nAchR) (Neri et 
al. 1990; Lentz 1985). This evidence has led to the belief that this is a binding site and 
route of entry of the rabies virus into neuronal cells in muscle tissue. However, in the 
same article by Lentz (1985), there was a reference to studies which looked at switching 
the Arg333 residue, of the glycoprotein, for other amino acids and showed this mutation 
dramatically changed the ability of the virus to infect the host cells (Dietzschold et al. 
1985). This alteration in uptake would be suggestive of either an alternate receptor for 
RVG with the host cells or show the structural importance of this residue in the 
confirmation of the protein as a whole. The binding of rabies virus to isolated Torpedo 
nAchR was shown to be competed by cholinergic receptor antagonists, such as α-
bungarotoxin and tubocurarine (Lewis et al. 2000; Lentz et al. 1986). 
This evidence presented above, as well as the accumulation of rabies virus in muscular 
tissue at the neuromuscular junction, is why the nAchR is believed to have a key role in 
rabies virus uptake and infection.  
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The RVG peptide (DYTIWMPENP RPGTPCDIFT NSRGKRASNG) itself is derived 
from the region 194-222 a.a. of the parent glycoprotein. Within this region is the 
homologous sequence, shared between RVG and several neurotoxins targeting nAchR, 
as shown in Table 3.1. Additionally, this peptide has been shown to reduce the binding 
of loop neurotoxins, such as α-bungarotoxin to isolated subunits of the acetylcholine 
receptor (Lentz TL 1990).  
Table 3.1: Analysis of homology between the Rabies Virus Glycoprotein 
sequence and the nAchR binding domains of long-chain neurotoxins 
1. C D I F T N S R G K R Rabies Virus Glycoprotein 
2. C D A F C S S R G K V α-Bungarotoxin  
(Bungarus multicinctus) 
3. C D K F C S I R G P V κ-Bungarotoxin  
(Bungarus multicinctus) 
4. C D A F C S I R G K R α-Cobratoxin  
(Naja naja) 
5. C D G F C S S R G K R Long Neurotoxin 2 
(Ophiophagus hannah) 
6. C D N F C A S R G K R Long Neurotoxin 2  
(Naja melanoleuca) 
7. C S P G E S S C Y N K Erabutoxin A  
(Laticauda semifasciata) 
 
Studies in bovine brain microvasculature have shown the presence of nAchR subunits in 
the endothelial cells and have linked these to modulation of BBB permeability following 
activity of nicotine and other nAchR agonists on these receptors (Abbruscato et al. 2002). 
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Further to this, expression of nAchR has been observed in non-cerebral endothelial cells 
from the human aorta (Macklin et al. 1998) which gave evidence of vascular expression 
of these receptors at other sites within the body. Questioning the selectivity of nAchR as 
a target for brain-specific delivery. A study using the RVG peptide to look at binding to 
Neuro-2a and HeLa cells showed a decrease in 4 oC binding of the peptide in the presence 
of increasing concentrations α-bungarotoxin (Kumar et al. 2007). The same study also 
showed that siRNA conjugated to and RVG peptide-R9 constructs was able to deliver the 
siRNA and mediate gene silencing in neurones both in vitro and in vivo. 
The precise internalisation mechanism for the nAchR is not fully understood. Several 
papers show the involvement of CME, while others implicate caveolin-mediated 
endocytosis and further suggest lipid raft partitioning as the mechanism for nAchR 
endocytosis. The receptor regulation of nAchR expression occurs without changes in 
mRNA levels, indicative of a conservation pathway by which these receptors may be 
stored within intracellular pools until required (Fenster et al. 1999). The data relating to 
nAchR trafficking has so far been collected using neuronal cell models, and any potential 
trafficking pathways within BMECs are unknown. Concerning rabies virus infections, 
while the nAchRs location on post-synaptic cell membranes is understood, evidence of 
their presence on the pre-synaptic membrane is not clear. As such the role of the nAchR 
in rabies virus infections is thought to be involved in the initial amplification of the virus 
in muscle tissue before retrograde transport to the CNS (Lafon 2005). 
3.1.2 Evidence for GABA receptor binding 
Recent studies looking at nanoparticles decorated with RVG29 showed co-administration 
with GABA reduced the uptake of these particles. However, the administration of nAchR 
agonists and antagonists appeared to not affect the uptake of these particles (Liu et al. 
2009). There is some kinetic data which suggests the loop neurotoxins have a lower 
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affinity for variants of the GABAA/B receptors than the nAchR, with an affinity in the 
range of 50-90nM for the GABA receptors (McCann et al. 2006; Hannan et al. 2015). 
However, there are currently no crystal or NMR models for this interaction, drawing 
questions as to these GABA receptors being putative receptors for the RVG29-peptide. 
GABA receptors are known to be endocytosed via clathrin-mediated pathways associated 
with this receptor (Kittler et al. 2000; Sato et al. 2009), which could contribute to the 
observed clathrin-mediated endocytosis of rabies virus as a whole (Piccinotti et al. 2013). 
However, as their ability to bind and internalise the RVG-29 peptide is currently 
unknown. And a binding site for the loop neurotoxins has not been identified and 
characterised on the GABA receptors, GABA receptors were not investigated as the major 
target receptor for the RVG peptide. 
While the previously discussed receptors appear to be able to bind both the RVG peptide 
or the whole virus, the next receptors discussed have only been studied with intact rabies 
virus or rabies virus glycoprotein internalisation. And have not been studied with loop 
neurotoxins or the RVG peptide. 
3.1.3 Evidence for p75NTR binding 
The low affinity nerve growth factor receptor, p75NTR, is considered a rabies virus 
receptor after studies using chimeric IgG Fc domain bound to the p75 protein was shown 
to reduce rabies infections and viral count in vivo (Langevin and Tuffereau 2002). 
Additionally, co-localisation between fluorescently labelled rabies virus and fluorescent 
anti-p75NTR IgG has been shown in endosomes of dorsal root ganglion cells of mice 
(Gluska et al. 2014).  This co-localisation could be observed throughout the length of 
neuronal axons, suggesting virons remain bound to the receptor throughout trafficking by 
this pathway. Studies into the co-localisation of rabies virus with putative receptors also 
show high percentages of the internalised virus, which did not co-localise with the 
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receptor of interest in their respective studies, highlighting the heterogeneity of rabies 
virus entry into cells. Indeed, a study by Jackson and Park (1999) demonstrated that mice 
deficient in p75NTR were not protected from developing viral encephalitis following 
rabies infection.  
The p75NTR receptor itself has been observed, in neuronal cell types, to alter endocytosis 
pathways from clathrin-independent to clathrin-dependent for axonal transport of the 
receptor (Deinhardt et al. 2007). This shift appears enhanced by the presence of bound 
rabies virus at the receptor, further indicating the heterogeneity of cellular infection 
mechanisms. 
3.1.4 Evidence for NCAM-1 binding 
An extensive study by Thoulouze et al (1998) showed that in both an in vitro and in vivo 
setting the expression of neuronal cell adhesion molecule-1 (NCAM-1) has a role in 
cellular uptake of rabies virus and transmission of infection. However, they also conclude 
that there are likely to be other receptor-mediated pathways that can affect viral entry as 
infections were observed to a lesser extent in knockdown models in vitro and in vivo 
(Thoulouze et al. 1998). NCAM-1 has several extracellular IgG-like domains that can 
interact with other NCAM molecules on adjacent cells (Sandi 2004). These molecules 
maintain the spacing between neurones, glial and other cell types in vivo. They also serve 
a protective role to limit overstimulation of cells by neurotransmitters and can cause cell 
migration and controlled neuronal plasticity. The NCAM L1 isoform of the receptor has 
been shown to associate with adapter protein 2 (AP2) in endocytosis, thus considered to 
undergo clathrin-mediated endocytosis when internalised by cells (Kamiguchi et al. 
1998). Other studies have shown that rabies infection and progression can be reduced or 
delayed by the co-administration of decoy, soluble NCAM-1 receptors or by competition 
with antibodies against the NCAM-1 receptors (Thoulouze et al. 1998). 
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In parallel to this, a recent study by Hsu et al (2014) showed that nanocarriers targeted to 
ICAM-1 appear to undergo transcytosis across the BBB endothelial cells in culture and 
other component cells of the neurovascular unit. ICAM is another example of a cell 
adhesion molecule (CAM) family of proteins. In this article, they postulate an endocytic 
route of transport that is independent of clathrin and caveolin, CAM-mediated 
endocytosis (Hsu et al. 2014). This idea is one that has been postulated for cell adhesion 
molecules previously, where anti-ICAM receptor antibodies were shown not to co-
localize with markers of clathrin- or caveolin-mediated endocytosis (Muro et al. 2003). 
As NCAM molecules also belong to the CAM family of proteins, it may be possible that 
this is an alternate route of entry for the receptor endocytosis into the cell and trafficking 
through the cytosol in transcytosis. 
3.1.5 Modulation of Protein Expression 
There are several techniques which can be utilised to downregulate or completely ablate 
expression of a protein within cells. These techniques can result in the transient 
knockdown of a protein (siRNA), the generation of a stable cell line with reduced protein 
expression (RNAi or Ribozyme) or the complete knockout of a protein (CRISPR/Cas9, 
Transcription Activator-Like Effector Nucleases - TALENs, Zinc Finger Nucleases - 
ZFNs). All these techniques utilise known biological mechanisms, within eukaryotic or 
prokaryotic cells as well as viral mechanisms to facilitate genome or transcriptome 
manipulation. More precisely, CRISPR/Cas9, TALENs and ZFNs, all cause double-
strand breaks at targeted sequences within genomic DNA. The latter two methods use a 
system of endonucleases, bound to DNA-recognition proteins to mediate the cleavage at 
the target location. However, the complexity of the endonuclease used in the TALEN and 
ZFN methods means redesigning the enzyme for each target site. Whereas CRISPR/Cas9 
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uses the same endonuclease, guided to the target by guide RNA (gRNA) and so can screen 
multiple sequences with ease. 
3.1.5.1 CRISPR/Cas9 Genomic Editing 
This system of genetic knockout utilises the Cas9 endonucleases from bacteria, such as 
Streptococcus pyogenes, S. themophilius and Neisseria meningiditis. These 
endonucleases are part of an adaptive immune system for bacteria to protect from 
bacteriophage infection by cleavage of targeted DNA regions, selected for by clustered 
regulated interspaced short palindromic repeats (CRISPR) RNA (crRNA). This crRNA, 
typically 20 nucleotides in length – the guide RNA (gRNA), with proximity to a 
protospacer adjacent motif (PAM), is specific to regions of the infecting organism. 
Additionally, these gRNAs require trans-activating crRNA (tracrRNA) to recruit the Cas9 
enzymes to the site of cleavage. In bacteria, the cleavage of the infecting, viral DNA 
results in its degradation and preventing the spread of infection. Within the field of 
genomic editing in eukaryotic cells the cleavage of genomic, double-stranded DNA 
requires endogenous repair mechanisms to correct the break. In the case of a “clean” 
double-stranded break, there are no overlapping sequences of DNA present, and so no 
template to facilitate the repair process. To overcome this and ensure the maintenance of 
chromosomal DNA the cellular process call non-homologous end joining (NHEJ) will 
take place to attempt to cleaved DNA (see Figure 3.1 below). The process of NHEJ is 
error prone and so is likely to result in either the insertion or deletion of regions of DNA 
around the cleavage site. This error-prone repair mechanism is exploited in the 
CRISPR/Cas9 technique to result in the expression of a non-functional mRNA and 
proteins within the cell. Leading to complete knockout of a target gene.  
With the CRISPR/cas9 technique, it is possible to remove entire sections of the genomic 
DNA, using multiple targeted gRNA sequences in the same cell. This approach is known 
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as a double nickase approach. Into the “gap” in the DNA created it is possible to insert 
sequences of DNA, rather than allowing the NHEJ approach to take place. In this way, 
the CRISPR/cas9 technique has been used as a way to produce stable cell lines co-
expressing a receptor with a fluorescent protein attached to it. Highlighting the versatility 
and functionality of the CRISPR/cas9 method in cell biology. 
 
 
 
Going beyond the field of cell biology and into complex organisms, the CRISPR/cas9 
genomic editing tool has been used in vivo. Embryonic modification has been used to 
create disease models for experimental use. While, also allowing for inducible genetic 
modulation, to trigger a disease causing mutations in adult species and study the effects. 
Figure 3.1: CRISPR/Cas9 system for genomic editing 
The above figure shows a schematic overview of crispr/Cas9 mediated genomic editing. 
In this example, the guide RNA (red) sequence recognises the region immediately 
adjacent to the PAM (yellow). The tracrRNA (orange) is then recognised by the Cas9 
enzyme (blue), which is recruited to the site to mediate genomic cleaveage. Adapted from 
Figure 1 Ran et al. (2013) 
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Overall, the CRISPR/cas9 approach in its simplest form offers a rapid and reproducible 
technique to create stable cell lines with genetic modifications. For the work clarifying 
the RVG peptide target receptor, this technique will be used as a method to create a 
permanent knockout of the α7-nAchR. Allowing testing of the target receptor with the 
brain targeting ligand and clarification of the reports in the literature about the putative 
receptors for the RVG peptide. 
3.1.6 Chapter Aims 
To assess the expression of putative receptors for the RVG peptide in BMECs, reverse 
transcription polymerase chain reaction (rtPCR) were performed in the immortalised, 
mouse b.End3 cell-line (ATCC) and primary porcine brain microvascular endothelial 
cells (isolated in the laboratory). Following this, the uptake of the RVG peptide and 
scrambled sequence control peptide were assessed in BMECs, to confirm the viability of 
the peptide as a potential targeting ligand for brain delivery, through the pulse-chase assay 
used in the previous chapter. The final aim of this chapter was to assess the involvement 
of the α7-nAchR in the uptake of the RVG peptide. The objectives for this chapter were 
as follows: 
1. To confirm the uptake at labelled RVG peptide into BMECs as an active, 
sequence-dependent and self-competitive process. 
2. To assess the uptake and efflux of the RVG peptide within BMEC models. 
3. To confirm the expression of putative target receptors within BMECs. 
4. To confirm the uptake mechanism of RVG into cells, through competitive uptake 
approaches and protein expression modulation (siRNA and CRISPR/cas9) . 
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3.2 Methods 
3.2.1 Materials 
Dulbecco’s modified eagle medium (DMEM) + Glutamax, Medium 199 (M199), 
Sensicell MEM, fetal calf serum (FCS), horse serum, trypsin-EDTA (0.5%) dissociation 
solution, Penicillin -Streptomycin (10,000U/mL), dispase, α-Bungarotoxin, α-
Bungarotoxin AlexaFluor® 647, Cell Mask AlexaFluor® 647, BODIPY-LACER, 
Dextran 10kDa Alexa Fluor® 647, gRNA Synthesis Kit, Genomic Cleavage Detection 
Assay and all custom synthesized DNA oligomers for PCR and RNA oligomers for 
CRISPR/Cas9 were purchased from Life Technologies, UK. Hoechst, Percoll solution 
and ethidium bromide were obtained from Sigma Aldridge. All plastics for cell culture 
were  purchased from Fisher Scientific as well as sodium chloride, potassium chloride, 
magnesium chloride, calcium chloride, disodium hydrogen phosphate, potassium 
dihydrogen phosphate, sodium dihydrogen phosphate, sodium bicarbonate, D-glucose, 
bovine serum albumin (BSA) and sodium hydroxide. Type 1 Rat Tail Collagen solution 
and collagenase-dispase were purchased from Millipore-Merck. See Appendix 1 and 2 
for the formulation of the buffers. The RVG derived peptides were synthesised by EZ Bio 
Labs, the fluorescent label used was tetramethyl rhodamine (Rho). 
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3.2.2 Overview of brain microvascular cell lines used in these studies 
The b.End3 (mouse brain microvascular endothelial cells) cell line was supplied by 
COMPACT from the GSK source and grown according to their SOPs and replenished 
from stocks when the cells had undergone 20 passages or 60 days after defrosting the vial. 
Briefly, the b.End3 cell line is the most commonly used mouse model of the BMECs in 
vitro, these were immortalised by use of a middle T antigen (Williams et al. 1989). The 
characterisation of b.End3 cells showed the expression of key transport proteins and 
efflux pumps as well as expression of tight junctional proteins (Omidi et al. 2003). When 
these cells are grown on insert membranes the electrical resistance across a confluent 
barrier, have been observed to be approximately 12.2 ± 1.6 Ω.cm2, much lower than 
known in vivo values for brain microvascular endothelial cells (Omidi et al. 2003). 
  
 
Table 3.2: Summary of growth conditions for cell-lines and media supplements 
Cell Line 
(Source) 
Medium Serum Antibiotics Dissociati
on Media 
Seeding Density 
b.End3 
(COMPACT) 
DMEM + 
Glutamax 
(90%) 
Fetal Bovine 
Serum (10%) 
NO Trypsin-
EDTA 
(0.05%) 
1 x 104 cells/cm2 
PBMEC 
(Gumbleton 
Laboratory) 
M199 (90%) Heat Inactivated 
Horse Serum 
(10%) 
YES  Single 
passage 
only 
12 x 104 cells/cm2 
hCMEC/D3 
(VH Bio) 
EBM-2 
(95%) 
Heat Inactivated 
Fetal Bovine 
Serum (5%) 
+bFGF (1ng/mL) 
YES  Trypsin-
EDTA 
(0.05%) 
2 x 104 cells/cm2 
SH-SY5Y 
(ATCC) 
EMEM (45%) 
+ DMEM/F12 
(45%) 
Heat Inactivated 
Fetal Bovine 
Serum (5%) 
+ HEPES (20 mM) 
YES Trypsin-
EDTA 
(0.05%) 
2 x 104 cells/cm2 
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Further, 1st/ 2nd passage porcine BMECs were used that had been isolated by other 
researchers in the Cardiff Laboratory. These porcine cells are grown on collagen-coated 
surfaces to promote closer cell-cell contacts in culture (5µg/cm2, see Appendix 3 for 
details on the mass and volumes required for coating various cell culture surfaces). 
Following seeding of frozen cells onto plastic, the PBMECs are washed with PBS 2 days 
post-seeding to remove debris, and the media was changed every third day until a 
confluent monolayer was observed. There are many well established primary cell lines 
used in research, for the modelling of the BBB, including porcine, rat and bovine models. 
These tend to exhibit phenotypes, at lower passages in vitro that are more similar to the 
in vivo vessel endothelium. The establishment of a porcine cell model was first reported 
and evaluated by Franke et al (1999) and subsequent studies have proven its integrity as 
an in vitro model for the BBB (Franke et al. 1999; Smith et al. 2007; Patabendige et al. 
2013).  Studies have shown it is possible to produce high trans-cellular resistance values, 
in excess of 800 Ω.cm2, in cultures where “switch” media is used to promote tight 
junctional formation through the removal of serum 3-4 days post seeding (Hoheisel et al. 
1998; Franke et al. 1999; Nitz et al. 2003). As well as sucrose permeability ranging 
between to 1x10-6 cm.s
-1 to approximately 3x10-6 (Smith et al. 2007; Patabendige et al. 
2013a), that is comparable to known in vivo data for sucrose permeability (Rapoport et 
al. 1978). 
The hCMEC/D3 cell line was purchased from Cedarlane and are immortalised human 
BMEC. These cells are cultured according to the manufacturer’s guidelines, between 
passages 26-35 for use in studies to maintain the BMEC phenotype. hCMEC/D3 cells are 
grown on collagen-coated surfaces. hCMEC/D3 was established by Weksler et al (2005) 
through the transformation of isolated frontal cortex endothelial cells with hTERT and 
SV40 T antigen to immortalise them for use. hCMEC/D3 cells are well characterised for 
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junctional proteins as well as use in transport studies. They typically show higher trans-
cellular resistance values than rodent models as well as an ability to undergo in excess 35 
passages while maintaining a non-transformed phenotype (Weksler et al. 2005; Dauchy 
et al. 2009). Studies have shown an electrical resistance vary greatly between 40Ω.cm2 
to in excess of 100Ω.cm2 (Hatherell et al. 2011; Daniels et al. 2013) and a high sucrose 
permeability of 26.6x10-6 cm.s-1. These TEER values are seen to be close to those of 
isolated primary cells (Daniels et al. 2013), however are still much lower than in vivo 
levels and the inherent “leaky” nature is confirmed by the sucrose permeability. 
In routine culture the b.End3 and hCMEC/D3 cell lines are passaged at 80-90 % 
confluency. Briefly, cells are washed 3 times with calcium- and magnesium-free PBS to 
remove any cellular debris. Trypsin-EDTA solution (0.05 %) is then applied to cells for 
5 minutes to dissociate cells from plastic. Finally, cells are re-suspended in the appropriate 
culture medium and counted for seeding. Primary porcine cells are typically only used 
for a single passage and so are seeded from frozen stocks for the desired assay. 
3.2.3 RNA Isolation 
Cells are grown in T25 flasks until a confluent monolayer can be observed by light 
microscopy. Trypsin-EDTA (Life Technologies) was used to dissociate cells from plastic 
and these are pelleted by centrifugation. The media was removed and cells are lysed by 
the addition of 1 mL TriReagent (Sigma Aldridge) and vigorous pipetting to homogenise 
the mixture. To this, 0.2 mL of chloroform (Sigma Aldridge) was added and the tube was 
vortexed then allowed to settle, on ice, for five minutes. The chloroform-TriReagent mix 
was then centrifuged at 12,000 x g for 15 minutes at 4 oC to allow phase separation of 
protein, genomic DNA and RNA. The upper, aqueous phase, containing RNA carefully 
collected and added to 0.5 mL of isopropanol (Sigma Aldridge) to allow pelleting of RNA 
by centrifuging at 12,000 x g for 10 minutes at 4 oC. The RNA pellet was then washed 
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twice with 70% ethanol and finally re-suspended in between 40-60 µL of DEPC water. 
The RNA extracts were quantified using Genequant machine and ensuring 260nm:280nm 
absorbance ratio of ~1.8. 
3.2.4 Reverse Transcription Reaction 
To an RNase free tube was added oligo (dT), dNTPs (200 µM of each), 500ng of isolated 
RNA and DEPC water (volumes shown in Table 3.4) and this mixture was heated to 65 
oC for 5 minutes. Following this heating the tube was placed on ice and 5x First Strand 
Buffer, DTT and RNasin were added to it. The tube was heated to 37 oC for 2 minutes. 
M-MLV was added and the tube is placed in the thermocycler with the following protocol 
in Table 3.3. 
Table 3.3: Reverse transcription reaction program 
 Temperature (oC) Time (min) 
Step 1 25 10 
Step 2 37 50 
Step 3 72 15 
Step 4 4 ∞ 
  
 
Following the reaction, the cDNA was diluted one in three with molecular biology grade 
water and kept at -20 oC until use. 
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3.2.5 Polymerase Chain Reaction 
PCR reactions were performed using HotStart Taq Polymerase kit (Qiagen,UK) and the 
protocol provided. In summary, cDNA from the previous step was added a microfuge 
tube containing PCR buffer (MgCl2 included), HotStart Taq polymerase, dNTPs, 
molecular biology grade water and the forward and reverse primers for the gene of interest 
(Table 3.5). In case of negative controls excess molecular biology grade water was added, 
equal to the cDNA volume. 
 
 
 
 
 
Table 3.4: Reverse Transcription reaction volumes 
Component Volume (µL) 
Oligo (dT) 1 
dNTPs (10mM) 1 
5x First Strand Buffer 4 
DTT (0.1M) 2 
RNasin (40 units/µL) 1 
M-MLV reverse transcriptase (200 
units/µL) 
1 
500ng RNA Variable 
DEPC water To give 20µL total 
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Table 3.5: PCR reaction components 
Component Volume (µL) 
10x PCR Buffer 2 
dNTPs (10 mM) 0.4 
HotStart Taq Pol (2.5 
units/reaction) 
0.1 
F-Primer (10 µM) 1 
R-Primer (10 µM) 1 
cDNA 1 
Molecular Biology 
Grade Water 
14.5 
Total Volume 20 
 
The reactions are run in thermocycler using the protocol in Table 3.6, steps 2-4 to amplify 
the desired gene products are cycled through 34 times in total. Due to the HotStart Taq 
polymerase an initial period of 15 minutes at 95 oC is used to activate the enzyme prior 
to the amplification process. 
Table 3.6: PCR reaction program 
 Temperature (oC) Time  
Step 1 Enzyme Activation 95 15 minutes 
Step 2 DNA Denaturing 94 30 seconds  
34 Cycles Step 3 Primer Annealing 54 45 seconds 
Step 4 Amplification 72 60 seconds 
Step 5 Final Amplification 72 10 minutes 
Step 6 Until Analysis 4  
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3.2.6 Gel Electrophoresis 
Amplification products are analysed on a 2% agarose gel. The agarose was dissolved in 
TBE buffer by rapid heating and stirring. As the agarose solution cools 30 µL of ethidium 
bromide (EtBr) solution was added and mixture is shaken to ensure an even distribution. 
Once the agarose solution has cooled to approximately 55-60 oC it can be poured into the 
gel cast and allowed to set for ~30 minutes. When set the gel was placed in the 
electrophoresis tank and TBE buffer was added to submerge the gel and ensure all wells 
are filled with buffer. PCR products were mixed with an appropriate volume of 5x Gel 
Loading Buffer (New England Biolabs). From this mixture 7.5 µL was added into a well 
of the electrophoresis gel and 5 µL of DNA ladder loaded into the first lane of the gel. 
The gel was run at 90V for 40 minutes to allow separation of the DNA bands. Immediately 
following the electrophoresis, the gels are imaged using the ChemiDoc (BioRad) with 
and EtBr filter and minimising saturation of control bands. 
3.2.7 Primer Design 
Gene accession numbers for mRNA of mouse and porcine genes were found using the 
Nucleotide search function of NCBI. Primers were designed using the Primer Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) with the melting temperature range 
between 57-63 oC, the GC content between 45-60%, primer length between 18-25 bases 
and a maximum product size of 1000 base pairs. The human primer pairs were 
predesigned from Life Technologies (Refer to table 3.9). 
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Table 3.7: Mouse PCR primers 
Gene 
Name F/R Sequence 5-3 
Amplification Length 
(bp) 
CHRNA3 F GAA GGT GAC GCT CTG CAT CT 416 
 R CCC TAC GGT GGT GGC AAT AG  
CHRNA4 F CGT CTA GAG CCC GTT CTG TG 191 
 R GGC CGA GAC CAC TTG TTG TA  
CHRNA5 F AGC ATG GCC TAC TCT GGA AG 876 
 R TCA GAA ACG AGA GCC CGA TG  
CHRNA7 F ACA TGT CTG AGT ACC CCG GA 264 
 R AGG ACC ACC CTC CAT AGG AC  
CHRNB2 F ACT CCT CCC CTA GTA GTT CCA C 777 
 R CAG GTC AAT CTC AGT GCG GT  
CHRNB3 F CGA GGC TCT GAA CCA CTT GT 356 
 R TGG TCT GTC CAT TCC ACA TCT  
CHRNB4 F CCG GCC ATG AGG GGT ACG 271 
 R GGC GGT AGT CAG TCC ATT CC  
NCAM-1 F CCA TCA TGG GCC TGA AAC CT 167 
 R GAG CGC TCT GTA CTT GAC CA  
p75 NTR F GGC TAC TAC CAG GAC GAG GA 580 
 R TGT CGC TGT GCA GTT TCT CT  
GAPDH F TGT TCC TAC CCC CAA TGT GT 382 
  R TGT GAG GGA GAT GCT CAG TG  
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Table 3.8: Porcine PCR primers 
Gene 
Name F/R Sequence 5-3 
Amplification Length 
(bp) 
CHRNA3 F TCA CTG GTG ATC CCC CTG AT 272 
 R GAC TCG GTA CGG TTG AAG CA  
CHRNA5 F GAA CCC GGA TGA CTA CGG TG 340 
 R CGC GCT CAC AAT TTC CCA TT  
CHRNA7 F TGA TGT GCA GCA GTG CAA AC 847 
 R CCG CAC CTC CTC CAA AAT CT  
CHRNB2 F CTC CCA CCA CTT TAG GCG AG 185 
 R TGG GCG GAT AAG CTT GTT GT  
CHRNB3 F AAC GTT CAC CAC CGA TCC TC 573 
 R CCC TGA GAC CAA CAC AGG AC  
CHRNB4 F GGA ACA GCT CCC GCT ATG AG 276 
 R ACC ATG TCG ATC TCC GTG TG  
NCAM-1 F TCC ATA GCC CTC CTC CAC AA 483 
 R CGG CTT TTC CAC ACA GGT TG  
p75NTR F GGA CTC CAC TGG AAG CCG AG 157 
 R GTG TAC ATG CCT GTG GGA CA  
B-actin F ACT ATC GGC AAT GAG CGG TTC 288 
 R AGA GCC ACC AAT CCA CAC AGA  
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Table 3.9: Human Primers 
Gene 
Name F/R Sequence 5-3 
Amplification Length 
(bp) 
CHRNA1 F TCC CTG TTA CCC ATA TTG ATT TCC T 503 
 R TCT GTT AGA AGG AAC TGA GGC TTA T  
CHRNA3 F TTT AAG CAC AGT GGG CCA AAA AC 248 
 R GGG AAG TAA AAC CAG GCT GAT TCT  
CHRNA4 F ATG CTG CAG GAG CTC TTG TAA ATG G 505 
 R GTG TGT CAG GCA CTC GTA GGT  
CHRNA5 F CTT AAG GAG CTC AGC ATA TTC CAA T 506 
 R ATA TGC ACA CCT ACC ACA TCC A  
CHRNA7 F GGG CCA GGT TTG GGA TCT C 266 
 R GAG TGG TTG CGA GTC ATT GG  
CHRNB2 F CCT CAT GTT CAC CAT GGT GCT 270 
 R AAG CAC GTG CAG GAG TCG  
CHRNB3 F GTG GTT GGG ACA TTA GAT GCA TTT 546 
 R GAG CTC AAG CCT GGA CCT ATG ATC  
CHRNB4 F TTG ATG GCC AAT GCT CAC ATA TTT ACT TA 258 
 R AGT ACG TGG CTA TGG TGG TG  
NCAM-1 F AAT GGC AGT AAA AAG AAT TTG AGA GC 503 
 R AAG CTG ACA CTT GTT GGC ACA T  
p75 NTR F GAC GGA GGC CTC TAC AGC 260 
 R CAC AGA CTC TCC ACG AGG TC  
GAPDH F CCA ACG TGT CAG TGG TGG A 268 
 R CCT GCA CTT TTT AAG AGC CAG TC  
 
3.2.8 Confocal Microscopy of RVG Uptake 
All imaging studies were performed on live cells using the Leica TCS SP5 inverted, 
confocal microscope. In these studies b.End3 cells were seeded in MatTek imaging dishes 
at a density of 10,000 cells/cm2 and allowed to grow until a confluent monolayer was 
observed. The culture media was then aspirated from cells and the cells were incubated 
with DMEM, HEPES with 0.1% bovine serum albumin (BSA) for 30 minutes at 37 oC to 
remove serum proteins from cells. DMEM + 0.1% BSA was then removed and cells 
incubated with RVG-rhodamine (5-100 µM) for 60 minutes at 37 oC or 4oC. Cells were 
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then stained with Hoechst (0.1µg/mL) for 5 minutes, washing three times with PBS before 
imaging. When comparing the uptake of RVG-rhodamine with the scrambled sequence 
peptide, a concentration of 5 µM was used for comparison for a 1 hour pulse duration at 
37 oC. Cells were then stained with Hoechst (0.1µg/mL) and Cell Mask Alexa Fluor® 
647 (diluted 1 in 1000 from stock) for 5 minutes. The cells were then washed 3 times in 
PBS prior to imaging. Cells were imaged live, in MatTek glass bottomed dishes, this 
allowed Z-stack images were taken through the cells at 0.75 µm intervals. These single 
slices were then combined to for a maximum projection image post acquisition using Fiji 
software. With the fluorophores used the lasers and corresponding emission settings were 
as follows: Hoechst - Excitation 405nm, Emission 420-440nm; Rhodamine - Excitation 
544nm, Emission 560-600nm; Alexa Fluor® 647 - Excitation 633nm, Emission 650-
680nm. 
 
Table 3.10: RVG peptide sequences 
Peptide Name Peptide Sequence 
RVG-[Rhodamine] Rho-DYTIWMPENPRPGTPCDIFTNSRGKRASNG  
RVG Unlabelled DYTIWMPENPRPGTPCDIFTNSRGKRASNG 
Scrambled Peptide-
[Rhodamine] 
Rho-DSRGTMPYANTWFTPGSRNECKPIDPRGNI 
RVG δC-  
[Rhodamine] 
Rho-DYTIWMPENPRPGTPADIFTNSRGKRASNG 
α-Bungarotoxin YTIVCHTTATSPISAVTCPPGENLCYRKMWCDAFCSSRGKVVELGCAA
TC PSKKPYEEVTCCSTDKCNPHPKQRPG 
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3.2.9 Fluorescence Plate Reader and Flow Cytometry Assays of RVG and α-
Bungarotoxin binding and uptake 
To quantify the binding and uptake of rhodamine-labelled RVG derived peptides into 
cells a fluorescence plate reader assay has been developed. For these studies b.End3 or 
hCMEC/D3 cells were seeded into 12-well plates at a density of 10,000 cells/cm2 or 
25,000 cells/cm2 respectively and allowed to grow until confluency. The culture media 
was aspirated from cells and the cells are then incubated with Krebs-Ringer buffer with 
0.1% bovine serum albumin (BSA) for 30 minutes at 37 oC to remove serum proteins 
from cells prior to assessing uptake or binding. When comparing the uptake of the RVG-
rhodamine, scrambled sequence-rhodamine (SCRAM) and the delta C peptides 
(sequences in Table 3.10) 10 µM of the peptide was applied to the cells for 1 hour at 37 
oC. Following this, cells were washed with PBS and rapidly dissociated using high 
concentration Trypsin-EDTA (0.125%) solution at room temperature. Cells were then 
pelleted by centrifugation at 1000 xg for 10 minutes at 4 oC and lysed using 0.1M sodium 
hydroxide solution for 1 hour on ice. Lysates were centrifuged at 10,000 xg before 
quantification of rhodamine fluorescence within the lysates. 
In binding assays cells were dissociated from plastic and concentrated to 106 cells per mL 
in Krebs-Ringer buffer. A concentration range of α-Bungarotoxin-Alexa 647 used was 0 
– 1000 nM, which was applied to cells for 1 hour at 4 oC. Cells were then washed by 
centrifugation at 300 xg for 10 minutes and re-suspended in PBS for analysis of cellular 
associated fluorescence using flow cytometry. Non-linear regression to estimate Bmax and 
the Kd were performed in Graphpad Prism 5. Bmax is the maximal binding that can occur 
within the system, when there is 100 % occupancy of the receptor with the ligand. 
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3.2.10 Pulse-Chase Fluorescent Plate Reader Assay 
As in the previous chapter, with transferrin receptor ligands, the pulse-chase assay was 
used to assess the ability of the RVG peptide to be endocytosed and released from the 
BMECs in vitro.  
3.2.11 siRNA Knockdown of α7nAchR 
The protocol for siRNA transfection and Western Blots are given in the previous chapter 
in sections 2.2.3 and 2.2.4 respectively. The siRNA sequences against the α7nAchR are 
shown in the Table 3.11 below and the primary antibody, rabbit anti-human-α7nAchR 
was obtained from Sigma Aldridge, UK, and used at a dilution of 1 in 250. The secondary 
antibody was an HRP-linked anti-rabbit IgG (Cell Signalling, UK) diluted to 1 in 10,000 
of the stock. 
 
3.2.11 CRISPR/Cas9 Genomic Editing 
3.2.11.1 gRNA Design 
The guide RNA sequences were designed in accordance with the requirements for 
recognition by both the Cas9 enzyme and the DNA. The guide sequences were designed 
to be between 18-20 base pairs in length, to reduce the chance of cross-reactivity with 
Table 3.11: siRNA sequences used in α7nAchR knockdown studies 
siRNA Name siRNA Sequence 
CHRNA1 GUACCUGCCUCCAGGCAUA(dTdT) 
CHRNA2 CCACGCCUGGUUCUGUACA(dTdT) 
CHRNA3 AGCCAGCAAUUCUGAGUUC(dTdT) 
Luc-1 CGUACGCGGAAUACUUCGA(dTdT) 
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other sequences of DNA. Secondly, the target sequence must be immediately downstream 
of a protospacer adjacent motif (PAM). This three-base sequence, 5’-NGG-3’ must be 
present for the Cas-9 enzyme, from Streptococcus pyogenes, to recognise and cleave the 
DNA at the target site. Cas9 enzymes from other species of bacteria have different PAM 
requirements, for example 5’-NNAGAA-3’ (Streptococcus thermophilius) and 5’-
NNNNGATT-3’ (Neisseria meningiditis).  Due to the requirement of the Cas9 enzyme 
to recognise a PAM, the Crispr/Cas9 can be targeted to any PAM site within the target 
species genome. The PAM sequences must immediately follow the 20-nucleotide, guide 
sequence, but are not included in the 20 bases.  
The off-target activity of the selected guide sequences was assessed within the design 
tools. For these studies, the guide sequences were designed using Thermo Fishers own 
GeneArt CRISPR Search and Design Tool. For designing guide sequences against Homo 
sapien, α7-nAchR, the gene ID (CHRNA7) and species were input into the application. 
The search identifies the gRNA sequences from a database of over 600,000 potential 
sequences and ranks them based on cross-reactivity with other genomic sites. The design 
tool also provides the PAM motif adjacent to the target site. From this information, it was 
possible to confirm the locations within the genomic sequence of the α7-nAchR. This 
allows for the design of primers, around the cleavage site for the detection of genomic 
cleavage at a later stage of the Crispr/Cas9 process.  
3.2.11.2 gRNA Synthesis 
This was done using the gRNA Synthesis Kit supplied by Thermo Fisher. Briefly, this 
process comprised three main steps: assemble the gRNA DNA template, in vitro 
transcription of the DNA template to form the gRNA, purification of the gRNA products. 
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To assemble the gRNA template, the pre-designed targeting oligonucleotides mixture was 
combined with the tracrRNA Fragment and T7 primer mix. The custom oligonucleotides 
are designed to anneal to the tracrRNA fragments and this product can be amplified by 
Taq polymerase and the T7 primers to produce the final template for transcription. 
Following the PCR amplification of the template sequences, agarose gel electrophoresis 
was performed to ensure the products were the correct size before proceeding to the 
second step.  The expected product size at this stage was 120bp. 
The gRNA template, from stage 1, was then incubated with TranscripAid Enzyme Mix 
and NTPs (ATP, CTP, GTP, UTP) at 37oC for 3 hours. This was longer than the 
recommended 2 hours, however it led to an increased yield of the gRNA product. Any 
template DNA remaining after the in vitro transcription (IVT) stage was removed by 
incubation with DNase I for 15 minutes at 37oC. Following this, the purity of the gRNA 
was assessed by agarose gel electrophoresis. For this, 0.5 μL of the IVT product was 
diluted in 10 μL DEPC water and then with 2x RNA loading buffer (10 μL). This mixture 
was heated to 70oC and then chilled rapidly prior to gel loading. The predicted product 
size for this step is 100 bases, 20 from the guide sequence and 80 from the TracrRNA. 
Having created the gRNA and degraded the DNA template, the gRNA was purified using 
the gRNA Clean Up Kit. This was done using micro-centrifuge, RNA purification 
columns, in combination with buffers to remove all unnecessary dNTPs, enzymes and 
salts from previous reactions. Briefly, gRNA products from the previous steps are diluted 
in water to give a final volume of 200 uL. To this, 100 uL of Binding Buffer and 300 uL 
of ethanol was also added and the mixed by pipetting. The mixture was added to the 
GeneJET purification column and centrifuged for 30 seconds at 14,000 xg. Flow through 
was discarded and 700 uL of Wash Buffer 1 is added, this was recentrifuged using the 
same settings as the previous step. The flow through was discarded and Wash Buffer 2 is 
Chapter 3 
 
121 
 
added to the upper chamber and centrifuged as before. Prior to elution of the RNA a final 
centrifuge was carried out of the empty GeneJet column to remove any excess residues 
from the tube. To elute the RNA 10 uL of nuclease free water was added to the column, 
and placed in a fresh Eppendorf tube. This was centrifuged for 60 seconds at 14,000 xg 
to elute the gRNA from the column. The concentration of the gRNA was then quantified 
by UV/VIS spectrophotometer and stored at -80 oC until required.  
3.2.11.3 Cas9-GFP plasmid preparation 
The Cas9-2A-GFP plasmid was purchased from Addgene, USA (Addgene ID: 48138) as 
an E.coli stab culture in agar. All bacteria work was performed in proximity to a Bunsen 
burner flame to ensure a sterile working field and to avoid contamination of the samples, 
waste was collected separately and autoclaved prior to disposal. To isolate the plasmid 
for transfection into mammalian cells, E.coli from the stab culture was plated onto LB 
Agar plates containing 100ug/mL kanamycin. The E.coli streaked onto the agar plate was 
left overnight at 37oC to allow the growth of single colonies.  
3.2.11.4 Bacterial Expansion 
Single colonies of bacteria are then “picked” from the LB Agar plate and incubated in 5 
mL of LB Broth, containing 100 ug/mL kanamycin, in a 15 mL Eppendorf centrifuge, for 
8 hours at 37 oC under agitation. This allowed the bacteria to enter the log-phase of 
growth. At this stage, the media appears cloudy when viewed. To allow further expansion 
of the E.coli for plasmid isolation, 1 mL of the bacteria solution was taken and incubated 
in 100 mL LB Broth containing kanamycin. The bacteria are incubated overnight for ~16 
hours to allow for maximal growth prior to plasmid isolation. After this step, the solution 
was opaque due to the presence of high bacterial numbers present. This was taken forward 
into the plasmid isolation stage. 
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To prepare bacterial stocks for future use, after the single colony had been expanded in 5 
mL of LB Broth, the remaining solution was diluted 1:1 with 80% sterile glycerol 
solution. From this, 1mL aliquots were taken for storage at -130 oC in cryovials.  
3.2.11.5 Plasmid Isolation 
Plasmid isolation from bacterial cells was done using the Qiagen Plasmid MidiPrep Kit, 
using the protocol provided. Briefly, the solution of expanded bacteria from the previous 
stage was first centrifuged at 5000 xg for 30 minutes at 4 oC to pellet and isolate the 
bacterial cells from the culture media. The pellet was then resuspended in the buffer 
provided (P1) and incubated with alkaline lysis buffer (P2) for 10 minutes at room 
temperature. The lysis reaction was stopped by the addition of neutralising solution (P3) 
and inversion of the reaction tube to ensure all cells are covered. 
Cellular debris was removed by filtration, through the provided filter cartridge, this initial 
stage removes cell membranes, leaving a solution containing the bacterial DNA and 
cytosolic proteins. The extruded supernatant was placed into a DNA binding column, that 
specifically allows for the binding of plasmid DNA, while all other components of the 
solution will pass through the gel matrix. The bound plasmid was washed three-times 
with the provided wash buffer (QC buffer) to ensure non-essential components of the 
bacteria have been eluted from the column. To elute the plasmid DNA itself, 8 mL of 
elution buffer (QBT buffer) warmed to 60 oC was added to the column. The eluted 
solution kept for further preparation steps.  
To concentrate the plasmid DNA to a useable concentration, isopropanol was added to 
the eluted solution to precipitate the DNA. The solution was centrifuged at 13,000 xg for 
30 minutes at 4 oC to pellet the DNA. The remaining solution was discarded and replaced 
with 75% ethanol to wash the DNA pellet. The pellet in 75% ethanol was centrifuged a 
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further three times, at 13,000 xg for 30 minutes at 4 oC, replenishing the solution after 
each centrifuge step. Following the final centrifuge step in the ethanol solution, the 
solution was aspirated from the plasmid DNA pellet and the pellet itself air-dried for ~15 
minutes. The plasmid DNA pellet was then resuspended in 50 uL of Tris-Buffer (pH 7.4) 
and stored at -20 oC until use. The DNA concentration was quantified by UV-
spectrophotometry. Typically, from this protocol yields were close to 1 ug/uL. 
3.2.11.6 Mammalian Cell Transfection 
The Cas9-GFP plasmid and the gRNA sequences were co-transfected into cells using 
Lipofectamine 3000 (Life Technologies). Optimization was performed on confluent 
monolayers of cells in 96 well plates to confirm the optimal DNA concentration for the 
final transfection for analysis. This optimization found that for transfection in 6-well 
plates 2.5 ug of DNA per well was optimal for maximum transfection efficiency. This 
was added to the cells in Optimem containing 2.5 uL of Lipofectamine 3000 and 5 uL of 
P3000 reagent. The gRNA was added into this complexation mixture to give a final mass 
per well of 200 ng. These masses of DNA and gRNA ensure an almost 1:1 molar ratio of 
the oligonucleotides for transfection. To transfect the cells the volumes and masses of 
transfection reagent and oligonucleotides, summarized in the table below, were added to 
Optimem (750uL per well) for 10 minutes to allow lipid complexation with the DNA and 
RNA. Following the complexation, the normal culture media was aspirated from cells 
and replaced with the Optimem-DNA-RNA-Lipofectamine 3000 solution. Cells were 
incubated with this for four hours without the presence of serum, to allow maximal uptake 
of the complexes into cells. After four hours 750 uL of media containing 20% serum was 
added into the transfection wells, to give a final serum concentration of 10% in the wells. 
The cells are cultured for a further 48 hours before analysis of transfection efficiency by 
genomic cleavage detection assay or cell sorting and clonal cell line generation. 
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3.2.11.7 Genomic Cleavage Detection Assay 
To confirm that the gRNA and Cas9 enzymes had been taken up into cells and had 
mediated genomic cleavage within the population, the genomic cleavage detection assay 
(GCD) was used. The GCD assay used here for these studies was from Thermo Fisher. 
For this protocol, transfected cells in 6-well plates were dissociated from plastic using 
trypsin-EDTA solution (as per standard cell culture protocols) and pelleted to removed 
serum proteins from the cells. The cell pellets could then either be stored at -20 oC or 
directly lysed to isolate the genomic DNA for analysis. For lysis, the cell pellets were 
resuspended in 50uL lysis buffer provided in the kit, containing protein degrader solution 
(25:1 ratio lysis buffer: protein degrader). The cell-lysis solution was then incubated in 
the thermocycler for 15 minutes at 68 oC, 95 oC for 10 minutes, then 4 oC to end the 
reaction.  
 
 
Table 3.12: PCR Reaction Mixture for GCD Assay 
Component DNA Sample Control Reaction 
Cell Lysate 2 μL - 
10μM F/R primer mix 1 μL - 
Control Template & Primers - 1 μL 
AmpliTaq Gold® 360 Master 
Mix 
12.5 μL 12.5 μL 
Water 9.5 μL 11.5 μL 
Total Volume 25 μL 25 μL 
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After cell lysis, the genomic DNA adjacent to the potential genomic editing site was 
amplified by PCR reaction. For this, primers are designed to produce products of ~600 
bp, that uneven spacing around the genomic cleavage site, i.e. the forward primer is 200 
bp from the gRNA site, the reverse was 400 bp from the gRNA site. This was important 
for the final detection step of the GCD process. Other primer criteria are as standard for 
primer design: 20 bases in length, 45 – 55 % GC content, melting temperature of 55 – 58 
oC. 
The lysates undergoing PCR are added to the reaction mixture as shown in the Table 3.11 
below. Samples are prepared on ice and transferred to the thermocycler for amplification, 
using the protocol shown in Table 3.13. 
Table 3.13: PCR reaction GCD Assay  
Stage Temperature  
Enzyme Activation 95 oC  
Denaturing 94 oC 
40 
cycles 
Annealing 55 oC 
Amplification 72 oC 
Final Amplification 72 oC  
Finish 4 oC  
 
Following amplification of the genomic DNA regions the integrity of the reaction was 
confirmed by agarose gel electrophoresis. Briefly, 1.8% agarose gels were cast by boiling 
agarose in TBE buffer to dissolve and pouring into the gel mould, while in the liquid form 
30 uL ethidium bromide was added to the gel for DNA staining. Once the agarose gel has 
been cast and was set, 5 uL of PCR product was mixed with loading buffer (5:1 ratio) and 
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added into a well in the gel. In addition, a 100bp DNA ladder was added to the first row 
of the gel to allow measurement of DNA product length. The gel was run at 80 V for 45 
minutes to allow product separation. After this, the gel was imaged on the ChemiDoc 
imager, using the ethidium bromide settings. 
Having confirmed the product of the PCR was the correct size and only a single product 
band was present, the sample can then be taken into the genomic cleavage assay stage. 
To set this up, 3 µL of DNA product was added to 1 µL of 10x Reaction Buffer and 5 µL 
of water. This now undergoes a re-annealing reaction, where the tube was heated to 95 
oC for 5 minutes to break apart double-stranded DNA, the reaction was then cooled slowly 
(0.1 oC/s) to 25 oC. This allows the formation of hetero-duplexes of DNA with mis-
matched DNA sequences. Adding the Detection Enzyme now allows for the detection of 
the % occurrence of DNA mis-matches within the sample. To control this process, every 
sample has a negative control, where water (1 uL) was added in place of the Detection 
Enzyme (1 uL) at this stage. For the reaction to take place the samples were kept at 37 oC 
for 1 hour and then placed at 4 oC to finish the reaction. 
Samples were immediately analysed by gel electrophoresis to confirm that genomic 
cleavage has taken place. The protocol for this was the same as described above to verify 
the PCR reaction product, with the only modification being that the entire 10 uL of the 
GCD product was added at this stage. Once the gel has been run and imaged the fraction 
cleaved can be calculated by measuring the sum of the intensities of the cleaved bands in 
a lane compared to the total DNA intensity of all bands in a sample (Equation. 3.1.). From 
this the % cleavage efficiency of the products was be calculated using Equation 3.2. 
Equation 3.1: 
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐶𝑙𝑒𝑎𝑣𝑒𝑑 =  
𝑆𝑢𝑚 𝑜𝑓 𝐶𝑙𝑒𝑎𝑣𝑒𝑑 𝐵𝑎𝑛𝑑𝑠
𝑆𝑢𝑚 𝑜𝑓 𝐶𝑙𝑒𝑎𝑣𝑒𝑑 𝐵𝑎𝑛𝑑𝑠 𝑎𝑛𝑑 𝑃𝑎𝑟𝑒𝑛𝑡𝑎𝑙 𝐵𝑎𝑛𝑑𝑠
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Equation 3.2: 
𝐶𝑙𝑒𝑎𝑣𝑎𝑔𝑒 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 100 ×  (1 −  √1 − 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐶𝑙𝑒𝑎𝑣𝑒𝑑) 
3.2.11.8 Cell Sorting and Cell Line Generation 
Having detected that genomic cleavage has occurred, using the gRNA sequences prepared 
against the α7nAchR, in the co-transfection cells, the next stage was to produce a clonally 
isolated cell line that has undergone genomic editing. To do this, SH-SY5Y cells were 
seeded into 6-well plates at a density of 100,000 cells/cm2, to produce a confluent 
monolayer 24 hours post-seeding. Cell were then co-transfected (as described above) with 
the gRNA and Cas9-GFP plasmid and allowed to grow for a further 48 hours post-
transfection. Where in the previous section cells were then dissociated and lysed, cells 
were dissociated from the 6-well plate, but prepared for flow assisted cell sorting (FACS). 
Briefly, grown in the 6-well plates were washed three times with PBS to remove serum 
proteins and Ca2+ ions from the cells and incubated with trypsin-EDTA (0.05%) for 5 
minutes until dissociated. The dissociated cells were then resuspended in PBS containing 
5% serum and pelleted by centrifugation at 500 xg for 5 minutes. The centrifugation steps 
were repeated three further times to remove the dissociation solution from cells and any 
cellular debris. Cell pellets were then resuspended in PBS at 4 oC for analysis by FACS.  
Cell sorting was performed using a BD Biosciences FACS Aria, with gating for GFP 
positive cell defined as the upper 0.5% of the un-transfected cell population. Each gRNA 
sample was sorted to fill two 96-well plates with a single cell per well for clonal 
expansion, this was visually confirmed by light microscopy as colony expansion 
occurred. In addition to the 4 gRNA sequences + Cas9-GFP plasmid samples, the 
negative control of the Cas9-GFP plasmid only was also sorted to control for the effects 
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of the enzyme alone, without the presence of targeting gRNA sequence. The sorted GFP 
positive single cells were maintained in standard culture media and monitored regularly 
for cell growth. The cells which grew were expanded into 48-well plates, when confluent 
in the 96-well plate. From here cells were further expanded into 6-well plates and 
subsequently T25 flasks as their growth continued. For each gRNA sequence, that was 
sorted, approximately 5% of wells grew to produce clonally different cell lines for further 
testing. Once cell-lines reached the stage of confluency in T25 flasks they were frozen-
down for storage before characterisation with the RVG peptide. 
3.2.12 Statistical Analysis 
3.2.12.1 Uptake assays 
In all uptake studies, data was analysed by initially subtracting the autofluorescence of 
blank cell lysates from the measured intensities of the cells in the assays. These 
fluorescence values are then normalized to the intensity of cells pulsed with RVG-Rho at 
37 oC, without any treatment applied to them. In the RVG uptake studies the 
unchallenged, active uptake of RVG peptide (RVG-Rho) into BMECs was compared to 
the uptake at 4 oC, uptake in the presence of unlabelled RVG peptide, the uptake of the 
scrambled sequence peptide (SCRAM-Rho) at 37 oC and the uptake of the δC peptide at 
37 oC. These comparisons were made using a one-way ANOVA with the Dunnett’s post-
test, with RVG-Rho pulse 37 oC used as the control for comparisons.  
In the competitive uptake assay, where labelled RVG-Rho peptide was competed with 
increasing concentrations of unlabelled RVG peptide or unlabelled α-BGT. The 
unchallenged uptake of RVG was used as the control for comparison by one-way 
ANOVA with Dunnett’s post-test. Significance was defined as a p-value < 0.05. 
When comparing the uptake of RVG into cells SH-SY5Y that have been transfected with 
different sequences of siRNA against the α7-nAchR. The raw fluorescence was first 
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normalized to the intensity of the uptake of RVG peptide into untransfected cells and then 
the effect of the siRNA transfection was assessed using a one-way ANOVA with 
Dunnett’s post-test. 
3.2.12.2 Pulse-Chase Assay 
As in the previous chapter the analysis of the pulse-chase assay first involves the 
subtraction of blank cell autofluorescence from the assayed cells fluorescence intensity. 
These values were then normalized as a percentage to the mean intensity of cells that have 
been pulsed with the RVG-Rho peptide at 37 oC. To assess the efflux of the peptide from 
the cells over the duration of the chase, the fluorescence at each chase time point was 
compared to the pulse only fluorescence through a one-way ANOVA with Dunnett’s 
post-test. To confirm that efflux was active, at each chase time point the fluorescence at 
the 37 oC chase was compared to the equivalent time point, chased at 4 oC, through a one-
way ANOVA with a Tukey multiple comparison post-test. 
 
3.2.12.3 Microscopy Studies: 
Following collection of z-stack image files, these were imported into the Fiji image 
analysis software for processing and co-localization analysis. Here each stack was split 
into individual slices for analysis using JACoP (Just Another Colocalization Plugin) in 
Fiji. In this analysis the Mander’s Colocalization method was selected, to observe the 
proportion of thresholded RVG-Rho fluorescence which was co-localized with 
thresholded dextran fluorescence or BODIPY-LaCer fluorescence, at the conclusion of 
the chase phase (Manders et al. 1993). The colocalization fractions for each slice in the 
z-stack were averaged to produce an output for value for that replicate, and for final 
analysis the combination of multiple microscopy stacks were used to produce the output 
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colocalization fractions for the ligands with dextran labelled lysosomes. These were 
expressed as mean ± standard deviation.  
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3.3 Results and Discussion 
3.3.1 Expression of Putative RVG receptors in BME cells 
In the mouse cell line repeated PCRs, performed in multiple passages confirmed 
expression of several potential RVG peptide receptors. Of these, NCAM-1 appears to 
have the strong expression in b.End3 cells. Other receptors expressed include the nicotinic 
receptor alpha 3 and alpha 7 subunits and p75NTR as seen in Figure 3.2. 
 
 
Of the receptors expressed in b.End3 cells the most probable for RVG peptide interaction 
is the alpha 7 subunit of the nAchR. This is due to the evidence of α-bungarotoxin 
competing the binding of the RVG-R8 construct (Kumar et al. 2007). As well as the high 
homology between the bungarotoxin binding region for nAchR-α7 and the RVG peptide 
sequences. 
The b.End3 cells are an immortalised cell-line and as such the expression of these 
receptors may be altered from the in vivo setting. It has been shown in several primary 
Figure 3.2: Putative RVG receptor expression in b.End 3 cell-line 
The above plot shows the output of a PCR in b.End3 cells to examine the expression of putative 
receptors for the RVG peptide. The lane numbers correspond to the following: Lane 1 - DNA ladder, 2 
– GAPDH, 3 – α1 nAchR, 4- α3 nAchR, 5 – α4 nAchR, 6 – α5  nAchR, 7 – α7 nAchR, 8 – β2 nAchR, 
9 – β3 nAchR, 10 – β4 nAchR, 11- NCAM-1, 12 – p75NTR. In this blot there was observed strong 
expression of α1, α3 and α7 nAchR and NCAM-1 
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cell-lines that taking the cells through only two or three passages can changes some of 
the key phenotypic characteristics of BBB endothelium. Further studies, performed in the 
primary porcine BMEC cells show similar receptor expression to the b.End 3 cell line. 
Primary porcine BMECs show expression of the alpha 3 and 5 subunits of the nAchR as 
well as weak expression of the beta 4 subunit and p75NTR (Figure 3.4). Expression of 
the alpha 7 subunit of the nAchR or NCAM-1 was not seen in these cells across 4 
independent isolations of the PBMECs. In the human hCMEC/D3 cell line the receptors 
observed were the alpha 3 and 4 and beta 3 and 4 subunits of the nAchR in addition to 
both NCAM-1 and p75NTR (Figure 3.3). In hCMEC/D3 there was inconsistent 
expression of the alpha 7 subunit of the nAchR between independent replicates. 
 
 
Figure 3.3: Putative RVG receptor expression in hCMEC/D3 cell line 
The above plot shows the output of a PCR in hCMEC/D3 cells to examine the expression of putative 
receptors for the RVG peptide. The lane numbers correspond to the following: Lane 1 - DNA ladder, 2 
– GAPDH, 3 – α1 nAchR, 4- α3 nAchR, 5 – α4 nAchR, 6 – α5  nAchR, 7 – α7 nAchR, 8 – β2 nAchR, 9 
– β3 nAchR, 10 – β4 nAchR, 11- NCAM-1, 12 – p75NTR. In hCMEC/D3 there was observed strong 
expression of α3, α4, β3 and β4 nAchR, NCAM-1 and p75NTR. There was also observed weak 
expression of α7 nAchR 
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Figure 3.4: Putative RVG receptor expression in Primary Porcine Brain 
Microvascular Endothelial Cells 
Lane 1 - DNA ladder, 2 – β-actin, 3 – α3 nAchR, 4 – α5 nAchR, 5 – α7 nAchR, 6 – β2 nAchR, 7 – β3 
nAchR, 8 – β4 nAchR, 9 – NCAM-1, 10 – p75NTR.  
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3.3.2 Uptake of RVG peptide by brain microvascular endothelial cells 
RVG-Rho peptide uptake at 37 oC was observed in b.End3 cells at concentrations from 5 
– 100 µM by confocal microscopy (Figure 3.5.A-C). However, binding to the cell 
membrane was not seen in studies performed at 4 oC (Figure 3.5.D). This may be due to 
low receptor numbers on the surface of the cells and the strength of signal from the 
rhodamine fluorophore. 
 
 
 
 
Figure 3.5: RVG peptide uptake in b.End 3 cells 
The images in the panel to the left are maximum projections from a 
minimum of 12 slices, taken at 0.75µm spacing through the cells. A-C 
have received a 1 hour pulse at 37 oC of 5, 20 and 100 µM RVG-Rho 
peptide respectively. D are cells pulsed for 1 hour at 4 oC with 5 µM of 
RVG peptide. The scale bars in A-C is 25 µm, in D is 20 µm, n = 3 in 
triplicate 
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The RVG-Rho peptide and the scrambled sequence peptide have the similar mass, charge 
and amino acid chain length characteristics. Nevertheless, the RVG-rhodamine peptide 
shows significantly higher uptake into cells that the scrambled sequence peptide. Shown 
by both confocal microscopy and a fluorescence plate reader assay (Figures 3.6 + 3.7). 
The use of the scrambled sequence peptide demonstrates the importance of amino acid 
sequence on the uptake capability of a targeting strategy. It has previously been shown 
that the presence a cysteine residue in short cell penetrating peptides causes entry through 
the formation of disulphide bonds with membrane proteins. In order to, test if the cysteine 
in the RVG sequence the cysteine residue was replaced with an alanine. Figure 3.6 shows 
that in the removal of the cysteine residue from the RVG sequence significantly reduces 
the uptake of the peptide into the b.End 3 cell line. The uptake of the δC sequence peptide 
was at similar levels to the scrambled sequence peptide, two orders of magnitude lower 
than the native RVG peptide sequence in b.End 3 cells. While in the human cell line, 
hCMEC/D3 the uptake of both scrambled sequence and delta C peptides was 
approximately five times lower than that of the standard RVG peptide (Figure 3.6.B). The 
differences in uptake between RVG and the scrambled sequence peptide were also visible 
in confocal microscopy studies (Figure 3.7) 
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Figure 3.6: Comparison of RVG peptide derivatives uptake in brain 
microvascular endothelial cells 
The graphs show the uptake of the RVG derived peptides in two in vitro BMEC cell lines, A is the 
uptake in b.End3 cells, while B is the uptake in the hCMEC/D3 cell line. All comparisons are made 
between the standard sequence (RVG-Rho) uptake and the scrambled sequence peptide (SCRAM-
Rho) and delta C peptide (δC-Rho). *** - P <0.0001, n = 3 in triplicate, mean ± std for both cell 
lines. 
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Figure 3.7: Comparison of RVG peptide and Scrambled sequence peptide uptake in b.End 3 cells  
The images above are maximum projections from a minimum of 12 slices, taken at 0.75µm spacing through the cells. Cells have received a 1 hour pulse at 37 oC with 10 
µM of either RVG-rhodamine or Scrambled sequence-rhodamine peptides. Cells are additionally stained with the nuclear stain Hoechst (blue) and Cell Mask Alexa 647 
(green), a cell membrane stain. The rhodamine labelled peptides are shown in red in the merged image. Scale bar = 50 µm. 
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3.3.3 RVG uptake is a self-competitive process 
The uptake of labelled peptide RVG into BMECs was shown to be a self-competitive 
process through direct competition with unlabelled RVG peptide. The addition of 
increasing concentrations of the unlabelled peptide decreased the uptake of RVG-[Rho] 
to ~40% of the unchallenged fluorescence. An experimental IC50 was calculated as 10.5 
µM, again an indicator that the RVG peptide has a specific binding site (Figure 3.8). This 
suggests the uptake of RVG peptide is through a receptor mediated process, with a defined 
binding site for the peptide. This initial decrease in fluorescence seen in Figure 3.8.A, 
with low concentrations of unlabelled RVG appears strange. In later studies with 
unlabelled α-bungarotoxin a similar effect was observed, where an initial decrease in cell 
associated fluorescence with low concentrations of unlabelled α-BGT was followed by 
an increase, before returning to the expected trend (Figure 3.13). It is unclear as to what 
may be affecting the behaviour of the peptide in this way but could highlight the potential 
complexity and multifactorial nature of ligand uptake. 
 
Figure 3.8: Self-Competition of RVG-[Rho] uptake with unlabelled 
RVG 
The above figure shows the ability of the RVG peptide to demonstrate self-
competitive uptake in hCMEC/d3 cells. Figure A demonstrates the decrease in 
labelled fluorescence in the prescence of unlabelled RVG. While Figure B shows the 
competition curve from this assay. * = p < 0.05 compared to RVG-[Rho] only cells 
(white bar), n = 3 in triplicate, mean ± std. 
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3.3.4 Pulse-Chase RVG Studies 
As with the studies in the previous chapter, these pulse-chase studies are designed to 
assess the ability of a targeting ligand to “escape” from the endothelial cells and 
potentially reach the CNS. In both b.End3 cells (mouse) and hCMEC/d3 cells (human), 
the RVG peptide demonstrated an ability to undergo active efflux from cells, over the 
course of the chase. At the conclusion of the 37 oC chase the proportion of pulsed RVG 
peptide fluorescence, remaining cell associated was 25% in b.End3 cells and 44% in 
hCMEC/d3 cells (Figure 3.9). In both cell lines, the proportion remaining cell associated 
at 37 oC and 4 oC were significantly different at all time-points. Indicating that the RVG 
peptide can be actively effluxed from BMECs. A desirable characteristic for a brain 
targeting ligand, as it means the peptide that is cell associated can undergo further 
trafficking and potentially reach the basolateral cell membrane and the CNS if this was 
in vivo.  
This proportion of RVG peptide remaining in b.End3 cells was comparable to the 
proportion of transferrin and 8D3 retained by b.end3 cells, in the previous chapter. While 
the proportion retained was higher in the hCMEC/d3 cells, the efflux profile was still 
different to the fluid phase marker, dextran in b.End3 cells from the from the previous 
chapter (Figure 2.5). Comparison of the respective 37 oC and 4 oC time-points confirms 
the active loss from the cells. To understand where the remaining RVG peptide was 
located within the endothelial cells, following the conclusion of the chase, colocalization 
microscopy was performed on the cells after the assay.  
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Figure 3.9: RVG peptide Pulse-Chase BMECs in vitro 
The above graphs show the pulse-chase results for the RVG peptide in two BMEC cell-lines. A + B 
show the pulse-chase in b.End3 cells (mouse), while C + D the pulse-chase in hCMEC/d3 (human). 
In both cell lines the RVG concentration as 5 µM In the bar graphs the bars in the red represent the 
37 
o
C chase and the blue bars the 4
 o
C chase. *** = P < 0.001 when comparing the column to the 
fluorescence within cells after the pulse at 37 
o
C. † = P < 0.05, when compared a time-point at 37 
o
C 
to 4
 o
C. n = 3 in triplicate. 
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Figure 3.10: Distribution of the RVG peptide following the 
conclusion of the Pulse-Chase assays in hCMEC/D3 cells 
The above microscopy images show the colocalization of the RVG peptide (5µM, 
pulse-chase) with both dextran labelled lysosomes (A) and BODIPY-LACER 
labelled golgi-apparatus (B). In the false colour merged images of A.(iii) and 
A.(vi), red = RVG-[Rho], green = dextran-[647] and blue = Hoechst. In the false 
colour, merged images of B.(iii) and B.(vi), red = RVG-[Rho], green = BODIPY-
LACER, intense green = golgi appartus and blue = Hoechst. Co-localization 
analysis of RVG-[Rho] with dextran gives a Mander’s Co-efficient of 0.582 ± 
0.012, while co-localization between RVG-[Rho] and the Golgi was a Mander’s 
Co-efficient of 0.213 ± 0.034. n = 3 in triplicate. Scale Bar in A and B i-iii = 
30µm 
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This revealed that ~21% of the RVG peptide fluorescence remaining in the cell was 
associated with the golgi apparatus (Figure 3.10.B). Suggesting that this can undergo 
further cellular trafficking and transport processes. However, the majority of the 
remaining RVG fluorescence is associated to the lysosomal compartment, as confirmed 
by co-localization with dextran. This lysosomal associated peptide accounted for 58% of 
the remaining cell associated RVG fluorescence (Figure 3.10.A). Due to the sensitivity 
of the fluorescence detection in the pulse-chase assay and the microscopy the pulse 
concentration of the RVG peptide was 5 µM, which is likely to be greater than the Kd for 
the receptor. As shown in the previous chapter, if the concentration of the ligand is 
significantly greater than the Kd of the receptor (50% receptor occupancy) there is an 
element of non-specific endocytosis. This non-specific uptake leads to an increase in 
lysosomal association of the ligand and may account for the high lysosomal association 
of the remaining RVG peptide following the chase. 
3.3.5 Competition of α-bungarotoxin by RVG peptide 
Due to the homology of the RVG peptide sequence with the loop 2 region of α-
bungarotoxin, the region known to bind nAchR, flow cytometry studies were performed 
to assess the binding α-bungarotoxin-Alexa 647 to b.End3 cells at 4 oC and thus the 
presence of a putative RVG receptor. This was shown to be a saturable process with the 
Kd of α-bungarotoxin in b.End3 cells calculated to be 191 nM (Figure 3.11). 
Competition of RVG-Rho uptake was performed using unlabelled α-bungarotoxin. 
Imaging of the cells reveals that the uptake of RVG-Rho can be decreased by the addition 
of increasing concentrations of unlabelled α-bungarotoxin. To further these findings 
competitive uptake studies were performed by flow cytometry, studies using α-
bungarotoxin labelled with Alexa 647. The labelled α-bungarotoxin was competed using 
both unlabelled RVG and unlabelled α-bungarotoxin to confirm a receptor specific uptake 
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process. Both unlabelled probes could reduce the uptake of the labelled α-bungarotoxin 
Alexa 647. The decrease in uptake appeared to be dependent on the concentration of the 
unlabelled probe (RVG or α-bungarotoxin). From this data, an estimation of the IC50 
values for both α-bungarotoxin and RVG for competing 250 nM α-bungarotoxin 647 have 
been found as 98 nM and 23 nM respectively (Figure 3.12). These findings support that 
RVG and α-bungarotoxin share a binding site for uptake in b.End3 cells. 
 
 
 
Figure 3.11: α-Bungarotoxin 
Binding Curve in b.End 3 cells 
The figure shows the flow cytometry 
data on the binding of α-
Bungarotoxin-Alexa 647 to receptors 
on the surface of b.End 3 cells. 
Concentrations range from 0-1000 nM 
of α-Bungarotoxin-Alexa 647. The 
data has been normalised to the 
estimated Bmax and the dashed line 
represents the Kd. n=3 
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Figure 3.12: The competition of α-Bungarotoxin-Alexa 647 uptake by unlabelled 
RVG and α-Bungarotoxin in b.End3 cells 
Figure A shows the competition of 250nM α-Bungarotoxin-Alexa 647 with varying concentrations of 
unlabelled RVG peptide. C the direct competition of α-Bungarotoxin-Alexa 647 (250nM) with varying 
concentrations unlabelled α-Bungarotoxin. Figures B+D shows the competitive uptake curves for the 
labelled α-Bungarotoxin when competed with unlabelled RVG and α-Bungarotoxin respectively.  * = 
P<0.05, **= P<0.01 compared to unchallenged cells (white bar), n=3 in triplicate, mean ± std. 
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A B C 
D E 
Figure 3.13: Competition of 
RVG-rhodamine uptake using 
unlabelled α-Bungarotoxin. 
The images above are maximum 
projections from a minimum of 12 slices, 
taken at 0.75µm spacing through the cells. 
Cells have received a 1 hour pulse at 37 oC 
with 10 µM of RVG-rhodamine in the 
presence of various concentrations of α-
Bungarotoxin (A = 0 nM, B = 1 nM, C = 
10 nM, D = 100 nM, E = 1000 nM). The 
RVG peptide is seen here in red, with the 
nucleus stained in Hoechst (blue). The 
scale bar represents 50 µm. 
Chapter 3 
 
146 
 
The competition of labelled RVG uptake into b.End3 cells was further analysed using the 
fluorescent plate reader assay (Figure 3.14). Here it was shown the unlabelled α-
bungarotoxin was able to significantly decrease the uptake of the RVG peptide into cells. 
With a calculated experiment IC50 of 8.3 nM for bungarotoxin’s competition of RVG 
uptake. The findings from the studies in this section are consistent with the findings of a 
study from Kasheverov et al. (2009), who examined the ability of synthetic peptides to 
the nAchR to compete bungarotoxin binding. The findings also align with those of Lentz, 
who, in multiple studies has demonstrated the ability of RVG and α-bungarotoxin to 
interact at the α7-nAchR (Lentz et al. 1987; Lentz TL 1990; Lewis et al. 2000). These 
findings will contribute to the evidence built within this chapter that the RVG peptide is 
internalized into cells through the α7-nAchR. 
 
Figure 3.14 Competition of labelled RVG peptide uptake into b.End3 cells by 
unlabelled α-bungarotoxin 
The above figure confirms the uptake of RVG-[Rho] peptide into b.End3 cells is competed by the 
presence of increasing concentrations of unlabelled α-bungarotoxin. Figure A confirms that significant 
inhibition RVG-[Rho] uptake was seen at higher concentrations of α-bungarotoxin (BGT-[UL]). While 
Figure B shows the competitive uptake curve for this study. From Figure B an experimental IC50 was 
estimated as 8.3 nM. * = p < 0.05 when compared to unchallenged cells (white bar), n = 3 in triplicate, 
mean ± std. 
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3.3.6 siRNA Knockdown 
To further confirm the role of α7-nAchR in the uptake of the RVG peptide into cells, 
transient knockdown of the CHRNA7 gene attempted using multiple siRNA sequences 
against the gene. Due to the low expression levels of the α7-nAchR in hCMEC/d3 cells 
and their inherent resistance to transfection, siRNA studies were not performed on this 
cell line. Instead the SH-SY5Y cells are known to express α7-nAchR at high levels on 
their cell surface, so making them the ideal candidate cell line to test the effect of 
knockdown on the uptake of the RVG peptide. Transfection of all three siRNA sequences 
produces a significant reduction in the uptake of the RVG-[rho] peptide into SH-SY5Y 
cells. The effect of the transfection was visible in the uptake assay, when comparing the 
targeted siRNA to the control sequence and untransfected cells (Figure 3.15.A).  Of the 
three sequences used, siRNA seq1 produced the greatest reduction in the RVG uptake, 
but all sequences produced significant reductions in uptake. Confirmation of the 
knockdown of α7-nAchR was done by Western blot, and confirmed the siRNA was acting 
on the desired target. However, due to difficulties with the antibody, a clear effect on the 
expression levels of α7-nAchR and the levels appeared reduced in the control sample 
compared to untransfected cells. This was confirmed by band quantification, in 
untransfected cells the expression of α7-nAchR relative to GAPDH intensity was 0.96 ± 
0.14, while the expression in luc-1transfected cells was decreased to 0.84 ± 0.11. In cells 
transfected with α7-nAchR siRNA had a mean relative expression of 0.69, 0.53 and 0.55 
respectively. These relative expression levels would suggest that the siRNA against the 
receptor is contributing to the decrease in RVG uptake. 
The combination of the bungarotoxin competition of RVG and the siRNA knockdown of 
RVG uptake both add significant evidence to the critical role α7-nAchR plays in the 
uptake of the RVG peptide. The use of multiple techniques is key in the confirmation of 
Chapter 3 
 
148 
 
the RVG receptor to ensure consistency in the findings. In the literature, thus far there has 
been confusion over the target receptor. But, by using this multi-technique approach a 
clear result can be found with regards to which receptor is the main target of the RVG 
peptide. 
 
3.3.7 Modulation of RVG uptake by crispr/Cas9 genomic editing 
Transfection of the plasmid into cells was confirmed by fluorescence imaging of the cells 
48 hours post transfection to ensure stable expression of the Cas9-GFP plasmid. This was 
seen to have greater expression in the control cells, where only the plasmid was 
transfected and no crRNA was present. However, all transfection conditions showed 
expression of GFP and were continued to the cell sorting by FACS. 
Figure 3.15: siRNA modulation of RVG uptake into SH-SY5Y Cells 
The above figure shows the effect of siRNA knockdown of the α7-nAchR decreased the uptake of the RVG 
peptide in the neuronal SH-SY5Y cell-line. Graph A is the quantification of the RVG uptake, normalized to 
the uptake in un-transfected cells. The images in B are the Western blots to show the effect of the three siRNA 
sequences on α7-nAchR protein expression. *** = p < 0.001, n = 3 in triplicate, mean ± std. 
Chapter 3 
 
149 
 
 
 
FACS sorting for GFP positive cells showed the transfected cells represented between 13 
– 15.9 % of the total cell population in the co-transfected cells and 38.1% of the Cas9 
plasmid only cells (Figure 3.16). This is based on a gating for GFP positive cells set such 
that 0.5% of the un-transfected cell population fall within it. GFP positive cells were 
sorted into one cell per well in 96-well plates and clonally expanded from this point. 
When sorting individual cells were directed into a single well that contained 100 µL of 
cell culture media in preparation. 
Figure 3.16: FACS sorting histograms for GFP positive transfected cells 
The graphs above show the FACS sorting and gating for the transfected cells for use in the 
CRISPR/cas9 studies. Graph A shows the auto-fluorescence associated to un-transfected cells 
and the gating for GFP positive cells was based on the upper 0.5% of this population. Graph B 
shows Cas9-GFP plasmid only transfected into cells. Graphs C-F Cas9-GFP co-transfected with 
the four gRNA sequences. 
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Additionally, 10,000 GFP positive cells from each treatment group were seeded into a 
well of a 24-well plate and allowed to grow to confluency. These cells were used to test 
the efficiency of genomic cleavage within the GFP positive cells, i.e. the efficiency of 
both sgRNA and the Cas9 plasmid being transfected into the same cell. Cleavage was 
observed with all sequences of sgRNA in the GFP enriched population, with sgRNA1 
and sgRNA3 showing the highest genetic modification efficacy, with 24.1% and 24.9% 
respectively. sgRNA2 and sgRNA4 showed lower modification efficacy, 10.3% and 
13.4% respectively (Figure 3.17). These values were calculated using Equations 3.1 and 
3.2 from the methods section of this chapter. The results confirmed that genomic editing 
had taken place within the sorted cell populations, that had been selected for clonal 
expansion.  
Of the 192 cells per population sorted for clonal selection (1 cell per well in two 96-well 
plates), between 7 to 16 colonies grew from the cells seeded for expansion. Each 
Figure 3.17: Genomic Cleavage Detection of transfected and sorted cells 
The above blot shows the results of a genomic cleavage detection assay performed on an 
expanded population of sorted cell (10,000 cells per treatment). It confirms that genomic 
cleavage events have occurred with all gRNA sequences, with sequence 1 and 3 showing 
greatest cleavage. 
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expanded population was grown to a stage where it was confluent in a T-25 flask, before 
stocks were made.  
 
 
At this stage, all clonal cell-lines were tested with the RVG peptide to assay the uptake 
into the cells. It was predicted, that due to the co-transfection of sgRNA and cas9-plasmid 
that not all cell-lines would be co-transfected and therefore showing a reduction in the 
uptake of the RVG peptide. Uptake assays found that seven cell lines showed a significant 
reduction in the uptake of the RVG peptide over a one-hour pulse experiment. This was 
Figure 3.18: The uptake of the RVG peptide into CRISPR/Cas9 modified cell-
lines 
The above graphs show the uptake of RVG-[Rho] peptide into genomically edited cell lines. Each 
graph represents the cell-lines generated from a one gRNA sequence (A – gRNA1, B – gRNA2, C – 
gRNA3, D – gRNA4). The empty bars on the graph represents the auto-fluorescence of cells not 
exposed to the RVG peptide for the 1-hour uptake study. The black bars are the controls: wt – wild-
type and con – Cas9-GFP plasmid only without a gRNA targeting agent. * = p < 0.05 and ** = p < 
0.01, when compared to the wt fluorescence. n = 4 replicates from two independent experiments, 
mean ± std. 
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significant compared to untreated cells and the control transfection cell line. However, 
Western Blotting to confirm the decrease in protein expression was unsuccessful with 
these cell lines on multiple occasion. Therefore it is not possible to say with certainty that 
the effects observed in Figure 3.18 are due completely to knockout of the α7 nAchR or 
through a secondary effect of the crispr/Cas9 system. 
 
3.4 Chapter Conclusion 
The difference in the expression of the receptor panel between b.End3, PBMECs, and 
hCMEC/D3 cell lines are likely to be due to the difference between immortalised and 
primary cell-lines. The porcine cell-line expression of nAchR subunits suggests the 
presence of an alpha 3, beta 4 pentameric receptor (Tsunoyama and Gojobori 1998). This 
confirmation of the nAchR is generally seen in ganglion of the autonomic nervous system 
and is generally not associated with other cell types. Within the b.end3 cells the alpha 7 
subunit is has the highest expression of the nAchR panel, indicating a potential for an 
alpha 7 exclusive pentamer (Tsunoyama and Gojobori 1998). This alpha 7 pentamer is 
considered a neuronal nAchR, however is seen in the peripheral nervous system and in 
developing muscle tissue. Additionally in endothelial cells the alpha 7 nAchR has a role 
in angiogenesis (Cooke and Ghebremariam 2008). Further studies into cerebral vascular 
nAchR expression show stimulation of the receptor with the cognate ligand triggers 
increased vascular permeability (Hawkins et al. 2005). As the full action of RVG on the 
acetylcholine receptors is currently unclear this effect could be a contributing factor to 
enhancing cerebral uptake of nanoparticles targeted with the RVG peptide. All cell lines 
show expression of p75 NTR, which has been shown to be a receptor for the whole virus 
and it is yet to be evaluated as a receptor for the RVG peptide. This is an aspect that will 
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be explored with later studies, looking to deplete these receptors and look at the effect on 
RVG peptide uptake by the cells. 
The initial uptake studies of the RVG peptide demonstrate the peptide localised in 
punctate vesicle like structures within the cells, typically associated with endocytosed 
materials. This appears to be an active process as no uptake was seen at 4 oC compared 
with 37 oC. However, binding was not observed on the cell membrane using confocal 
microscopy. Alternative assay using a fluorescent plate reader or flow cytometry based 
assay are currently being utilised to enhance the sensitivity of detection and allow lower 
concentration ranges to be used in later studies. The peptide sequence was shown to be 
key for uptake with a scrambled sequence peptide showing undetectable uptake by 
confocal microscopy and present in significantly lower concentrations in plate reader 
based assays. Additionally, the role of the internal cysteine in the RVG sequence has been 
demonstrated to be necessary for cellular entry of the peptide. Studies into α-bungarotoxin 
binding to the nAchR show the cysteine residue in α-bungarotoxin corresponding to the 
cysteine within the RVG peptide interacts with an aspartic acid residue in the nAchR 
(Huang et al. 2013). Although the binding curve for the RVG peptide has yet to be 
established in the b.End3 cell-line, it may be that the loss of this interaction through the 
substitution with alanine critically reduces the ability of the peptide to bind its receptor. 
Further investigations into this will be undertaken in the coming months to evaluate the 
importance of this residue in the uptake process. 
Pulse-chase studies with the RVG-[Rho] peptide demonstrated that it can undergo active 
efflux from both b.End3 and hCMEC/d3 cells. With the proportion retained by the cells 
at the conclusion of a 1 hour chase comparable to transferrin and both 8D3 antibodies in 
the previous chapter. This characteristic of the RVG peptide is desirable for potential 
targeting ligands as it show the capacity of the ligand to both be taken up and effluxed 
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from BMECs. Suggesting that there may be the potential to undergo transcytosis across 
the barrier cell-type in vivo. 
The competition of RVG peptide uptake by α-bungarotoxin would be indicative of a 
receptor-mediated process, most likely involving a nAchR. These findings are concurrent 
with previous research using this peptide. The additional competition studies using α-
bungarotoxin Alexa 647 in b.End3 cells showed the neurotoxin uptake can be inhibited 
by the addition of increasing concentrations of both unlabelled α-bungarotoxin and RVG 
peptide. This provides further evidence of the involvement of the nAchR in the RVG 
uptake process. Further, the uptake of the RVG peptide was inhibited by competition with 
unlabelled α-bungarotoxin, providing further evidence that the uptake of the RVG peptide 
is a receptor-mediated process, involving the α7nAchR. Additionally, due to the 
confounding data on the importance of the cysteine residue in the sequence structural and 
functional analysis of the interaction of the peptide with any putative receptors will be 
done to clarify the uptake process. However, overall, it possible to conclude from the 
bungarotoxin competition and siRNA knockdown studies, that the α7nAchR is a target 
for RVG peptide uptake into cells.  
To progress this work further, the testing of dendrimer constructs targeted with the RVG 
peptide could be synthesised and used to study the effect of targeting ligand density, on 
the uptake and efflux of the dendrimer complexes from the BMEC cell lines. This would 
be of particular interest, in relation to the work with monovalent targeting antibodies, 
directed against the transferrin receptor (Yu et al. 2011; Niewoehner et al. 2014). Through 
the use of the pulse-chase assay and combination with confocal microscopy, any potential 
cross-linking events and alterations to trafficking efficiency could be measured with these 
assays. 
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Chapter 4: Advanced microscopy techniques for the imaging 
of cellular trafficking events in brain microvascular 
endothelial cells 
 
4.1 Introduction 
4.1.1 What is TIRF microscopy? 
Total internal reflection fluorescence microscopy (TIRFM) was developed in the 1980s 
by Daniel Axelrod. It enables selective excitation and imaging of fluorescent artefacts, 
located within close proximity to the coverslip surface; such artefacts can be lost within 
noise when samples were imaged with alternative microscopy techniques (Axelrod 1981).  
Light waves are refracted at the interface between different materials, due to the 
differences in the speed of light within different materials. The extent to which light will 
is refracted at an interface is determined by respective refractive indexes of the materials 
(Harrick and Beckmann, 1974; Axelrod, 1981). Other factors influencing the refraction 
of light include the wavelength of the light used, with longer wavelengths (far red) 
undergoing less refraction at a phase interface than shorter wavelengths of visible light 
(blue). If the angle of incidence of the light is less than the critical angle of the material it 
passes through, then the process of refraction will occur as standard, and the sample will 
receive direct illumination from the excitation source.  
In the case of TIRFM, the angle of incidence from the excitation source exceeds the 
critical angle of the coverslip material. This causes the excitation beam to be reflected at 
the coverslip-sample interface and generates an electromagnetic wave, the evanescence 
wave, with the same wavelength as the excitation source, which propagates into the 
sample. The evanescence wave decays exponentially with distance above the coverslip 
surface, allowing for the selective excitation of fluorophores within 100-200nm above the 
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coverslip. The selectivity of the illumination field provides for the increased signal to 
noise within the evanescence field with high axial resolution, allowing for single 
molecule imaging above the coverslip surface (Axelrod 1981; Jaiswal and Simon 2007). 
To ensure the generation of the evanescence wave into the sample the objective lens, 
immersion oil and coverslip must have matched refractive indices. 
The evanescence wave penetration depth in the sample is determined by the wavelength 
of the excitation light, lower wavelength, lower field depth, and the incidence angle of 
the reflected light, increasing the angle beyond the critical angle decreased the 
evanescence field depth. Lenses of high numerical aperture (NA) are therefore essential 
to allow for the greatest range of supercritical angles (Axelrod 1981). 
Calculating the Critical Angle 
Equation 4.1. 
𝜃𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 =  𝑠𝑖𝑛
−1 (
𝑛1
𝑛2
) 
As previously stated the critical angle of a TIRFM system was determined by the 
difference between the refractive index of the glass (n2) and the refractive index of the 
sample solvent (n1). By knowing this angle, it is possible to calculate the illumination 
depth of the sample using Equation 4.2.  
The depth of illumination field will vary based on the wavelength of the laser, the power 
of the illumination and the angle at which the laser is hitting the coverslip. However, the 
effect of laser power is minimal, due to the exponential decay of the evanescence field. 
Equation 4.2. 
𝑑 =  
𝜆
4𝜋𝑛2
(
𝑠𝑖𝑛2𝜃
𝑠𝑖𝑛2𝜃𝑐𝑟𝑖𝑡
− 1)
−
1
2
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As the evanescence wave propagates from the coverslip surface, through the sample, the 
power decays exponentially, meaning that a fluorophore which is 1 nm from the coverslip 
will typically receive 5000 times the power of a fluorophore 1000 nm from the coverslip 
(Axelrod 1981). This change in power can be modelled using Equation 4.3, where the 
power (I) at a given (z) depth will be related to the initial laser power (Io), and the depth 
of the evanescence field (d), calculated from Equation 4.2. A diagrammatic overview of 
the equations in this section as shown in Figure 4.1. 
Equation 4.3. 
𝐼 =  𝐼0. 𝑒
−(
𝑧
𝑑) 
 
The high, localised excitation powers (100-300 nm from coverslip) allows for a high 
signal to noise ratio of excited fluorophores. While the z-axis resolution is typically below 
the diffraction limited resolution within this plane. TIRF microscopy has the advantage 
over other, epifluorescence microscopy, where the whole of a sample is exposed to the 
excitation light. This causes collection of fluorescence from both within the focal plane 
and out of focus light, giving a poor signal to noise ratio and axial resolution. The details 
of structures located in the basolateral region of cells can be lost to the fluorescence signal 
from other areas of the cell. Whereas in TIRF microscopy, due to the exponential decay, 
of the propagating evanescence wave, only structures in the basolateral compartment of 
the cell, that are less than ~300nm from the coverslip surface, are illuminated. The signal-
to-noise with TIRF allows for axial resolutions below the diffraction limit, and tracking 
accuracy has improved to a resolution of within 2nm, with appropriate, post-capture 
analysis. 
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4.1.2 Using TIRF microscopy for cell imaging 
Coupling of the TIRF microscopy method with drug delivery research allows for the 
analysis of the basolateral membrane of cells and the real-time imaging of cellular 
trafficking events occurring at this site (Midorikawa and Sakaba 2015; Machado et al. 
2015; Wennmalm and Simon 2007). A schematic diagram of the TIRF microscopy in 
cells is shown in Figure 4.2. By careful design of the studies and the analytical approaches 
taken it would be possible to track the arrival and delivery of a ligand to the basolateral 
membrane of the cells, that has come from an apical receptor. Cellular studies using TIRF 
microscopy, in the literature, have focused on the kinetics fluorescently tagged receptor 
Figure 4.1: Increasing the Light Angle at an Interface Causes Total 
Internal Reflection 
The above figure shows the effect of increasing the angle at which light passes across the 
interface between two materials with different refractive indexes. A represents an angle 
below the critical angle, so the light is refracted at the interface. In B, the light arrives at 
the interface at the critical angle and is refracted back along the interface. In C, the light 
has an angle greater than the critical angle and so is reflected at the interface and an 
evanescence wave propagates into the sample. The decay of this wave is exemplified in 
D. Adapted from Figure 2., Fish (2009) 
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arrival within the Evanescence Field, typically, without looking at a ligand directly 
(Axelrod 2001; Betzig et al. 2013). 
 
TIRF microscopy has been used to study vesicle release and fusion at the basolateral 
membrane. However, when examining the literature, there are differences in terminology 
and the way events are characterised. For exocytosis characterisation, the steps would be 
Figure 4.2: Simplified schematic of the light-path in a TIRF 
Microscope 
The red line represents the path of the excitation laser light through the microscope. 
Having passed through excitation filters (not shown) it will be reflected into the 
objective lens of the microscope, where lenses within it ensure the light path leaves 
the objective at the correct angle for TIRF. The light is reflected at the coverslip-
sample interface, and forms the evanescence wave (red rectangle), which propagates 
a short distance into the sample. Exciting fluorophores within the field (green). 
Fluorophores outside the evanescence wave are not excited (grey). Light emitted 
from the excited fluorophores (green rectangle) passes back through the microscope 
and into the detector (EMCCD).  
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as follows. Firstly, a vesicle enters the evanescence field and becomes bound to the fusion 
site; this is an arrest of free movement of a vesicle through the cytosol and confinement 
of its location for an extended duration. The attachment to the cell membrane, before 
complete membrane fusion and content release is through the interaction of v-SNARE 
and t-SNARE protein complexes (Axelrod 2001). Once in place the attachment proteins 
“unzip” and the membranes of the vesicle and cell fuse (Vrljic et al. 2010). 
Most protocols for examining exocytosis events will look at event duration, to ensure the 
vesicle is fully bound to the plasma membrane before release. Prior to the completion of 
vesicle fusion, the motion of the vesicle was restricted to the site of membrane binding. 
Some studies will then use a secondary signalling marker, such as Ca2+ to allow for 
completion of the fusion process. Due to the requirement of calcium for exocytosis to 
take place (Lock et al. 2015; Walker et al. 2008). Other studies use a pH-sensitive probe 
to confirm when the vesicles content is exposed to the extracellular environment (Shen et 
al. 2014; Bauereiss et al. 2015).  
In “simpler” studies fluorescently tagged receptors (GFP-labelled) can be monitored at 
the basolateral membrane of cells to assay their exocytosis. Here studies look at the peak 
intensity, spot radius and total intensity to confirm vesicle release (Schmoranzer et al. 
2000). An increase in spot diameter confirms the event as exocytosis, as the vesicle 
membrane “spreads” into the plasma membrane. Another study worked to characterise 
the types of events into arrival, loss and diffusion events at the membrane (Midorikawa 
and Sakaba 2015). Other studies found that some vesicles do not release their entire cargo 
at a single docking. Instead, several discrete fusion events were required to release the 
full content of the vesicle. These events have been termed as “kiss-and-run” exocytosis, 
or partial release events have been seen in the analysis of capture (Roman-Vendrell et al. 
2014; Jaiswal et al. 2009). 
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Several studies have used TIRF microscopy to monitor cellular trafficking at the 
basolateral membrane of the cell. The group of Sally-Ward have manipulated the TIRF 
microscopy setup to allow for 3-dimensional tracking of vesicles, through cells, on-route 
to and from the basolateral membrane. The setup for this imaging is complex, involving 
multiple detection EMCCDs at differing locations from the microscope. Using beam 
splitters within the emission pathway light from a given focal plane may be deflected into 
the path of the detector, while allowing other light to pass through the splitter. Using this 
technique antibodies, and membrane receptors have been imaged at up to eight focal 
planes simultaneously, and the endocytosis tracked in 3D. Within the field of endothelial 
research, the FcRn receptor has been extensively characterised using the 3D tracking 
protocols (Ober et al. 2004).  
 
4.1.3 Photoswitchable Proteins in Cell Imaging 
For many years now the transferrin receptor (TfR) has been one of the principal targets 
for the study of receptor-mediated transcytosis across the brain microvascular endothelial 
cells (BMECs) of the blood-brain barrier (BBB). However, despite multiple 
investigations into the TfR, the efficiency of delivery across BMECs remains low. Indeed 
the precise mechanism of TfR transcytosis remains unclear. The TfR itself is known to 
undergo constitutive recycling within barrier cell types to facilitate the delivery of iron, 
bound to transferrin, within the cells.  
Additional studies by both Roche and Genentech with mono- and di-valent antibody 
constructs as well as low and high-affinity construct showed an ability to perturb the 
standard trafficking. The high affinity and di-valent anti-TfR antibodies caused receptor 
downregulation from the surface of BMECs and increased lysosomal residence, leading 
to a decrease in the total TfR within BMECs. Low affinity and mono-valent antibodies 
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against the TfR were able to successfully deliver a protein cargo into the CNS in-vivo in 
addition to showing lower toxicity to animals in studies.  
 
4.1.3.1 Fluorescent Protein Constructs 
Fluorescent proteins have had increasing prominence in life science research since the 
identification of green fluorescence protein (GFP) in 1962 and its cloning in 1992 
(Hughes 1998; Shimomura et al. 1962; Prasher et al. 1992). The initial studies of the GFP 
proteins were in association to bioluminescence in marine creatures. It was not until 1994 
that GFP was used to label intracellular structures and for the study of the subcellular 
distribution of proteins (Chalfie et al. 1994). Studies of aquatic creatures including, 
Hydrozoa and Anthozoa revealed fluorescent proteins (FPs) with chromophore structures 
similar to that of GFP. Further studies along the evolutionary hierarchy of these species 
revealed FP both GFP-like and novel FPs such as DsRed and Kaede (Labas et al. 2002). 
Increased interest in the use of FPs in life science research has led to the discovery and 
cloning of FPs covering the entire range of the visible spectrum with improved fluorescent 
stability and intensity. 
Many FPs exist in a barrel-structure with the central core forming the chromophore, 
comprising the internal facing amino acid side-chains (Evdokimov et al. 2006). Variation 
of these amino acid residues can tune the spectral properties, stability, catalytic activity 
and even generate a non-fluorescent form of the protein. The arrangement of the barrel of 
the FP is the process of fluorescence maturation, the process of formation of the final 
chromophore within the pore of the barrel. This process is considered self-catalytic with 
no external factors, except oxygen molecules (Evdokimov et al. 2006). However, beyond 
this little is known about the precise mechanism of the biogenesis of the chromophore 
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with the exact sequence of the formation being poorly understood for the even the most 
commonly studied, GFP. 
More recent studies have found it is possible to engineer fluorescence proteins with 
multiple states, ie. Off or on; green or red. These FPs fall into several categories: 
photoactivatable (on/off), photoswitchable or photoconvertible (Zhou and Lin 2013). 
Changes to chromophore structure which lead to the permanent alteration of the 
fluorescence profile of the FP are termed photoconvertible and most deemed most useful 
for the studies proposed. Photoconversion requires exposure of the FP to high energy light 
(typically ~ 400nm) to facilitate chromophore structural alterations, shifting the 
excitation-emission profile of the protein. The characteristics of photoconvertible proteins 
can be seen in Table 4.1, below. All photoconvertible proteins require stimulation with 
high-energy wavelengths of light to initiate the state change (Zhou and Lin 2013). This 
state change often involves the breaking of peptide bonds within the structure of the 
chromophore, which will alter the excitation and emission profile of the protein. In some 
cases, these changes can be reversed by exposure to longer wavelength light and these 
proteins are termed as photoswitchable (Zhang et al. 2016). If only a single conversion is 
possible (i.e. green to red only), then the protein is termed as having undergone 
photoconversion. With these proteins, the only progression from the photoconverted state 
is to photobleach.  
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Table 4.1: Photoconvertible Fluorescent Proteins 
Protein 
Ex.1 
(nm) 
Em.1 
(nm) 
Conversion 
(nm) 
Ex.2 
(nm) 
Em.2 
(nm) 
Dendra2 490 507 400±10 553 573 
mEos2 508 516 400±10 571 581 
mEos3.2 507 516 400±10 572 580 
mEos4a 505 516 400±10 569 581 
mEos4b 505 516 400±10 569 581 
dEos 505 516 400±10 569 581 
tdEos 505 516 400±10 569 581 
mKikGR 507 517 400±10 583 593 
Kaede 508 518 400±10 572 580 
mGeo-M 503 514 400±10 569 581 
PSmOrange  548 565 488 634 662 
PSmOrange2 546 561 488 619 651 
 
To explore this difference in trafficking of the receptor further, we have generated a TfR 
that is co-expressed with the photo-switchable protein PSmOrange. This protein was 
developed by Subach et al. (2012), in its standard form, PSmOrange fluoresces in the 
orange region of the visible spectrum (excitation 548nm, emission 565nm). However, if 
exposed to blue/green light sources (488nm) PSmOrange undergoes photo-oxidation and 
cleavage of the protein backbone to produce a chromophore with far-red fluorescence 
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with an excitation wavelength of 636nm and an emission wavelength of 662nm (Figure 
4.3) (Pletnev et al. 2014). The half-life of conversion of PSmOrange is 15s so for these 
studies apical membrane regions were exposed for a period of 60s to ensure greater than 
90% conversion within a field of view before incubation at 37oC (Subach et al. 2011; 
Subach et al. 2012). Further, the far-red form of PSmOrange displays favourable 
photostability and resistance to photobleaching making it ideal for the analysis of the 
arrival of potentially low levels of the construct at the basolateral membrane. In 
combination with the electron multiplying CCD camera (EMCCD) of the TIRF 
microscopy imaging of single fluorescent events should be possible at the basolateral 
membrane.  
Using this switchable PSmOrange-TfR in combination with TIRF microscopy, we will 
be able to selectively “switch” the fluorescence at the apical membrane to the far-red. The 
cells will then undergo an incubation with various ligands against the TfR at 37oC for 
differing time courses; we will then be able to examine the basolateral cell membrane, 
again using TIRF microscopy to assay the arrival of an apical receptor which has 
undergone a transcytosis process. 
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4.1.4 Chapter Aims 
The primary aim of this chapter was to assess the feasibility of using TIRF microscopy 
to image the basolateral cell membrane of BMECs. This was done using a fluorescently 
labelled ligand (transferrin) and the tagging of its receptor (TfR). To enable the 
characterisation of both ligand and receptor dynamics in basolateral regions of BMECs. 
The objectives for this chapter were as follows: 
1. The characterisation of fluorescently labelled transferrin at the basolateral cell 
membrane, to identify putative exocytosis events.  
2. The construction of photoswitchable fluorescent proteins, tagged to the TfR 
(PSmOrange) 
3. Mathematical modelling and characterisation of PSmOrange photoswitching with 
BMECs using confocal and TIRF microscopy techniques.  
 
Figure 4.3: Structure of PSmOrange and Chromophore changes in 
photoswitching 
The above shows the structure of the entire PSmOrange protein (A) with the 
chromophore highlighted by the black circle. The changes that occur in the 
chromophore structure, when exposed to photoswitching light are then shown in B, 
and the excitation and emission wavelengths of both states are given. Adapted from 
Pletnev et al (2014) Figure 3 and Figure 4. 
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4.2 Methods 
4.2.1 Materials 
EBM-2 Media was purchased from Lonza, UK. Fetal calf serum (FCS), trypsin-EDTA 
(0.5%) dissociation solution, Penicillin-Streptomycin (10,000U/mL), Phenol Red Free 
DMEM + Glutamax high glucose, Anza™ 10pk Starter Kit Restriction Enzymes, Anza™ 
T4 DNA Ligase Master Mix, PureLink™ Quick Gel Extraction Kit, Ethidium Bromide 
solution, 10x TBE buffer, Agarose, Lipofectamine™ P3000 Kit and Transferrin 
AlexaFluor® 647 were purchased from Life Technologies, UK. The following filters, 
used in the TIRF microscopy setup were purchased from SEMROCK, USA: 
ZET473/10x, ZET532/10, ZET635/20, FF01-676/29, FF01-593/40, NF03-633E, BLP01-
473R, NF01-532U, FF640-FDi01 and DI03-r405/488/532/635. The EMCCD camera was 
purchased from Andor, UK. All plasmids were purchased from AddGene, USA. Plasmid 
Midi Prep Kit was purchased from Qiagen, UK. BSA, Hoechst and any salts not 
mentioned here were purchased from Sigma Aldridge, UK. 
4.2.2 Cell culture 
These studies were performed in hCMEC/d3 (human immortalised brain endothelial 
cells). These are cultured on collagen coated plastic, in media containing: 92.5% EBM-2 
media supplemented with 5% FBS, 1% penicillin-streptomycin, 1% HEPES (1M stock 
solution) and 0.5% vitamin C. hCMEC/d3 cells were split at between 75-90% confluency 
by use of trypsin-EDTA solution (0.05%) and incubating the cell at 37oC for ~5 minutes. 
The dissociated cells are then resuspended in fresh, culture media and centrifuged at 300 
xg for 5 minutes, to remove trypsin-EDTA from the cells. The cell pellet is resuspended 
in 5 mL of media and the cells counted by haemocytometer. For maintenance, 1 million 
cells were seeded into a T75 flask, for assays hCMEC/d3 cells are seeded at a density of 
20,000 cells/cm2, onto collagen coated plastic ware.  
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4.2.3 Uptake and Pulse-Chase Study design 
hCMEC/d3 cells are grown in glass-bottomed MatTek dishes (No. 1.0 coverslip) until a 
confluent monolayer can be observed by bright field microscopy (5-7 days post seeding). 
Once confluent remove the culture media from the MatTek dish and replace it with Kreb’s 
Ringer buffer, containing 0.5% BSA (KRB). Incubate the cells with this buffer for 30 
minutes at 37oC to remove serum proteins from the cell surface. For the uptake and pulse-
chase studies, following the starve in KRB, the cells are then incubated with the 
fluorescent ligand, transferrin-Alexa Fluor 647 (100pM) for 45 minutes at 37oC (the 
uptake phase). Following this, cells are washed 5 times with PBS to remove the 
extracellular, unbound ligand from the imaging dish. To image at this stage cells are 
incubated with KRB + 2.5% BSA for the chase/imaging phase. Dishes undergoing a chase 
phase were incubated at 37oC and 4oC for up to an hour, prior to imaging. With cells 
being chased they are washed a second time with PBS to fluorescent ligands that are no 
longer cell associated following the chase. 
4.2.4 TIRF microscopy design 
There were multiple imaging approaches available to use with the TIRF setup available 
in Cardiff. The simplest form was tracking the arrival and motion of particles within the 
evanescence field. This can be done by recording a video of the cells, 1000 frames in 
duration (30ms exposure time), and post-acquisition analysis using the Fiji software. For 
the Alexa Fluor 647 labelled proteins, imaging setup used 634nm excitation laser, with a 
minimum, fibre coupled power, of 20mW, and a long-pass 660nm emission filter in place. 
Video acquisition was done using an EMCCD camera, with a pixel resolution of 512x512. 
Imaging was done through a 60X magnification lens with an additional 1.5X added within 
the microscope and 10X magnification at the coupling of the microscope to the camera.  
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4.2.4.1 Photobleaching 
TIRF microscopy offers a way to track the dynamics of protein trafficking events at the 
basolateral membrane of cells. This can be done by live tracking of events at the 
membrane in long-duration videos. However, other methods exist to monitor fluorescence 
at the basolateral membrane and dynamics of receptor-ligand trafficking. To ensure that 
fluorescence arrival into the basolateral region is from the apical areas of the cells, and 
not merely fluorophores “flip-flopping” in and out of the evanescence field. By 
photobleaching fluorophores in the evanescence field, with a long exposure (30s) and 
then looking at the recovery of fluorescence into the field of view. This technique is 
known as fluorescence recovery after photobleaching (FRAP). To analyse these studies, 
it was proposed to study the total fluorescence recovery into the bleached region, over ten 
minutes, while also looking at the total number of fluorescent spots. If the trafficking of 
the protein is limited to purely basolateral recycling then after the photobleaching there 
would be limited or no return of fluorescence in the recovery. However, if the trafficking 
pathway of the protein is non-restrictive throughout the cell, then the recovery into the 
basolateral region will be more rapid.  
 
4.2.5 Plasmid Design 
To generate the PSmOrange-TfR construct, the TfR sequence was restriction cloned into 
the vectors pPSmOrange-N1 and pPSmOrange-C1 to produce constructs with N- and C-
terminal labelling with the fluorescent protein. This was to ensure the stability and the 
normal functioning of the construct within cells, without interference to cognate ligand 
binding. The most optimal construct will be taken forward for the transcytosis studies. 
Two-site restriction enzyme digest of the donor and acceptor plasmids should ensure 
maximal incorporation of the TfR sequence within the final plasmid, before purification. 
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The restriction sites EcoR1 and Age1 have been selected, due to their flanking of the TfR 
sequence in the donor plasmid and their presence within multi-cloning site (MSC) of the 
acceptor plasmids in the desired insertion site. Also, the use of multiple restriction 
enzymes ensures the inserted sequence will maintain the correct orientation in the final 
plasmid. Thus, ensuring the expression of the sense sequence of the desired protein. 
 
 
4.2.6 Restriction Digest 
Restriction digests were performed as per the supplier’s information. Briefly, 1μg of 
donor and acceptor plasmid were incubated with both restriction enzymes for 1 hour at 
37oC to ensure maximal cleavage of DNA. The cleavage products were then separated by 
purification along an agarose gel (0.8%) with the correct bands being collected for and 
the DNA extracted from the gel. The insertion fragment, containing the TfR DNA 
sequence, flanked by the overhanging sticky-ends, containing the complement to the 
restriction site, was then incubated with the cleaved, recipient plasmid and annealed using 
T4-ligase. Blank, insert sequence only and recipient only ligations were also performed 
to establish the self-annealing occurrence.  
Figure 4.4: PSmOrange-TfR Plasmid Structure and Synthesis 
In the above figure, the plasmids used and created are shown. Figure A shows the structure of the 
PSmOrange-N1 plasmid (Addgene ID = 31898). B the structure of (Addgene ID = 61505). While C 
is the proposed structure of the synthesized plasmid TfR-PSmOrange. 
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4.2.7 Bacterial Transformation 
The newly created plasmids will then be transfected into DH5α E. coli cells by heat-shock 
transformation. Briefly, an aliquot of the bacterial stocks were thawed on ice and 100μL 
of the cells will be transferred into a chilled tube, one tube per transfection. The ligation 
product should be diluted 1 in 5 from the reaction and from this 1μL is added to the cells 
and pipetted to disperse the DNA among the cells. Cells are kept on ice for a further 30 
minutes before heat-shocking the cells at 42oC for 45s and placing the cells back on ice 
for 2 minutes. Cells are incubated with 900μL of S.O.C. media (room temperature) and 
shaken for two an hour at 37oC. Streak the transformed bacterial cells onto LB agar plates 
containing selection antibiotics (ampicillin – 100μg/mL or kanamycin - 50μg/mL) and 
incubated overnight. The following day single colonies are picked and incubated in 5 mL 
LB broth and cells were incubated for 12 hours, under shaking at 37oC, allowing for initial 
bacterial growth. From this 1 mL of bacterial cells are incubated in 250mL of LB broth, 
for 4 hours to expand bacteria for plasmid isolation. 
Following isolation of plasmid from E. coli, the insert was confirmed by restriction digest 
of the plasmid with EcoR1 or EcoR1 plus Age1 restriction enzymes. This confirmed the 
molecular weight of the newly constructed plasmid and the presence of the TfR DNA 
within the plasmid. Additionally, the plasmid digests were extracted from the gel and 
sequenced to further confirm the presence of the TfR insert within the pPSmOrange-N1 
plasmid.  
4.2.8 Cell Transfection 
To optimise the transfection protocol within hCMEC/d3 cells, three concentrations of 
plasmid were selected, 0.5, 1, 2 μg/well. Briefly, cells were seeded into 6-WP, MatTek 
imaging dishes and other plastic ware at a concentration to give 70-90% confluency 24 
hours post-seeding. Plasmid transfection solutions were prepared in accordance with the 
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manufacturer’s protocol. For example, 1 μg of plasmid was combined, in 50μL Optimem, 
with 2μL of P3000 reagent and 3.75μL Lipofectamine 3000 reagent and incubated at 
room temperature for 15 minutes before transfection. For the other concentrations of 
plasmid the ratios of DNA:P3000:Lipofectamine 3000 remains constant, and the volume 
of Optimem remains at 50μL per well. The prepared transfection solution is added to cells 
in culture in serum-containing media and allowed to incubate for 48 hours before analysis. 
Confocal microscopy was performed to confirm the transfection and the ability of the 
pPSmOrange-TfR plasmid to undergo photoswitching with our microscopy setup. Cells 
were imaged 48 hours post-transfection with the plasmid. Before imaging the culture 
media was removed and replaced with imaging media (phenol red-free DMEM 
containing HEPES and supplemented with 0.5% BSA), to equilibrate cells for 
microscopy. Five minutes before imaging, cells were stained with Hoechst to ease 
identification and allow for visualisation of the nuclei. Cells are then washed 3 times with 
PBS before re-incubation with new imaging media for analysis by microscopy.  
When imaging plasmid positive cells were identified by fluorescence in the orange 
channel (ex. 543nm, em. 560-610nm), as this is the native state of the PSmOrange. A 
single image was captured, by exposing cells to 543nm and 633nm lasers, this will be 
referred to as “Time Zero”, and represents the fluorescence distribution, within to the 
imaging plane, before photoswitching. A time series was then taken, of the same field of 
view, exposing the cells to 543nm, 633nm and the switching wavelength, 488nm (at 
different powers). By imaging in this manner, it is possible to see the fluorescence state 
shift over time and establish the photoswitching kinetics for different laser powers. 
Analysis of the switching kinetic series is done using Fiji software to identify regions of 
interest (ROIs) and quantify the mean fluorescence within these ROIs. This is done in 
each frame of the series and each fluorescence channels (orange and far-red). The values 
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are then normalised so that the fluorescence at time zero in the orange channel is equal to 
1 and in the far-red channel is 0. The far-red fluorescence is then further normalised so 
that the maximum value for far-red fluorescence is equal to 1. 
Having established the optimal switching time for the fluorescent protein, it is then 
possible to switch the protein without needing to simultaneously image in the orange and 
red channels. This allows for the performance of a modified FRAP study, where, by 
switching in selected regions of the cells and then imaging the entire cell it is possible to 
see the redistribution of the receptors within the focal plane. 
4.2.9 Setting up TIRF for two colour imaging 
To further optimise the TIRF microscope for photoswitching experiments, efforts were 
made to establish dual colour imaging with the TIRF microscopy setup, to allow 
simultaneous imaging of switched and native state of the protein. The optical pathway of 
the TIRF microscope was altered to allow for multi-excitation and image-splitting to 
collect two different wavelengths of emitted fluorescence simultaneously. A diagram of 
the light paths involved was shown below. However, in simplistically terms, excitation 
light from the laser sources is columnated and aligned, so that the laser spot for all three 
excitation sources is in the same position. This ensures maximal power output from all 
lasers once they were coupled into the fibre launch system. The fibre system, although 
reducing the laser output power at the stage, ensures uniform illumination of the sample 
during imaging. Free-space coupling of the excitation lasers into the microscope allows 
for higher excitation powers at the microscope stage. However, it also produces a 
Gaussian excitation profile, that is different for each excitation laser, so uniform, 
comparable illumination is harder to achieve. 
Once the excitation light is within the microscope, it must be reflected “up” through the 
objective lens to the sample. To do this in multi-excitation imaging, a quad-edge dichroic 
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mirror was used. This dichroic mirror can reflect the excitation light from all the lasers 
into the objective lens, while crucially allowing the emitted light from excited 
fluorophores to pass back through it. The angle at which the excitation lasers hit the 
dichroic mirror will determine the position, relative to the centre of the objective lens, 
that the light will arrive at and therefore the angle at which it will leave the objective and 
reach the sample. 
Having been totally internally reflected and exciting the fluorophores in the sample the 
emitted fluorescence will travel back through the objective lens. In this case, passing 
through the dichroic mirror and through a set of emission notch filters to “remove” any 
photons of light that may have come from the back reflection of the laser. The emitted 
light is then directed into the image splitter unit. Here there is another dichroic mirror, 
which will allow long wavelengths (>640nm) to pass through while reflecting 
wavelengths below this. The now, two paths of now pass through bandpass filters for their 
respective fluorescence (red = 676/29nm filter, green = 593/40nm filter). The photons 
that passed through the bandpass filters is then focused onto the EMCCD detector of the 
camera, such that half of the detector will detect “red” fluorescence and the other half 
“green” fluorescence. 
4.2.10 Microscopy Study Preparation 
For these studies, the PSmOrange-TfR plasmid was transfected into hCMEC/d3 cells, 
using the protocol in section 4.2.8, and cells left for 48 hours to express the fusion protein 
construct. After 48 hours cells were lysed, using the lysis protocol described previously 
and the protein concentration quantified and adjusted to 1 µg/µL with PBS. This stock of 
protein lysate was stored, in 10 µL aliquots at -20 oC until use. Additionally, lysates from 
un-transfected control cells were collected, to ensure that any observed photoswitching 
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was due to the predicted switch in the PSmOrange protein and not another component of 
the cell lysate. 
4.2.11 Imaging Optimization – Channel Cross-Talk 
The cell lysate (1 µL) was pipetted onto a plasma treated coverslip, at the stock 
concentration (1 µg/µL), and allowed to dry, so the fluorophores were in contact with the 
coverslip, with limited diffusion. This concentration of cell lysate allowed for the imaging 
of single fluorescent molecules when TIRF.  Initial optimisation was done to characterise 
the fluorescence cross-talk between the microscope channels with the different laser 
configurations. These included: green laser only, red laser only, green and red lasers 
simultaneously, blue and green lasers simultaneously, blue and red simultaneously and 
all three lasers simultaneously. This cross-talk study was performed on regions of the 
native state (green) protein and then on regions exposed to the blue laser for a period of 
up to 10 minutes. This long blue exposure allows for photoswitching to take place, while 
not bleaching the fluorescence with the green and the red lasers.  
4.2.12 Imaging Optimization – Photoswitching Procedure 
The previous optimisation stage found as the number of lasers was increased the noise in 
the red and green imaging channels increased. This was most apparent in the far-red, as 
the signal to noise was much lower than in the green channel, and there was bleed-through 
from the brightest “spots” in the green channel. It was therefore decided to image the 
photoswitching process; long capture videos would be taken, 1000 frames at 30 ms 
exposure. With the protein exposed to the green laser only for approximately the first 50 
frames, to give the locations of the fluorescent protein at the before the photoswitching. 
Then simultaneously exposed to the blue and red laser, for the duration of the switch 
(~900 frames). Before finally exposing with the green laser for the last 50 frames of the 
capture, these allowed the visualisation of the location of any native fluorescence at the 
     Chapter 4 
 
176 
 
conclusion of the photoconversion. The total exposure time was varied by changing the 
number of accumulations per frame while keeping the total number of frames constant. 
This means, if the frame accumulation was “5”, the camera would z-project five frames 
into one, which it saves in the video before capturing the next frame, a 1000 frame video 
is the length of a 5000-frame video. The number of accumulations used was: 1, 2, 3, 5 
and 10; which created a series of videos from 30 seconds to 5 minutes. 
4.2.13 Imaging Optimization – Image Analysis 
All image analysis and quantification, unless stated otherwise was performed using Fiji 
and the plugins and custom macros within the software. Using two colour imaging creates 
a 512 x 512-pixel image, visually divided in two, based on the green (upper) and the far-
red channels (lower). Before any quantification was done, the video was duplicated to 
produce two videos, for the green and far-red channels. These channels are then merged 
into a single video and assigned accordingly.  
The videos were then examined to establish the frame number where the switch was made 
from green laser only, to blue and red lasers, back to green laser only. This was done by 
visual inspection and plotting the z-axis profile of the green channel to locate the “jumps” 
in fluorescence signal. The video is split in three at the points of laser combination change 
and labelled accordingly (“greenPre”, “Photoswitching”, “greenPost”). Z-projections of 
the AVERAGE INTENSITY were made for the greenPre and greenPost videos, and a 
SUM SLICES projection of the Photoswitching video. 
To identify the events in the green channel that have disappeared during the 
photoswitching phase of the capture, image maths was performed as follows: 
Equation 4.4 
𝑐ℎ𝑎𝑛𝑔𝑒𝐼𝑛𝐺𝑟𝑒𝑒𝑛 =  𝑔𝑟𝑒𝑒𝑛𝑃𝑜𝑠𝑡 –  𝑔𝑟𝑒𝑒𝑛𝑃𝑟𝑒 
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If an event was present in the greenPre, but not the greenPost, a black spot appears in the 
output image. Conversely, if the spot was present in the greenPost projection, but not the 
greenPre a bright green spot was seen. This new image is then combined with the z-
projection for the Photoswitching video and is examined to check for the co-localization 
of red spots with black spots. These indicate the presence of a “switched” fluorescent 
protein from the start of the capture. The co-localization of green spots with red spots 
would potentially represent a region of partial photoconversion, where several “new” 
native state of the fluorescent proteins arrived during the photoswitching phase. Some of 
these may have undergone photoswitching, into the far-red form and so fluorescence from 
both forms is detected at that location. 
Using the built-in JACoP plugin in Fiji and the Mander’s threshold co-localization test, 
the exact percentage of red spots that were localised with green spots could be found. 
This is then compared across all the frame accumulations to see the change in 
colocalization with increased photoswitching time.  
4.2.14 Mathematical Modelling of PSmOrange Photoswitching  
The mathematical modelling of the distribution of the states of the chromophore at a set 
time-point was done in MatLab, using the Simulink plugin. The equations were created 
by LaPlace Transformations based on a closed system consisting of three compartments. 
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4.3 Results and Discussion 
TIRF microscopy allows for the detailed imaging of cellular events at the basolateral 
membrane of cells. As such it has a high potential for use in the understanding of cellular 
trafficking across brain microvascular endothelial cells. 
 
Figure 4.5: Transferrin-AlexaFluor 647 Trafficking at the Basolateral 
Membrane of BMECs 
Figure A shows a single frame from a capture video of transferrin-AlexaFluor 647 trafficking 
at the basolateral membrane of hCMEC/d3 cells. The yellow square highlights a region of 
interest for a potential exocytic event. Graph (B) to the left shows the changes in the mean 
fluorescence of an ROI (yellow circle) as a vesicles arrives (ii) is fused to the membrane (iii) 
and is released (iv) and the fluorescence returns to background (i). The panel of images show 
the 17x17px area containing the ROI and illustrate vesicle arrival (C) and vesicle release 
events (D). 
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4.3.1 Transferrin TIRF Results 
Initial analysis of TIRF microscopy on transferrin at the basolateral membrane of 
hCMEC/d3 cells was performed manually. This found several events that demonstrated 
a fluorescence profile that would be expected from a potential exocytic event, as 
demonstrated in Figure 4.5. Events arrived rapidly into the evanescence zone, in an 
“empty” region of the cell. The event is present in the evanescence zone for a prolonged 
time, and in a confined location for the entire time, it is present. Loss of fluorescence from 
the event occurs rapidly and returns to the background fluorescence level, following 
release. The second peak that was seen in Figure 4.5.B, is from a secondary event that 
originated outside the ROI boundaries but was partially trafficked into the ROI over the 
course of the capture.  
Having identified characteristics indicative of potential exocytic events the process of 
identification was automated through criteria setting and the gating of events in the image 
analysis software. This process is in line with previous work on TIRF microscopy in cells. 
Looking at the following variable: time in evanescence field, net displacement from the 
arrival point, finally to ensure events of interest are arriving from within the cell, the 
events present in the first 100 frames were excluded from the analysis. The last 
characteristic was added as part of this analysis, to enhance the likelihood that the arrival 
event has come from within the cell, potentially by the process of transcytosis. In work 
by the Sally-Ward group, more complex TIRF microscopy techniques have allowed for 
the visualisation of cellular events approaching the membrane from further within the cell 
(Ober et al. 2004). While work with more fluorescently stable, fluorescent proteins have 
been able to demonstrate a spreading effect observable as vesicles reach the basolateral 
membrane (Schmoranzer et al. 2000). However, no work has been done using TIRF 
microscopy to observe the trafficking of fluorescently labelled targeting ligands. And 
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while the Alexa-dyes have a generally high photostability. The very high laser powers, 
decaying away from the coverslip does cause rapid photobleaching of individual 
fluorophores at the cell membrane. This effect is less observable in larger vesicles, 
containing more molecules of ligand. Any work on ligands has looked at naturally 
expressed proteins, labelled fluorescently to examine their release from the cells. Several 
studies have shown that vesicles that are undergoing directional trafficking within cells, 
along microtubules can have a velocity of 0.5 µm/s, and in some neuronal cells, up to 3 
µm/s (Kreft et al. 2004, Grafstein and Forman 1980; Goldstein and Yang 2000). 
Events following directional patterns were observed in transferrin AlexaFluor 647 capture 
videos. However, they appeared infrequently and were difficult to analyse using the ROI 
methodology described in Figure 4.5. If there were fewer events present in the 
evanescence field, then detection and tracking of these events would be more robust. As 
this was not the case an example has not been included in this chapter. 
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Other events observed in the cells mimic the kiss-and-run profiles described in previous 
work (Roman-Vendrell et al. 2014; Jaiswal et al. 2009). Here events appeared into the 
evanescence zone then retreated and returned to the same location in the field of view 
(Figure 4.6). With both the retreat and return characterised by rapid changes in 
fluorescence intensity at the location of the spot. In the event shown here the same spot 
appears and retreats from the same location (6 x 6-pixel area) four times within the course 
Figure 4.6: Vesicle Retreat and Return into the Evanescence Field 
In some cases the vesicle can be seen to arrive into the evanescence field, retreat out 
of the field and then return in the exact same location within a short time frame (<1 
second). Graph A shows an example of the fluorescence profile of events like this. 
The schematic in B shows the difference between a fusion event that stays in the same 
location throughout release, and the retreat and return vesicles that move in and out of 
the excitation field. 
A 
B 
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of the 16-second video. Each appearance was sustained over several frames and 
immediately followed by a return to the background fluorescence level for that region. 
The potential trafficking routes of a vesicle that has arrived and departed the evanescence 
field were summarized in Figure 4.6 below. Events such as these may be caused by 
vesicles which are in fact not docking with the basolateral membrane. Instead, they are 
transiently entering and retreating the field of view without docking. In the example, in 
Figure 4.6 this may be the case, as there is no loss of fluorescence intensity between the 
major peaks in the graph. If full or partial docking and exocytosis had occurred before the 
retreat from the evanescence field. Then the second observed peak would have been at a 
lower intensity than the first peak. This was shown in previous work on TIRF microscopy 
of receptors tagged with a fluorescent protein. Here partial exocytosis was observed as a 
decrease in localised fluorescence, but not a complete loss from the localised region 
(Roman-Vendrell et al. 2014). This contrasts with the observations in this study, 
confirming the likelihood that no exocytosis occurred in this event, but that the event 
observed was purely intracellular vesicular movement.  
To develop the detection methodology further would require an automation approach to 
the detection of the different types of cellular trafficking events. This would go beyond 
the current offerings of Fiji plugins, such as TrackMate, as it would require a 
classification method to link tracks that reappear in the same location as previous one. To 
do this effectively, a data science approach may be most efficient, to analyse the large 
datasets generated from each video capture. This would be an area of potential 
development in the future. 
As a short-term method to quantify the number or percentage of total events that show 
the desired characteristics for potential exocytic events as sequential filtering method was 
developed for analysis. In this method, a field of view is loaded into Fiji and any potential 
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spots of fluorescence intensity are identified in the TrackMate plugin. These spots were 
examined, and tracks are build based on a nearest-neighbour search method within 
TrackMate. This produces a total number of tracks for a capture video (100 %). The total 
population of all the tracks was then filtered by the following: duration (number of spots 
in track), displacement (distance travelled) and arrival time (to ensure only “new” tracks 
are examined). Using these it was possible to get an estimate as to the proportion of total 
tracks that may be undergoing exocytosis. This method is shown in Figure 4.7, and the 
proportion of tracks of transferrin AlexaFluor 647 that were potential exocytic was 
calculated as 10.1%. These filter methods are similar to ones used in other TIRF 
microscopy experiments (Midorikawa and Sakaba 2015). However, it should be clarified 
that the findings shown in Figure 4.7 are not stating 10.1% of all tracks observed were 
undergoing exocytosis, instead that 10.1 % of all tracks exhibit characteristics that are 
expected of exocytic vesicles. To confirm whether the events truly exocytic or not a 
secondary label would be required, to detect if ligand and receptor are present together 
and attempt to visualise the dissociation of ligand from receptor on completion of the 
exocytic process.  
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4.3.2 Photoswitching 
4.3.2.1 Confocal Microscopy Results 
Initial tests with the PSmOrange-TfR construct in hCMEC/d3 cells confirmed the 
expression of the plasmid. The imaging of cells in the orange- and far-red channels before 
exposure to the switching wavelength confirmed that the far-red fluorescence is 
negligible prior to photoswitching. Cells that express the PSmOrange-TfR plasmid show 
strong, stable fluorescence signal in the orange channel. Exposure of PSmOrange-TfR 
positive cells to 543nm light allowed the calculation of the photobleaching half-life for 
the PSmOrange protein. The was calculated to be 316.8 seconds and a rate constant of 
2.19 x 10-3 s-1 when exposing the PSmOrange-TfR positive cells to the 543nm laser at 
0.09 mW power (Figure 4.8). The rate of photobleaching is related to the exposure power 
Figure 4.7 Filtering of transferrin trafficking events in TIRF microscopy 
The above figure shows an example of the filtering of all detected track events in a capture video of 
transferrin AlexaFluro 647 (100 pM) in hCEMC/D3 cells when viewed by TIRF microscopy. The 
tracks shown in the images (A) are colour coded based on their start time. Any purple dots that become 
visible as filters are applied represent spots that were detected in that frame of capture but are no longer 
included in a track after filtering. The effect of the sequential filtering method on the proportion of the 
total number of spots is quantified in B, with the percentage of spots remaining after each filter 
highlighted in red and given as mean ± std (n = 10 capture videos). 
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of the laser. However, for the photoswitching studies the power of the 543nm laser was 
kept constant at this power. 
 
Initial studies, exposing PSmOrange positive cells, to the switching wavelength (488nm) 
triggers a rapid shift from the orange to far-red fluorescence states, Figure 4.9 below. The 
rate of switching was calculated by the “arrival” of far-red fluorescence into the field of 
view and was confirmed by comparing it to the loss of orange-fluorescence from the 
image. With imaging in this manner, we see the far-red fluorescence increase rapidly in 
the early frames, but as the amount of protein to be switched decreases the far-red 
fluorescence begins to plateau and even decreased in later frames. This decrease was 
likely due to the bleaching of the far-red form and movement of the PSmOrange-TfR 
from the plane of view. 
Figure 4.8: Photobleaching of the orange form of 
PSmOrange 
The graph shows how exposure of the native state PSmOrange to 
only “orange” excitation light bleaches the fluorophore. The half-
life of photobleaching, at a laser power of 0.09mW was calculated 
as 316.8 seconds. N = 3 in triplicate, mean ± std 
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Having confirmed that the PSmOrange-TfR construct can undergo photoswitching when 
exposed to high laser powers, the next stage was to explore the dynamics of the 
photoswitching with varied 488nm laser power. Throughout these studies, the power of 
the 543 nm and 633 nm laser power was kept constant. In this way, the rate of 
photoswitching was shown to be modulated by the power of the 488nm laser. As the 
488nm laser power was increased the photoconversion rate also increased. To calculate 
the rate of photoswitching from the loss of orange fluorescence the following equations 
were applied. 
 
Figure 4.9: TfR-PSmOrange switching by confocal microscopy 
The above images in A show the effect of exposing the PSmOrange fluorophore to 
488nm switching light. The decrease in signal in the orange channel (left) is 
accompanied by the rapid rise in signal in the far-red channel (right). The 
quantification of the fluorescence in orange and far-red channels is shown in B, with 
all values expressed relative to the fluorescence in first frame of switch exposure. n 
= 3 in triplicate, mean ± std. 
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Equation 4.5 
 
In Eqn 1., the combined rate of loss of orange fluorescence, from both photobleaching 
and photoswitching is represented by Ktotal. The Ktotal value will be equal to the sum of 
the photoswitching rate (Kswitch) and photobleaching rate (Koff1), as shown in Equation 4.6 
Equation 4.6 
 
From this analysis, it was possible to observe the relationship between the laser power 
and the photoswitching rate. With a linear relationship between the log10(Laser Power) 
and log10(Kswitch). This is shown in the graph below (Figure 4.10) and relationship was 
shown mathematically as seen in Equation 4.7. 
 
 
𝑶𝒓𝒂𝒏𝒈𝒆(𝒕) = 𝑒−(𝐾𝑡𝑜𝑡𝑎𝑙)𝑡 
𝑲𝒕𝒐𝒕𝒂𝒍 = 𝑲𝒔𝒘𝒊𝒕𝒄𝒉 + 𝑲𝒐𝒇𝒇𝟏 
Figure 4.10: The effect of changing photoswitching power on PSmOrnage-
TfR. 
The graphs show the effect that switching power has on the orange form of PSmOrange. As the 
power of 488nm is increased to maximum power, the rate of switching (K
switch
) increases. Graph 
A shows the quantification of the orange fluorescence during the switch exposure. While graph 
B plots the estimates K
switch
 values against the laser power. Figure A has n = 3 in triplicate, mean 
± std, Figure B uses the calculated Kswitch from the replicates in Figure A as the data points. 
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Equation 4.7 
 
Quantification of the fluorescence within the far-red channel while exposing the 
PSmOrange-TfR cells to the switching laser, confirms the more rapid loss of fluorescence 
in the orange channel is matched by an increase in the fluorescence in the far-red channel. 
 
4.3.2.2 Modelling the Fluorophore State Transitions 
Understanding the behaviour of the fluorophore and its distribution between the 
fluorescence states is key for predicting and defining the optimal switching conditions. In 
the following section, we will derive the equations to summarise the distribution of 
fluorescence between the orange, far red and bleached states. The relationships between 
the fluorescence states of PSmOrange is summarised below, the model assumes a closed 
system, with all fluorescence existing in the orange state (X1). Fluorescence can be lost 
from the orange state by either photobleaching (exposure to 543nm laser) or 
photoswitched (exposure to 488nm laser). The far-red state (X2) will accumulate 
fluorescence from the orange state with the rate of Kswitch; this rate could be controlled by 
the power of the 488nm laser. Further, the far-red state will lose fluorescence by 
photobleaching (exposure to 633nm laser). The bleached state (X3) will be an 
accumulating compartment, receiving fluorophores from both the orange state (rate = 
Koff1) and the far-red state (rate = Koff2). A diagrammatic representation of the fluorescent 
states of PSmOrange is shown below in Figure 4.11. 
𝑲𝒔𝒘𝒊𝒕𝒄𝒉 =  10
(1.524×𝐥𝐨𝐠𝟏𝟎(𝑳𝒂𝒔𝒆𝒓 𝑷𝒐𝒘𝒆𝒓)−2.069) 
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Using the rate constants described above it is possible to form the following three 
differential equations (Equations 4.7-4.9), describing the change within each 
compartment. 
Equation 4.7: 
𝑑𝑋1
𝑑𝑡
=  −𝐾𝑠𝑤𝑖𝑡𝑐ℎ𝑋1 −  𝐾𝑜𝑓𝑓1𝑋1 
 
Equation 4.8: 
𝑑𝑋2
𝑑𝑡
=  𝐾𝑠𝑤𝑖𝑡𝑐ℎ𝑋1 − 𝐾𝑜𝑓𝑓2𝑋2 
Equation 4.9: 
𝑑𝑋3
𝑑𝑡
=  𝐾𝑜𝑓𝑓1𝑋1 + 𝐾𝑜𝑓𝑓2𝑋2 
Integrations of Equations 4.7-4.9 and the use of Laplace transformations will allow for 
the derivation of formulae for the proportion of fluorophores within a given state at any 
given time. The assumed starting for the compartments at time zero are as follows: X1
0 = 
1, X2
0 = 0 and X3
0 = 0, these values will be substituted into the proof at the required stages. 
Figure 4.11: States of PSmOrange for mathematical modelling of 
conversion rates 
     Chapter 4 
 
190 
 
Equation 4.10: 
𝑠?̅?1 −  𝑋1
0 =  −𝐾𝑠𝑤𝑖𝑡𝑐ℎ?̅?1 − 𝐾𝑜𝑓𝑓1?̅?1 
Equation 4.11: 
𝑠?̅?2 −  𝑋2
0 =  𝐾𝑠𝑤𝑖𝑡𝑐ℎ?̅?1 − 𝐾𝑜𝑓𝑓2?̅?2 
Equation 4.12: 
𝑠?̅?3 −  𝑋3
0 =  −𝐾𝑜𝑓𝑓1?̅?1 − 𝐾𝑜𝑓𝑓2?̅?2 
Substitution of X1
0 = 1 into Equation 4.10 and rearrangement to make X1 the subject of 
the equation results in the following (Equation 4.13). 
Equation 4.13: 
𝑋1 =  
1
𝑠 +  𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1
 
As Kswitch + Koff1 are both constants, the sum of Kswitch and Koff1 will therefore also be a 
constant, termed ‘a’. The formula is suitable to be used with the Laplace transformation 
(Equation 4.14) to produce the equation to solve for X1 with respect to time (Equation 
4.15). 
 
Equation 4.14: 
1
(𝑠 + 𝑎)
=  𝑒−𝑎𝑡 
 
Equation 4.15: 
𝑂𝑟𝑎𝑛𝑔𝑒(𝑡) =  𝑒−(𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1)𝑡 
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Having found the equation to calculate the fraction of fluorophores within the orange state 
at any given time, it is possible to substitute the equation for X1 (Equation 4.13) into the 
integration for the far-red compartment (Equation 4.11). Further, as X2
0 will be equal to 
zero, this component is removed from the equation. 
Equation 4.16: 
𝑠?̅?2 =  
𝐾𝑠𝑤𝑖𝑡𝑐ℎ
(𝑠 + 𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1)
− 𝐾𝑜𝑓𝑓2?̅?2 
The equation is then rearranged to solve for X2
. 
Equation 4.17: 
?̅?2(𝑠 +  𝐾𝑜𝑓𝑓2) =  
𝐾𝑠𝑤𝑖𝑡𝑐ℎ
(𝑠 + 𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1)
 
Equation 4.18: 
?̅?2 =  
𝐾𝑠𝑤𝑖𝑡𝑐ℎ
(𝑠 + 𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1)(𝑠 +  𝐾𝑜𝑓𝑓2)
 
 
Equation 4.18 is now in the correct format to undergo the Laplace transformation 
(Equation 4.19 and give the equation for the far-red component at any given time. 
Equation 4.19: 
 
1
(𝑠 + 𝑎)(𝑠 +  𝑏)
=  
1
(𝑏 − 𝑎)
(𝑒−𝑎𝑡 − 𝑒−𝑏𝑡) 
Equation 4.20: 
𝐹𝑎𝑟 𝑅𝑒𝑑(𝑡) =  
𝐾𝑠𝑤𝑖𝑡𝑐ℎ
𝐾𝑜𝑓𝑓2 − (𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1)
(𝑒−(𝐾𝑠𝑤𝑖𝑡𝑐ℎ+𝐾𝑜𝑓𝑓1)𝑡 − 𝑒−𝐾𝑜𝑓𝑓2𝑡) 
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Now having rearranged the integration formulae for X1 (Equation 4.13) and X2 (Equation 
4.18) it is possible to substitute these into Equation 4.12. The equation can then be 
rearranged to make X3 the subject of the formula. 
Equation 4.21: 
?̅?3 =  
𝐾𝑜𝑓𝑓1
𝑠(𝑠 + 𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1)
+
𝐾𝑜𝑓𝑓2𝐾𝑠𝑤𝑖𝑡𝑐ℎ
𝑠(𝑠 + 𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1)(𝑠 + 𝐾𝑜𝑓𝑓2)
  
 
Both sections of Equation 4.21 are Laplace transforms and represent the bleached 
components coming from the orange and far-red forms of PSmOrange respectively.  
 
  Equation 4.22: 
1
𝑠(𝑠 + 𝑎)
=  
1
𝑎
(1 − 𝑒−𝑎𝑡) 
 
 
Equation 4.23: 
1
𝑠(𝑠 + 𝑎)(𝑠 + 𝑏)
=  
1
𝑎𝑏
[1 +
1
(𝑎 − 𝑏)
(𝑏𝑒−𝑎𝑡 − 𝑎𝑒−𝑏𝑡)] 
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Equation 4.24: 
𝐵𝑙𝑒𝑎𝑐ℎ𝑒𝑑(𝑡) =  
𝐾𝑜𝑓𝑓1
(𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1)
(1 − 𝑒−(𝐾𝑠𝑤𝑖𝑡𝑐ℎ+𝐾𝑜𝑓𝑓1)𝑡)
+  {
𝐾𝑠𝑤𝑖𝑡𝑐ℎ𝐾𝑜𝑓𝑓2
𝐾𝑜𝑓𝑓2(𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1)
[1
+
1
((𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1) − 𝐾𝑜𝑓𝑓2)
 (𝐾𝑜𝑓𝑓2𝑒
−(𝐾𝑠𝑤𝑖𝑡𝑐ℎ+𝐾𝑜𝑓𝑓1)𝑡
− (𝐾𝑠𝑤𝑖𝑡𝑐ℎ + 𝐾𝑜𝑓𝑓1)𝑒
−𝐾𝑜𝑓𝑓2𝑡)]} 
 
For the three equations (Equation 4.15, 4.20 and 4.24) to be valid, at any given time point 
the sum of the orange, far-red and bleached states must equal one. This is due to the closed 
nature of the system.  
Having established the equations for the distribution of fluorophores between states, these 
were tested using values for Kswitch, Koff1 and Koff2 that had been measured in preliminary 
microscopy experiments. For these studies, the power of the 543nm and 633nm lasers 
were kept constant, while the power of the switching laser was varied between 0-60% of 
maximum power. Values for Koff1 and Koff2 were calculated by exposure of the 
PSmOrange-TfR expressing cells to just the bleaching wavelengths, 543nm and 633nm 
respectively. From these graphs rates of photobleaching can be found. As the 543nm and 
633nm laser powers are not altered throughout the experiment, these values were viewed 
as constant.  
By knowing the values of Koff1 and Koff2 in standard, non-converting conditions, it is 
possible to simulate a range of Kswitch values to assess the minimal requirements for 
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efficient photoswitching. This is shown in Figure 4.12, where the maximal values for Far-
Red state are plotted vs. Kswitch. 
 
4.3.2.3 Photoswitching with TIRF microscopy 
With TIRF microscopy, only a limited region of the sample, in close proximity to the 
coverslip, is excited at any given time. As such the signal to noise ratio in this technique 
is greater than that of confocal microscopy. However, the excitation field in TIRF decays 
exponentially with distance from the coverslip surface. This means that the switching 
power will decrease as the distance from the coverslip increases, causing the overall 
switching time to increase. To demonstrate this, hCMEC/d3 cells transfected with the 
PSmOrange-TfR plasmid were imaged by TIRF microscopy to establish the rate of photo-
conversion at the basolateral membrane. In contrast to photoswitching by confocal 
microscopy, where the conversion half-life was in the seconds range. TIRF microscopy 
Figure 4.12: The effect of varying the Kswitch on the distribution of 
PSmOrange’s fluorescence states after 100 second switch exposure 
The above shows the simulated model of PSmOrange states based on the equations derived 
previously. The simulation was done with constant K
off1 
and K
off2
 rates with only K
switch 
values between 10
-6 
and 10
-1
 s
-1
. Blue = orange fluorescence, Red = far-red fluorescence, 
orange = bleached chromophore. 
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photoswitching appears to take several minutes for an effective switch to occur, as shown 
in the Figure 4.13 below. 
 
To explain this “slow” switching fully, the decay of excitation power across the 
evanescence field must be studied (Figure 4.13). Using the standard TIRF equations listed 
earlier in the chapter, more specifically Equation 4.2. This allows a graphical visualization 
of the field decay when modelled with a defined power, in this example 25mW of the 
blue laser at the microscope stage (Figure 4.14). By using the switching data from the 
confocal microscopy, the photo-conversion rate at a given power could be modelled. 
Now, knowing the decay of the laser power and relationship between photo-conversion 
and laser power the change in switching rate across the evanescence can be estimated. 
This modelling shows that although the photoswitching rate is greatest at the coverslip 
surface, 50 nm into the sample the photoswitching rate has decreased by 10-fold. By 
Figure 4.13: PSmOrange-TfR photoswitching by TIRF microscopy 
This graph shows the quantification of both the orange and far-red fluorescence states of 
PSmOrange, while exposed to the switching laser in TIRF illumination. N = 3 in triplicate, 
mean ± std. 
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looking at electron micrographs of BMECs grown on a collagen matrix it was estimated 
that the depth of collagen, between the coverslip and the cell basolateral membrane, is 
~40nm. The phospholipid bilayer depth must also be accounted for (~10nm). Therefore, 
there is approximately 60 nm between the coverslip and the PSmOrange fluorophore 
fused to the TfR. This will decrease the laser power by over 80 % and so greatly reduce 
the photoswitching rate. 
 
 
This depth, before the fluorophore can be excited, is likely to be the main reason why 
photoswitching of PSmOrange-TfR is lower using TIRF microscopy compared to 
confocal microscopy.  
4.3.2.4 Imaging Optimization – Channel Cross-Talk 
As was predicted, the highest signal to noise was observed in the images where only a 
single excitation laser was used. This was true both pre- and post-photoswitching with 
Figure 4.14: Change of the photoswitching rate at different depths in the 
evanescence field 
Graph A shows how the laser power decays as the depth from the coverslip increases, based 
on a laser power out of the microscope of 25 mW. Graph B converts the laser powers in 
graph A to an estimate of K
switch
 using Equation 4.7. This is then plotted against depth from 
coverslip surface. Marked onto this graph is the depth of collagen and cell membrane to 
show the power of the that is reaching the intracellular compartment and the fluorophore. 
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the red and the green lasers. When imaging, if a second excitation laser was added, mid 
video, there was seen to be a “jump” in the average fluorescence intensity in both the 
green and red channels. This “jump” in fluorescence intensity was seen again when a third 
laser was added to the imaging, mid-capture.  
These changes in fluorescence are likely due to inefficiencies in the emission filter sets 
used. As all emission filters are not perfect restrictors of fluorescence transmission and 
have oscillating profiles at the maximum (99.8-100%) and minimum (0-0.2%) 
transmission points. With the high laser powers used in these studies, even small 
inefficiencies, such as these, are likely to allow enough of the lasers’ back-reflection 
through to cause the number of photons at the detector to increase. This appears as an 
increase in the fluorescence signal in the imaging channel. 
Due to this increase in signal, with the addition of more excitation lasers, it was decided 
that for photoswitching studies, a maximum of two lasers should be used at any given 
stage of the capture. To maximise the fluorophores able to undergo photoconversion that 
the exposure to the green laser should be minimal (at the start and conclusion of capture), 
while the exposure to the red laser should be in parallel to blue laser exposure. Thus, 
ensuring that any converted state, far-red fluorescence is recorded in the conversion time.  
 
4.3.2.5 Photoswitching Procedure Optimization 
Having established the optimal laser setup for the photoconversion studies the next stage 
was for the live capture of the switching and validation that the far-red fluorescence 
generated by the switch has come from the orange form of the protein. The macro used 
for analysis allows for the change in fluorescence in the green (orange) channel to be 
visualised and compared to all red (far-red) events for co-localization analysis.  
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In this way, it was observed that ~5% of “new” red spots, appearing over the course of 
the photoswitching time, colocalised with green spots that were no longer present at the 
conclusion of the switch. This low colocalization value following the switch may result 
from several factors. Firstly, the green capture at the start of the video does not account 
for the arrival of any new green events that may occur during the switch. These new 
events, if converted to the far-red form would not appear in the green-channel despite 
being present in the red maximum projection for the time course. The laser power from 
the blue laser (488 nm) was sub-optimal for photoswitching, with an output from the fibre 
launch of 3-4 mW. This is compared to green and red laser powers both more than 20 
mW. As modelled earlier in the chapter, the photoswitching efficiency is related to the 
laser power output reaching the sample and the depth above the coverslip of the 
fluorophore. If the laser power is less than a fifth of the anticipated laser power, then the 
photoswitching efficiency will be reduced. For the use of PSmOrange to measure 
exocytosis this means that the fluorophore takes longer to switch between states than 
initially predicted. Therefore, if measuring the turnover of receptors at the basolateral 
membrane, based on the proportion of unswitched (newly arrived) to switched (already 
present) receptors will be difficult as complete conversion of receptors is less likely to 
have taken place if the conversion time is longer. Meaning the ability to accurately 
measure the arrival of receptors from the apical membrane is not possible. To overcome 
this, an alternative photoswitchable protein may be used, such as Dendra2 or dEOS, as 
these have a higher rate of photoconversion than PSmOrange. And so, despite lower laser 
powers at the cell membrane, would be able to undergo a more efficient switch that 
PSmOrange. However the conversion wavelengths for Dendra2 and dEOS (405nm) are 
not currently supported by the TIRF setup, and so were not selected as fluorophores for 
these studies (Chudakov et al. 2007). 
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4.4 Conclusions and Future Developments 
While, using TIRF it was possible to visualise, transferrin molecules at the basolateral 
membrane of hCMEC/d3 cells and to identify potential events of interest. It was not 
possible to distinguish between an endocytic or exocytic event at the basolateral 
membrane. However, this was to be expected, as the majority of studies with TIRF have 
so far been concerned with the trafficking of fluorescently labelled receptors, or calcium 
signalling events associated to release and not targeting ligands (Mattheyses et al. 2010; 
Roman-Vendrell et al. 2014; Walker et al. 2008). The photostability of the AlexaFluor® 
647 fluorophore, relative to fluorescent proteins, means that long capture videos lead to 
photobleaching of most fluorophores within the excitation field, making tracking over 
time periods greater than 10s challenging. As well as obscuring, potentially exocytic 
events with bleaching of the fluorophore rather than the release of a vesicle. To overcome 
this the use of alternatively labelled ligands, with quantum dots, resistant to 
photobleaching could be used, as done by Roche in their work with TfR antibodies 
(Niewoehner et al. 2014). 
To optimise the photoswitching protocol with PSmOrange, the selection of a more rapidly 
converted photoswitchable protein would ideally lead to an improved sensitivity of the 
assay and a reduction in the time required to expose cells to switching laser. This would 
allow for more sensitive measures of the dynamics of receptor trafficking at the 
basolateral membrane of cells. However, was not attempted initially due to machine setup 
constraints and laser configurations.  
The end goal would be to photoconvert the fluorophore at the basolateral cell membrane 
and examine the replenishment with native state fluorophores. If this replenishment was 
not present, then it could be inferred that within the switch all receptors at the basolateral 
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cell membrane are trafficked in an independent pathway to the apical transferrin 
receptors. A ligand undergoing transcytosis must release the receptor within the 
endosomal compartment and find an alternate route to the basolateral membrane. If, 
however, the native fluorescence is replenished within the basolateral evanescence zone, 
the receptors from apical compartments are likely to be able to be trafficked to the 
basolateral compartment. Giving them the potential to undergo transcytosis across the 
cell. 
To further confirm that a receptor from the apical membrane was capable of trafficking a 
ligand to the basolateral membrane, combining the photoswitching assay (described in 
Figure 4.15) with a fluorescent ligand would be required. If a receptor arrived in the 
basolateral region in the native state (following the switch), with a ligand colocalised to 
it. Then it could be inferred that both the receptor and ligand had come from the apical 
region of the cell and been trafficked together across the cell. However, without these 
feasibility studies, then it is unclear if this technique could be used to characterise receptor 
and ligand transcytosis. 
Limitations of the microscope setups meant the fastest photoconverting fluorophores 
could not be used. To improve the sensitivity and feasibility of the assay further, a more 
fluorophore that undergoes more rapid photoswitching would be more suitable. 
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Figure 4.15: Future Development of the Photoswitching TIRF assay 
1. Photoswitching of receptors in the basolateral field – Done by exposing the 
fluorescent protein to the switching wavelength of light for an extended duration 
to ensure maximal photoconversion, prior to the start of the assay. And providing 
a differentiator to determine if a ligand is bound to an apical TfR that has arrived 
in the Evanescence field or been internalized by a basolateral receptor. 
2. Ligand Binding – The transferrin (blue circle) binds to TfR at the apical 
membrane. There is no fluorescence signal here from either the transferrin or the 
receptor as they are outside the evanescence field (black rectangle) 
3. Receptor-Ligand endocytosis – This will occur constitutively with the 
transferrin receptor, without the presence of a ligand. The clathrin scaffold and 
associated proteins, will form around the pit to facilitate the internalisation 
4. Association to the Early Endosome – once the vesicle is cleaved away from the 
plasma membrane it will be trafficked to the early endosome for initial sorting. 
From here it is possible for the receptor to undergo recycling back to the apical 
membrane of the cells. 
5. Trafficking of vesicle into Evanescence field – Now, if the receptor and the 
ligand, internalized at the apical membrane are trafficked into the evanescence 
field together. New, native state, photoswitchable protein will be present at the 
membrane. The pre-switching at the basolateral membrane allowing the 
differentiation of the two states. The ligand would then appear co-localized with 
the receptor. 
6. Docking of vesicle to basolateral membrane – The vesicle is now bound to the 
basolateral membrane and begins to “open” out to the extracellular 
microenvironment. 
7. Complete vesicle fusion and opening – The vesicle is now completely 
integrated into the basolateral membrane and the ligand can be released from the 
cell. Due to the proximity of the cell membrane to the coverslip this may not be 
seen as a loss of ligand fluorescence, but the remaining signal from the apical 
(green fluorescence state) will remain in this location. Confirming that the ligand 
must have come from a more apical compartment of the cell to be released at the 
basolateral membrane and potentially having undergone transcytosis. 
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Chapter 5: General Conclusion and Future Work 
Due to complexity, restrictive nature and extensiveness of the BBB in vivo will remain 
the main bottle-neck for the delivery of therapeutics to the CNS for the treatment of 
neurological pathologies. Methods that can overcome the BBB and improve delivery 
standards will remain a research goal, with the identification of novel, efficient targeting 
ligands being essential. The methods used in vitro must go beyond “simple” permeability 
assays across BMEC monolayers and look at the intracellular trafficking of targeting 
ligands and DDSs within endothelial cells. Full characterisation of targeting ligands and 
DDSs in vitro before in vivo testing will improve pre-clinical and clinical outcomes. The 
studies in this thesis aimed to bring forward this, through the pulse-chase assay and 
combination with subcellular microscopy imaging techniques. 
The use of immortalised cell lines to test BBB ligands is limited, by the loss of the 
restrictive phenotype as cells are cultured. However, immortalised cell lines have the 
benefit of overcoming the inconsistencies between isolations, which is associated with 
primary BMEC cells. Chapter 2 highlighted the limitations of using permeability assays 
with immortalised cell lines, demonstrating the benefits of the pulse-chase assay. Pulse-
chase methodologies allowed for confirmation, in static conditions, that a targeting ligand 
or DDS could be internalised by the BMECs. It was shown to be able to differentiate 
between probes with receptor-driven, cellular trafficking pathways (transferrin, 8D3) and 
those without (dextran). Further, the pulse-chase methodology could distinguish between 
the saturated and unsaturated ligand uptake and trafficking. In the case of saturation of 
the receptor-mediated uptake mechanism, excess ligand, at the cell surface was seen to 
be trapped within the cells throughout the chase phase. This was observed with all 
targeted probes used within the assay (transferrin, 8D3, 8D3-4). Coupling of the pulse-
chase assay with microscopy techniques to examine the subcellular distribution of remain 
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ligand allows a further layer of detail to the assay. Allowing for the visualisation of 
“trapped” excess ligand within lysosomal compartments, and unable to undergo further 
cellular trafficking. The impact of the receptor saturation was seen when using the assay 
to characterise the 8D3 antibody variants. With the low-affinity, 8D3-4 showed a greater 
ability to be effluxed by cells at high concentrations, compared to the native 8D3 antibody 
(high affinity). The main conclusion of this chapter was the benefits of using multiple 
techniques when attempting to characterise BMEC targeting strategies.  
In Chapter 3 the focus was the characterisation of the uptake of the RVG peptide into 
BMECs and the confirmation of the target receptor for the peptide. The uptake of the 
RVG peptide was compared to a scrambled sequence peptide and a peptide with the 
internal cysteine mutated for an alanine. These uptake studies confirmed the sequence of 
the RVG peptide and the internal cysteine of the RVG peptide were required for cellular 
uptake of the peptide. The uptake of the RVG peptide was shown to be self-competitive, 
and the pulse-chase profile of this targeting ligand suggested a defined trafficking 
pathway within BMECs. Finally, in this chapter, studies to confirm the target receptor of 
the RVG peptide demonstrated the role of α7nAchR as a receptor for uptake of RVG into 
BMECs. Competition with α-bungarotoxin, siRNA knockdown of the receptor decreasing 
the uptake of RVG into cells. PCR tests for α7nAchR confirmed the receptor was 
expressed in b.End3 and hCMEC/d3 cell-lines, making this a viable target for the ligand 
in BMECs. Through the use of pulse-chase assays, as described in Chapter 2, the 
internalisation and efflux of RVG was characterised. This showed that RVG can undergo 
active efflux from BMECs, confirming its suitability as a targeting strategy for CNS 
delivery. 
To expand on the assays described previously and enhance the understanding of cellular 
trafficking at the basolateral membrane of cells, TIRF microscopy was used to look at 
     Chapter 5 
 
204 
 
ligand localisation to the basolateral compartment of BMECs (Chapter 4). The technique 
confirmed that the transferrin ligand, if applied to the apical surface of cells, can be 
visualised at the basolateral membrane. However, due to the inherent “leakiness” of 
immortalised BMEC cell-lines, this may be due to ligand passing between cells and 
entering the cell from the basolateral membrane. An inability to identify if the events 
visualised were exocytic or endocytic, with single colour imaging, was a key issue with 
this technique. But, it was possible to identify individual events within the capture videos 
that may be of interest. To improve the assay and add to the potential for exocytic 
readouts, the use of photoswitchable proteins expressed with a receptor of interest was 
suggested, and PSmOrange selected for use in the studies. The distribution of the 
fluorescent states of PSmOrange was modelled mathematically, to demonstrate the effect 
of varying the switching rate on the distribution of the chromophore states. The 
PSmOrange-TfR plasmid was synthesised and expressed in hCMEC/d3 cells for 
characterisation. Confocal microscopy confirmed expression of the photoswitchable 
receptors and the ability to convert rapidly between the states when exposed to the 
switching. However, when used in TIRF microscopy studies, the decreased depth of the 
excitation field, coupled with its decay with distance from the coverslip surface meant 
that the switching powers the sample was exposed to were far less than those used in 
confocal imaging. As such the rate of photoswitching using TIRF microscopy was seen 
to be significantly lower than confocal. And will require further development to take the 
assay forward and this will be covered in the future work section below. 
Future Work and Development 
RVG Peptide 
Having characterised the RVG peptide, concerning uptake and loss and the receptor 
target, the next step with this would be to look at the effect of ligand valency on the ability 
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of the RVG peptide to deliver a sample cargo in BMECs. This could be done using 
dendrimer, with a fluorescent cargo, to allow for the assessment of cellular localisation 
of the constructs. In this way, the valency of the constructs could be altered, and the sub-
cellular distribution assess. Through the pulse-chase assay developed here, it would be 
possible to assess the impact of ligand density on the potential to be taken up by BMECs 
and the ability of internalised constructs to undergo further trafficking within the 
endothelial cells. Optimization of ligand density in vitro would then allow for favourable 
constructs to be taken forward for use in vivo, to test the capability of them reaching the 
brain parenchyma. 
TIRF microscopy 
The work with TIRF microscopy, to develop an exocytosis assay for delivery of cargo 
across the cell requires several studies to progress it further. The critical step will be the 
combination of the photoswitchable receptor with a fluorescently labelled targeting 
ligand. Imaging in this manner will allow for the visualisation of the receptor and ligand 
co-localized together at the basolateral membrane, in the first instance. Moving this 
further, by then periodically switching the switchable fluorophores within the basolateral 
region of the cells, it would be possible to detect whether the ligand-receptor complex 
was residing purely in a basolateral trafficking loop. For instance, if this were the case, 
then you would reach a point where only the switched form of the receptor was present 
in the evanescence field. Due to an inability of the “new” apical receptors to enter this 
pathway. However, if there is not a localised trafficking pathway within the basolateral 
region of the cell, and receptors may come from the apical compartment. Then there 
would be the presence of both fluorescent states of the receptor in the field at any given 
time. If this occurred and a ligand was co-localized with the un-switched fluorophore that 
had arrived in the evanescence field, then this must have come from a more apical 
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receptor within the cell and potentially undergone transcytosis to reach the basolateral 
region of the cell. Progression of the assay to this stage, with the transferrin receptor and 
ligands, would be required before this could be used with other BBB targeting ligands.
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Appendices 
Appendix 1 – PBS buffer composition 
Table 2.1.1 – Composition of PBS buffer 
Chemical Concentration (g/L) Source 
Sodium Chloride 8.00 Fisher scientific 
Potassium Chloride 0.20 Fisher scientific 
Disodium Hydrogen Phosphate 1.44 Fisher scientific 
Potassium Dihydrogen Phosphate 0.24 Fisher scientific 
 
Appendix 2 – Krebs-Ringer Buffer composition 
Table 2.1.2 – Composition of Krebs-Ringer Buffer 
Chemical Concentration (g/L) Source 
Magnesium Chloride 0.047 Fisher scientific 
Potassium Chloride 0.340 Fisher scientific 
Sodium Chloride 7.000 Fisher scientific 
Calcium Chloride 0.277 Fisher scientific 
Disodium Hydrogen Phosphate 0.100 Fisher scientific 
Sodium Dihydrogen Phosphate 0.180 Fisher scientific 
Sodium Bicarbonate 1.260 Fisher scientific 
D-Glucose 1.800 Fisher scientific 
Bovine Serum Albumin 1.000 Sigma Aldridge 
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Appendix 3 – Collagen Coating of Plastic 
Table 2.2.1 - Collagen Coating volumes for plastic cell culture surfaces 
Culture 
Surface 
Surface 
Area (cm2) 
Mass of collagen 
(µg) 
Volume of 
collagen (µL) 
PBS volume 
(µL) 
Total volume 
(µL) 
24 Well 
Insert 0.33 1.65 0.7 59 59.7 
24 Well Plate 1.9 9.5 4.1 195 199.1 
6 Well Insert 4.67 23.35 10.2 490 500.2 
6 Well Plate 9.5 47.5 20.7 480 500.7 
Imaging dish 9.5 47.5 20.7 480 500.7 
T 25 Flask 25 125 54.3 345 399.3 
T 75 Flask 75 375 163.0 837 1000.0 
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Appendix 4: Isolation of Porcine Brain Microvascular Endothelial Cells 
The isolation of PBMECs is performed using four pigs heads obtained on the day from a 
local abattoir. 
Brain removal 
1) A mid-line incision is made from the top of the snout to the back of the head and 
the skin removed to expose the skull. 
2) The exposed skull is cut in three places to give a loose wedge of bone that can be 
removed to expose the brain, within the meninges beneath. 
3) An incision along the length of the meninges exposes the brain. 
4) The brain can now be pulled free from the skull and placed in ice-cold PBS 
 
Cell Isolation 
1) After the brains have been removed from the skulls they are transferred to a 
Category 2 cell culture hood for the following steps of the isolation. 
2) The large, surface vessels and the white matter are removed from the brain using 
forceps and the remainder of the brain stored in PBS until further use. 
3) The brains are minced into a fine paste and divided into four equal volumes in 250 
mL centrifuge bottles. 
4) To each bottle 40mL of porcine preparation medium (M199 + penicillin - 
100units/mL, streptomycin 100 µg/mL) containing, 1g of dispase, is added and 
the bottles incubated at 37 oC on a roller shaker for two hours (Digestion 1). 
5) The bottles are placed on ice to inhibit the action of the dispase and the bottles 
filled with 30% percoll solution, prior to centrifuging at 6000 xg for 10 minutes 
at 4 oC. This step allows the separation of fats from other components of the brain. 
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6) The fats will be floating at the surface of the centrifuge bottles and should be 
removed by stripette. At this stage red streaks of vessels will begin to be visible 
at the base of the centrifuge bottles and care must be taken not to disturb these 
while removing fats from the tube. 
7) The remaining solution in the bottles is then re-centrifuged at 1700 xg for 10 
minutes at 4 oC to pellet the remaining vessels in the solution. 
8) The remaining supernatant is carefully removed to ensure the red streaks remain 
at the base of the bottle. 
9) The streaks are re-suspended in 7 mL of porcine culture media, PCM (90% M199, 
10% horse serum, penicillin 100 units/mL, streptomycin 100µg/mL) and the 
mixtures collected into one tube. 
10) To this tube is added collagenase/dispase to give a concentration of 1 mg/mL. The 
tube is placed at 37 oC for 1-1.5 hours and monitored throughout this time to see 
if a single cell suspension could be observed (Digestion 2). 
11) Following the conclusion of Digestion 2 the tube was placed at 4 oC to stop the 
enzymatic digest.  
12) The cell suspension is passed through 180μm and 20μm meshes to prevent any 
larger vessels being present in the final collection. Care must be taken in this step 
to avoid rupturing the membranes. 
13) The volumes remaining are split evenly between two centrifuge tubes and pelleted 
by centrifugation at 185 xg for 10 minutes at 4 oC. The resulting pellets were then 
re-suspended in 10mL of PCM. 
14) While the tubes are centrifuging the discontinuous percoll gradients were 
prepared. This was done by adding 10mL of Heavy Percoll (density = 1.07g/mL) 
beneath 10mL of Light Percoll (density = 1.03g/mL), ensuring a sharp interface 
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between the densities. To the gradients is added 5mL of the re-suspended cell 
solution, again ensuring a sharp interface between the Light Percoll and the cell 
solution.  
15) The gradients are centrifuged at 1300 xg for 13 minutes at 4oC with slow 
acceleration and no deceleration to ensure the interfaces between the different 
densities remains. 
16) The endothelial cells are located at the interface between the heavy and light 
percoll gradients (density of 1.05-1.052 g/mL). The excess upper solution is 
discarded and the cells at the interface collected into a new centrifuge tube. 
17) Fresh PCM is added to the cells and the tubes are centrifuges at 1300 xg for 10 
minutes to pellet the endothelial cells and remove the percoll from the solution. 
18) Cells are re-suspended in 40mL Porcine Freezing Medium (70% M199, 25% 
horse serum, 5% DMSO) and divided into 1mL aliquots for long term storage at 
-140 oC. 
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Appendix 5 – PBMEC cell growth 
The porcine microvascular endothelial cells isolated in laboratory were grown on plastic 
with daily imaging to assess the growth and morphology of the cells in the culture. Small 
islands of cells were visualised on the plastic from day 3 onwards and have been seen to 
expand day by day until a complete monolayer could be observed, day 6-7.  
 
 
 
 
When a monolayer is observed cells have a “spindle” morphology, typical of endothelial 
cells can be seen by light microscopy. Trials into collagen coating density confirmed that 
5µg/cm2 coating density was optimal for cell growth and was continued with for all 
studies presented here unless otherwise mentioned. 
Imaging of primary porcine brain microvascular endothelial cell growth 
Cells have been seeded onto collagen coated plastic cell culture dishes and inspected using phase-
contrast microscopy daily until a confluent monolayer of cells was observed across the plate. 
